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Abstract
Leishmania mexicana express several cysteine proteinases, some of which 
appear to be good drug targets. Findings suggested that cysteine proteinases may 
have an immunomodulatory role within the mammal and recently it has been 
shown that cysteine proteinase-deficient mutants stimulate a Th 1 response in 
susceptible mice strains compared with the Th 2 phenotype normally observed in 
wild-type infections.
To investigate further the immunomodulatory activity of leishmanial 
cysteine proteinases and their role in host-parasite interactions, a major cysteine 
proteinase of L. mexicana^ CPB, was produced in recombinant form. The 
enzyme, CPB2.8ACTE, generated without its C-terminal extension was 
successfully expressed in Escherichia coli and purified fi*om inclusion bodies to 
yield enzyme with high specific activity. The successful method was also used for 
the attempted production of a full length CPB with its C-terminal extension of L. 
infantum in recombinant form. This proved less successful apparently because of 
the presence of the hydrophobic C-terminal extension.
The recombinant CPB of L. mexicana was analysed for its effects on the 
host response to the parasites and parasite antigen. In vitro analysis entailed 
incubation of explanted peritoneal exudate cells with recombinant CPB2.8 to 
assess production of inflammatory mediators considered to be important in 
leishmanial infection. The enzyme did not affect the production of interleukin-12 
or nitric oxide but it did reduce the level of IL-10.
The vaccine potential of the enzyme was investigated by co-administration 
with recombinant IL-12 as a vaccine, in three mouse strains, before challenge with 
wild-type L, mexicana. The consequent infection and host immune responses 
were monitored. The enzyme was partially protective when administered with IL- 
12 even in the highly susceptible BALB/c line. The activity of the enzyme was 
shown to be unimportant in its ability in promoting a Th 1 response rather than 
the exacerbative Th 2 response normally seen in wild-type infection. These results 
demonstrate the potential of recombinant CPB as part of a vaccine against 
leishmaniasis.
Targeted gene deletion of the cysteine proteinases of L. mexicana has 
produced several null mutants including the single and double null mutants. The 
single null mutant (denoted by hcpb) is generated by deletion of the entire cpb 
array, which encodes the 19 CPB isoenzymes, while deletion of both the cpb array 
and the cpa gene generates the double null mutant (denoted by Acpb/cpa). The 
latter mutant produces a no lesion growth phenotype in BALB/c mice and has 
been suggested as being a potential vaccine candidate. The parts played by the 
cysteine proteinases were investigated further by using these mutant parasite lines 
in which CPB was analysed by methods of re-integration directly into the 
chromosome or by re-expression via a cosmid vector.
In order to compare metacyclic-specific and amastigote-specific genes and 
see if time of cysteine proteinase expression was important in establishing 
infection, the single null mutant was re-integrated with either metacyclic- 
expressed CPB2 or amastigote-expressed CPB2.8. Furthermore, each proteinase 
was engineered with its native promoter or with a chimaeric promoter, to assess 
expression levels and to investigate if there was a direct correlation between CPB
II
expression and virulence since metacyclic CPBs are normally not expressed in the 
amastigote and vice versa.
Re-integration of metacyclic CPB2 with its native and chimaeric promoter, 
significantly increased parasite proliferation resulting in increased lesion growth, 
re-integration of amastigote CPB2.8, did not promote an increase in virulence as 
the enzyme with its native promoter but did promote virulence when the enzyme 
was re-integrated with the chimaeric promoter. Analysis of the humoral and 
cellular responses to the single null mutants, indicated a mixed Th phenotype with 
IFN-y and IL-4 being produced by ex vivo splenocytes in response to leishmanial 
antigen stimulus.
Antibody and lesion analysis of the double null mutant-infected mice was 
also carried out and did not result in an increase in virulence. Indeed re­
integration of either CPB2 or CPB2.8 resulted in significantly higher IgG2a 
production indicating more of a Th 1 response than that already seen in double 
null-infected mice. Re-expression of the cpb array as a cosmid vector into the 
single null mutant did not result in a significant increase in virulence in mice 
compared with that of the single null mutant alone.
The methods used to analyse these immune responses have been 
developed to permit further examination of other leishmanial CPs and should help 
to elucidate the role of these important parasite molecules.
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Introduction
1.1 LEISHMANIA: DISEASE AND IMPLICATIONS
The genus Leishmania contains the etiologic agents for a diverse range of 
diseases, ranging from a simple cutaneous lesion to the potentially fatal visceral 
leishmaniasis. The diseases afflict 12 million people in 88 countries of the world and 
have proven difficult to control due to the lack of any prophylactic agent, the toxicity 
of effective anti-leishmanials, the innate ability of the parasite to infect many species 
of mammals, the difficulties in controlling vectors and the emergence of AIDS-related 
leishmaniasis (WHO, 1997).
1.1.1 Life Cycle
Successful infection of a mammalian host by Leishmania involves transmission 
of the infective metacyclic form, inoculated by the sandfly vector Phlebotomus (in the 
Old World) or Lutzomyia (in the New World). By preferentially accessing 
macrophages via complement receptors, CRl and CR3, the promastigotes fail to 
trigger the respiratory burst which is leishmanicidal (Alexander et al, 2000). The 
promastigotes rapidly change to amastigotes after phagocytosis, then multiply within 
the parasitophorous vacuole of the macrophage. The infected cell bursts, the released 
parasites are again phagocytosed and the process is repeated.
Depending on the infecting species of Leishmania, the pathology of the 
infection can be quite different. It ranges from a self-limiting cutaneous lesion to a
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life-threatening condition, if left untreated. The life cycle (Figure 1.1) is complete 
when another sandfly takes a bloodmeal from an infected host and ingests the 
parasitised blood whereupon amastigotes transform back into promastigotes and bind 
to the insect gut, before migrating to the insect mouthparts (Neva & Brown, 1994).
1.1.2 Pathology
Cutaneous leishmaniasis, caused by L. major and L. ti^opica in the Old World, 
results from multiplication of the parasite in the phagocytes of the skin. In the classic 
course of this type of disease, lesions first appear as papules, progress to ulcers, then 
spontaneously heal with scarring over several months. However, diftuse cutaneous 
leishmaniasis, attributed to L. mexicana and L. aethiopica, causes widespread 
thickening of the skin with lesions, resembling those of lepromatous leprosy, which do 
not heal spontaneously and can be severely disfiguring (Jawetz, 1995).
Infection with L. braziliemis results in mucocutaneous leishmaniasis due to 
metastasis of organisms to mucosal sites from a primary cutaneous lesion established 
much earlier. Parasite metastasis may spread to the oronasal and pharyngeal mucosa 
causing highly disfiguring leprosy-like tissue destruction and swelling. Visceral 
leishmaniasis or kala-azar is caused by L. donovani, L. infaniiim or L. chagasi and is 
characterised by fever, hepatosplenomegaly and anaemia which, if left untreated, is 
lethal within weeks or months.
1.1.3 Chemotherapy
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The drugs currently used, such as sodium stibogluconate and pentamidine, 
were all derived empirically many years ago and yet still little is known about their 
modes of action (Berman, 1997), As the leishmaniases became more extensively 
treated and more carefully studied, treatment failures with the arcane antimonials, 
sodium stibogluconate and glucantime, the first line drugs in most cases, became 
recognised (Beiman, 1997), Alternative treatments including pentamidine and 
amphotericin B have been used with varying degrees of success but toxicity, 
resistance and high cost mean that alternative therapies are being constantly 
investigated. However, since infectious diseases such as the leishmaniases mainly 
affect people in developing countries, research into drug development is not afforded 
high priority by pharmaceutical companies.
1.1.4 HFV co-mfection
The co-existence of HIV and viscQXdilising Leishmania species in southern 
Europe, where leishmaniasis is endemic, has resulted in a large number of dually 
infected individuals in the HIV-infected population (Berman, 1997). Approximately 
300 cases of dual infection had been reported in Europe by 1994 but by 1997 the 
total number of cases had increased to 1000. HIV infection causes disease in 
previously asymptomatic people with latent leishmanial infection and this 
emphasises the fact that visceral leishmaniasis is an opportunistic infection that now 
infects patients in the developed world.
1.2 SURFACE MOLECULES INVOLVED IN INFECTION
During leishmanial infection there is interaction between the host 
macrophage and the parasite's surface molecules, some of which are purported to be
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viiTilence factors. These are therefore important in establishment of intracellular 
infection and the main ones studied are briefly described in this section.
1.2.1 Lipophosphoglycan
The glycolipid, lipophosphoglycan (LPG) is anchored in the plasmalemma of 
the cell by a phosphatidylinositol-glycan and occurs at 2 - 5 x 10^  copies per cell in the 
promastigote stage (Turco & Descoteaux, 1992). While LPG is present in abundance 
on the cell surface of the promastigotes, it is down-regulated in the amastigote stage 
with approximately 2 - 5 x lO'* copies per cell. The structure of the molecule varies 
between Leishmania species but in all isolates characterised it is comprised of 
repeated phosphorylated saccharide units linked via a mannose-rich carbohydrate core 
to a lysoalkylphosphorylinositol hpid anchor (Ferguson, 1999).
L. major promastigotes modulate LPG by varying the number of saccharide 
units and their terminal sugars, increasing the length of LPG during transformation 
from non-infective, dividing promastigotes to infective, non-dividing metacyclics.
This alteration is responsible for the release of the promastigotes from the midgut 
(Turco & Descoteaux, 1992).
LPG has been considered to be a multi-functional virulence factor because of 
its apparent involvement in several key aspects of host-parasite interaction. After 
binding to a macrophage receptor and during phagocytosis of the parasite into the 
macrophage, LPG causes unresponsiveness of macrophages to activators of protein 
kinase C (PKC) (Turco, 1999). Activation of PKC leads to the activating events of 
the respiratory burst, c-fos gene expression, IL-1 production and chemotaxis. The 
mechanism by which LPG inhibits PKC activity appears to be related to the 
observation that intercalation of LPG into membranes stabilises the bilayer against
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the formation of an inverted phase structure. This bilayer stabilising property of LPG 
is the converse of the bilayer destabilising property of diacylglycerol, the physiological 
activator of PKC, and this inhibits the ability of PKC to phosphorylate proteins. LPG 
can therefore inhibit the respiratory burst, a mechanism by which the parasite subverts 
a potentially leishmanicidal response of the macrophage. As well as actively 
modulating macrophage activation, LPG can scavenge reactive oxygen radicals which 
are potentially harmful to the parasite (Russell, 1994).
Thus LPG has been considered important for attachment of the parasite 
within the insect vector, and mammalian host and to help down-regulate one of the 
mammalian host cell’s microbicidal responses. However, recent findings suggest that 
LPG is in fact not a virulence factor in L. mexicana infection as it was shown that 
LPG-deficient parasites remain lethal in BALB/c mice (Ilg, 2000).
1.2.2 Glycoinositol-phospholipids (GIPL’s)
The GIPL’s of Leishmania were shown to share a structural motif with 
protein GPI-anchors and LPG (Thomas et al, 1992). The majority of the GIPL’s 
contain shorter alkyl chains and are the most abundant surface component of the 
promastigote and amastigote form of the parasite. The precise function of cell- 
surface GIPL’s in trypanosomatid parasites is largely unknown. Their abundance 
suggests that they may play a general protective function by providing a dense, 
negatively charged glycocalyx, close to the surface of the plasma membrane through 
which other macromolecules project. It has recently been reported that these 
molecules are essential for infection in Leishmania (McConville & Menon, 2000).
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1.2.3 The surface metalloproteinase gp63
The surface metaJloproteinase, gp63, occurs at 5 x 10^  copies per cell in the 
promastigote in which it is, as the name suggests, exposed at the cell surface. L. 
mexicana amastigotes express at most only very small amounts of gp63 on their 
surface and instead a soluble form of the proteinase is located in the lysosomes of the 
parasites (Russell, 1994).
Although gp63 has been shown capable of cleaving a range of different 
substrates, including the third component of complement, its relative activity on 
substrates of biological significance remains unconvincing (Chaudhuri & Chang,
1988). The demonstration of a homologue for a leishmanial gp63 in Crithidia 
fasciculata suggests that the ancestral function of the enzyme lies within the sandfly 
(Inverse et al, 1993) even though gp63 has been found to mediate attachment to the 
macrophage. Targeted gene deletion of gp63 has shown that this molecule is clearly 
involved in conferring resistance to complement-mediated lysis (Joshi et al, 1998). 
Nevertheless, it seems that surface gp63 is not essential since surface gp63-deficient 
L  major parasites were capable of lesion formation in BALB/c mice (Joshi et al,
1998).
gp63 was one of the first polypeptides from Leishmania to mediate protection 
against infection (Russell & Alexander, 1988) and DNA vaccines based on this 
molecule have also been shown to afford significant protection against infection (Xu 
& Liew, 1995).
Chapter 1
1.3 PROTEINASES
1.3.1 Mode of action
Proteolytic enzymes catalyse the enzymatic degradation of peptide bonds in 
both proteins and peptides and are ubiquitous throughout the plant, animal and 
prokaryotic kingdoms. They are characterised according to the way they cleave the 
peptide bond. Proteases that catalyse the cleavage of an internal peptide bond are 
known as endopeptidases or proteinases (McKerrow et ai, 1993). Those that 
catalyse the cleavage of amino acids from their amino or carboxy terminus are known 
as exopeptidases.
The endopeptidases are sub-classified into four main groups, these being 
serine, cysteine, aspartic and metalloproteinases. They are so-called because the 
amino acid or metal ion is essential for the binding of the substrate at the active state. 
For example, cysteine proteinases (CPs) contain a thiol-imidazoyl system wdthin the 
active site with catalysis proceeding via a thiol ester formed transiently between the 
substrate and Cys-25. For this reason they are sometimes known as thiol proteinases. 
Furthermore, CPs can have a very broad pH optima from pH 5.5 to 7.5 and thus can 
function in several environments provided there is sufficient reducing agent to ensure 
that the active-site thiol group is not oxidised.
1.3.2 Mammalian CPs
The most abundant mammalian CPs are cathepsin B and L which function 
within lysosomes (Kirschke et al, 1995). They are generally present in aU cells and 
are members of the papain superfamily of CPs. The papain family is the largest family 
of CPs which includes a wide range of enzymes from both prokaryotes and
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eukaryotes. Catalytic activity of these enzymes is dependent on pH values below 7 
and the presence of reducing compounds.
CPs are synthesised as inactive pre-pro-enzymes (Nishimura et al, 1988).
This is to protect the cell from potentially disastrous consequences of uncontrolled 
protein degradation. The pre-region is cleaved before the full-length protein is 
synthesised and is possibly involved in targeting to the endoplasmic reticulum.
The pro-segment of cathepsin L and B is a potent inhibitor of the mature 
enzyme. Binding of the pro-region in the substrate binding site (SBS) is comparable 
with that of E-64, an irreversible CP inhibitor, since it too binds in the reverse 
direction (Coulombe et al, 1996). The pro-region is fastened in the SBS by a two- 
tum helix positioned in the S’ subsites. It follows the groove in the opposite direction 
to that of the substrate and although the pro-region passes very close to the catalytic 
machinery of the proteinase, it is not cleaved by the enzyme. The reversal of the 
direction of the polypeptide chain in the SBS results in an appropriate positioning of 
the peptide bond for hydrolysis to occur (Cygler & Mort, 1997). The pro-segment is 
also essential for correct folding of the newly synthesised protein and stabilises it to 
the denaturing effects of neutral to alkaline pH, conditions which rapidly inactivate 
most of the mature CPs (Coulombe et al, 1996). Furthermore, a specific region of 
the pro-segment provides at least part of the recognition site for modification with 
mannose-6-phosphate, a signal for targeting to the lysosomal compartment within 
mammalian CPs.
Cleavage of the pro-enzyme with subsequent activation of the proteinase 
occurs as the result of auto-catalysis under acidic conditions (Mason et al, 1987). In 
v/vo, this occurs as the newly synthesised pro-enzyme is routed from the Golgi 
apparatus to the lysosome. The exact pH in the Golgi is unknown but is considered
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to be less acidic than in lysosomes, where the mature enzymes are situated. Degraded 
peptides diftuse through the lysosomal membrane and are available again for protein 
synthesis in the cell (Kirschke et a l, 1995).
In the case of human cathepsin L, the disruption at low pH of salt bridges 
involved in the interaction between the pro-peptide and mature enzyme is believed to 
trigger the processing event (Roche et al, 1999). In parallel, activation and 
processing of pro-papain is achieved by auto-proteolytic cleavage (intramolecular) 
and, once free papain is released, processing can occur in trans (intermolecular) 
(Vemet et al^ 1995). It is thought that a conserved motif and its electrostatic status 
within the pro-region participates in the control of intramolecular processing of the 
papain precursor.
Cathepsin L is a strong endopeptidase degrading several proteins and 
inactivating many enzymes. It is catalytically active at pH 3.0 - 6.5 in the presence of 
SH-containing compounds and has a requirement for hydrophobic amino acid residues 
in subsites Si and S2 (Kirschke et al, 1995). Pro-cathepsin L has also been shown to 
interfere with antigen processing (Menard et al, 1998).
Cathepsin B is one of the most abundant and thoroughly studied lysosomal 
CPs and is involved in many normal cellular processes including intracellular 
degradation of protein and antigen processing (Guagliardi et al, 1990).
Cathepsin C has been found to participate in the activation of pro-enzymes and 
is implicated in several pathological events (Cigic et al, 1998). It has been found to 
aid cancer invasion and its subsequent metastasis (Mort et al, 1981). Unique among 
the lysosomal CPs to cathepsin C is the requirement of halide ions in addition to a 
SH-containing compound for the catalytic activity of this enzyme (McDonald et al, 
1966). Several metabolic functions have been attributed to cathepsin C in addition to
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its main function in protein degradation in lysosomes, including activation of 
neuraminidase.
1.3.3 Parasite proteinases
Proteinases have been implicated in a wide variety of adaptations of micro­
organisms for survival in the host, including modulation of the host’s immune system 
and tissue destruction which enable further invasion of the micro-organism in the host 
(Travis et al., 1995). There have been many studies on parasite proteinases, too 
numerous to detail comprehensively and so I mention just three examples of the 
different classes of proteinases. Two aspartic proteinases (plasmepsins) from 
Plasmodium falciparum have been implicated in the degradation of haemoglobin and 
both have been successfully purified and crystallised from E. coli (Hill et al, 1994).
A metallocollagenase from Entamoeba histolytica has been proposed to play an 
essential role in invasion by degradation of collagen, the connective tissue, which 
would allow further infection of the host (Munoz et al, 1982). Leishmania species 
also contain a metalloproteinase, gp63, which is abundantly expressed and protects 
promastigotes from hydrolytic enzymes in the gut of the sandfly while in the 
mammalian host, it can inhibit complement mediated lysis and promote parasite 
uptake by cleaving C3b to C3bi - see section 1.2.3.
1.3.4 Parasite CPs
The major CP of Trypanosoma cruzi, cruzipain, is largely responsible for the 
proteolytic activity of the organism and inhibitors of the enzyme blocked mammalian 
cell infection to a considerable degree suggesting that the intracellular development of 
T. cruzi is critically dependent on cruzipain (Meirelles et ah, 1992). Cruzipain also
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cleaves kininogen to form a pro-inflammatory peptide, bradykinin, as well as 
activating pre-kalHkrein which could be a second and indirect way by which the 
parasite proteinase can release bradykinin (Del Nery et al, 1997). Thus, by acting as 
a kininogenase, cruzipain has been found to induce plasma leakage in post-capillary 
venules (Svensjo et al, 1997). Further studies on this enzyme showed that an 
irreversible CP inhibitor proved effective in blocking parasite replication and so this 
enzyme has been considered as a model for anti-parasite drug design (Engel et al,
1998).
A CP which shares some homology to cathepsin L has also been identified in 
P. falciparum . Inhibitor studies have shown that the enzyme is probably required for 
haemoglobin degradation and therefore parasite development (Rosenthal e ta l, 1998). 
Clearly this enzyme plays an important role in the host-parasite interaction and is 
considered as being a potential target for chemotherapeutic attack (Olson et al,
1999).
Generally, proteinases can be considered good targets for chemotherapy if 
they have different substrate specificities from the host enzymes, if there is unusual 
location of the parasite proteinase, or if the enzyme is involved in a process that is 
unique to the parasite (Coombs & Mottram, 1997). Essential enzymes are considered 
the best targets but inhibiting others can also be effective (Barrett et al, 1999).
1.3.5 Leishmanial Type I CPs
For all trypanosomatid species analysed, the Type I enzymes are encoded by 
multicopy genes arranged in tandem arrays and usually have the highest CP activity 
(Robertson et al, 1996). The Type I CPs of the parasite L. mexicana have received 
considerable attention over the last few years as they may be important in the host-
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parasite interaction, are considered to be potential vaccine candidates and provide 
good targets for chemotherapeutic attack (Coombs & Mottram, 1997). One feature 
that distinguishes the Type I enzymes from other CPs of the papain superfamily is the 
presence of a long C-terminal extension (Mottram et al, 1997). It may possibly have 
a role in immune evasion since it has been shown to be highly immunogenic and so 
could potentially divert the host immune response (Martinez et al, 1993). The Type I 
CPs of L .mexicana^ known as CPB, are encoded by 19 cpb gene copies (see figure 
1.2), arranged in a tandem array and are cathepsiu L-like (Mottram et ai, 1996). 
Transfection of different copies of cpb genes into null mutants showed individual 
isoenzymes differ in their substrate preferences (Mottram et al, 1996). This suggests 
that the enzymes have different roles in host-parasite interaction.
CPBl, which is encoded by the first gene in the array, has a truncation in the 
C-terminus and transfection into cpb null mutants resulted in active enzyme 
expression. This enzyme is targeted to lysosomes and is active, showing that the C- 
terminal extension is not essential for activation or correct intracellular trafficking.
CPB2.8 is the enzyme that has been most studied. This is a cpb gene internal 
to the tandem array of the 19 genes. It has been found to restore infectivity to 
macrophages in vitro when it is re-expressed in the cpb null mutant suggesting that it 
is indeed a virulence factor (Mottram et al, 1996). Thus, the other CPBs may be 
targets for novel anti-leishmanial drugs based on specific inhibitors or pro-drugs, 
activatable by amastigote CPs (Rabinovitch, 1989).
The intracellular amastigote form of L. mexicana has a much greater CP 
activity than promastigote forms (Coombs & Mottram, 1997). This high enzyme 
activity may be essential for the survival of the amastigote in the microbicidal 
environment of the host mammalian macrophage.
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Figure 1.2 Schematic representation of the cysteine proteinases encoded by 
the cpb genes of L. mexicana (taken from Coombs & Mottram, 1997). The four 
regions of CPB2.8 are shown and compared with five other CPB isoenzymes on 
the 19-copy cpb tandem array. The number of amino acids present in each region of 
CPB2.8 are shown. The positions of amino acid differences between isoenzymes are 
indicated by a vertical line.
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1.3.6 Leishmanial Type II/III CPs
Two other CP genes have been isolated from L  mexicana: CPA, designated a 
Type II CP is also cathepsin-L like but is encoded by a single-copy gene {cpa) and 
lacks a C-terminal extension (Mottram et al, 1992). However, gene deletion 
experiments have shown that cpa does not compensate for the loss of cpb in a null 
mutant of L. mexicana (Mottram et al, 1996). Furthermore, L. mexicana cpa null 
mutants did not differ significantly from wild-type L. mexicana in groAvth and could 
infect macrophages in vitro while also being able to establish lesions in CBA mice 
(Souza et al, 1994). Thus, cpa does not appear to be essential for infection of the 
host cells. CPC designates the Type III CP, which is a cathepsin B-like enzyme and it 
too is encoded by a single-copy gene {cpc) (Bart et al, 1995). Disrupting both alleles 
of the cpa and cpc genes produced null mutants similar to wild-type parasites in their 
infectivity to mice, even though the cpc null mutant had a lower rate of survival than 
the wild-type parasite in macrophages in vitro (Souza et al, 1994; Bart et al, 1997). 
This suggests that these enzymes are not essential for parasite survival.
The cathepsin L and B-like proteinases do not solely exist in L. mexicana but have 
also been found to occur in several other species including L  major, L. pifanoi and L 
amazonensis (Sakemari et al, 1997).
1.4 IMMUNE RESPONSE IN LEISHMANIASIS
1.4.1 Immunological polarity
Once a T cell response begins to develop along one pathway, either a Th 1 or 
Th 2, it tends to become progressively polarised in that direction (Abbas et al,
1996). Indeed, studies of cutaneous leishmaniasis in inbred mice provided the first
15
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clear demonstration that resistance and susceptibility to an infectious disease 
correlates with anti-microbial Th 1 and Th 2 responses respectively (Heinzel eta l, 
1989).
The ultimate dominance of Th 1 and Th 2 cells in any immune response is at 
least initally due to either interleukin-12 (IL-12) or EL-4 induced T cell differentiation. 
Thus, for example, BALB/c mice can be made resistant to L, major by administration 
of EL-12 or anti-EL-4 during the first week of infection but not later (Heinzel et a l, 
1998). Also, it has been clearly demonstrated that there is an absolute requirement 
for EL-4 for susceptibility to Leishmania mexicana (Satoskar et al, 1995). These 
concepts can be exploited for developing vaccines to parasites by inclusion of certain 
cytokines, for diseases such as Leishmania in which a polarised immune response is 
required.
1.4.2 T cell cytokines important in Leishmania
IL-4 prevents macrophage activation and blocks most of the macrophage 
activating effects of interferon-y (EFN-y), leading to a more disseminated infection 
(Finkelman & Urban, 1992). In contrast, EL-12 stimulates differentiation of CD4^ T 
cells towards a polarised Th 1 phenotype. Dendritic cells are the critical source of 
early IL-12 production following Leishmania infection (Gorak et al, 1998). In 
response to Leishmania infection, which fails to trigger IL-12 production by 
macrophages (Carrera et al, 1996), dendritic cell-T cell clusters may provide the 
micro-environment for initial natural killer (NK) cell activation in response to L. 
donovani infection (Gorak et al, 1998).
In the early phase of the infection, leishmanicidal activity is not triggered in 
resting macrophages that become parasitised. Therefore infected macrophages will
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not present antigens to immune T cells because major histocompatibility complex 
(MHC) class II expression is not upregulated (Antoine et al, 1998). Parasites 
replicate unhindered and the lesion will expand. In the course of infection, focal 
activation of individual infected macrophages may occur (Aebischer et al, 2000)
These cells will be able to present amastigote antigens to parasite-specific Th 1 cells. 
The interacting Th 1 cells will be reciprocally stimulated and due to their secretion of 
IFN-y and tumour necrosis factor-a (TNF-a), will activate neighbouring infected 
macrophages (Abbas et al, 1996).
Eventually, the density of infected macrophages will decline and lesions will 
resolve. In this phase the process becomes inefiScient and will lead to the persistent 
state of the infection where there is a balance between parasite destruction and 
replication (Aebischer et al, 2000 ).
1.4.3 Th 2 type cytokines
IL-4 has a major role to play in the Th 1/Th 2 paradigm which exists during 
Leishmania infection. For example, it has been found that disruption of the murine 
IL-4 gene can inhibit disease progression during L. mexicana (Satoskar et al, 1995). 
IL-4 deficient mice produced more IFN-y than the wild type strain in response to X. 
mexicana infection, which was indicative of a Th 1 response. Furthermore, the 
inhibition of macrophage activating factor (MAF) fi om spleen cells isolated firom mice 
susceptible to Leishmania infection appears to be mediated by IL-4. Anti-IL-4 
antibodies completely abrogated the MAF-inhibiting capacity of culture supernatants 
fi’om spleen cells of susceptible mice (Liew et al, 1989).
Secretion of early IL-4 is decisive in aiding Leishmania infection even in the 
presence of other cytokines such as IL-12 (Himmelrich et al, 1998). It has been
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found that production of IL-4 is necessary only during a short period of time (< 48 
hours) for irreversible Th 2 cell development to occur in susceptible BALB/c mice 
(Himmelrich et al, 1998). It is possible that IL-4 itself appears to inhibit the ability of 
IL-12 to promote Th 1 cell development, possibly by providing a more powerful 
stimulus for Th 2 cell development than IL-12 provides for Th 1 cell development 
(Scott, 1993).
Recent evidence has shown, however, that IL-4 is rapidly produced in 
BALB/c mice after infection with L. major and acts by down-regulating IL-12 
receptor expression on CD4^ T cells resulting in a state of unresponsiveness to IL-12 
(Himmelrich e/fl/., 1998). IL-4 also enhances production of IgE by increasing the 
frequency of B cell isotype switching (Finkelman et al, 1990). Transforming growth 
factor-p (TGF-p) supports differentiation of Th 2 cells and suppresses the 
development of Th 1 cells. TGF-P deactivates macrophages causing a down- 
regulation of inducible nitric oxide synthase (iNOS) and therefore production of nitric 
oxide (NO) (Lohoff et al, 1998). This is important since NO produced this way is 
the most important mechanism by which the macrophage has been demonstrated to 
kill Leishmania in vitro and in vivo (Liew et al, 1990). Recombinant TGF-P added 
to cultures of peritoneal exudate cells (PECs) has been shown to increase L. 
braziliensis replication whereas addition of anti-TGF-P antibody decreases the level 
of infection. TGF-P seems to have a synergistic effect with IL-10, another important 
Th 2 cytokine which is released concomitantly (Barrai <3/., 1993). IL-10 can also 
deactivate macrophages by downregulation of iNOS and is a known negative 
regulator of IL-12 production (Melby et al, 1996). It is induced by phagocytosis of 
Leishmania promastigotes and can inhibit T cell development (Weinheber et al,
1998).
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IL-13 may play a role in L  major infection since BALB/c mice doubly 
deficient for IL-4 and IL-13 were significantly more resistant to L. major infection 
than either of the single cytokine-deficient mutants (Matthews et al, 2000). IL-13 
has also been shown to share many activities with IL-4 and can also utilise the IL-4Ra 
receptor (Matthews et al, 2000). However, it has recently been reported that signals 
mediated by the IL-4Ra are not necessary to induce and sustain an efficient IL-4 
expression and Th 2 polarisation in L. wu/ur-infected BALB/c mice and suggest that 
IL-4Ra -independent mechanisms underlie the default Th 2 development in L. major- 
infected mice (Mohrs et al, 2000).
1.4.4 Th 1 type cytokines
Th 1 cells produce IL-2 and IFN-y among other cytokines but these two are 
the most important for promoting delayed type hypersensitivity (DTH) and in 
Leishmania infection, IFN-y is essential for macrophage activation (Heinzel et al,
1989). IL-12 is produced by macrophages and B lymphocytes and this stimulates 
production of IFN-y fi'om both T and NK cells thus driving Th 1 cell development 
(Scott, 1993). IL-12 also induces TNF-a, granulocyte monocyte-colony stimulating 
factor (GM-CSF) and monocyte-colony stimulating factor (M-CSF) which are 
required for attraction and upregulation of macrophages (Trinchieri, 1995). 
Furthermore, when IL-12 is added, in the presence of allergen, to cultures of 
lymphocytes fi’om atopic patients, it induces IL-2 dependent cell lines that display a 
Th 1 like phenotype, instead of the Th 2 like phenotype observed in the absence of 
IL-12.
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It has also been shown that genetically resistant mice lacking IL-12 are 
susceptible to infection with X. major and mount a polarised Th 2 response (Mattner 
et al, 1996). In Leishmania infection, IL-12 is crucial for cure and required for 
stimulation of a Th 1 response. Its efficacy in eliciting a protective immune response 
in the murine Leishmania model has been demonstrated repeatedly (Scott, 1993). 
Infection of quiescent murine macrophages with X. mexicana amastigotes does not 
induce IL-12 production (Weinheber et al, 1998). Endogenous IL-12 in leishmanial 
infection is presumably triggered by the macrophage T cell interactions and is 
dependent on cross-linking of CD40 on the macrophage with its ligand on the T cell 
(Heinzel et al, 1998). Data indicates that IL-12 production by the macrophage after 
infection with X. mexicana amastigotes is suppressed by a mechanism that is most 
likely to be affecting post-transcriptional events. One plausible explanation for lack of 
expression of IL-12 by infected cells in vivo is that X. mexicana amastigotes may 
engage CR3 or the receptor for IgG upon infection of the macrophage, which inhibits 
IL-12 upregulation when the host cell is activated by cell-cell contact e.g. with a T- 
cell (Weinheber et al, 1998).
IFN-y is essential for activation of macrophages and upregulation of MHC 
class II presentation (Heinzel er a/., 1989). This results in increased antigen 
presentation to T cells as well as inducing macrophages to generate nitrites that can 
kill ingested amastigotes. IFN-y may also be beneficial with regard to its control of 
infection by its ability to inhibit IL-4 production, reducing the clonal expansion of Th 
2 cells (Heinzel et al, 1998). IFN-y works synergistically with TNF-a to induce this 
leishmanicidal activity by inducing iNOS (Liew & O' Donnell, 1993). IFN-y also 
enhances the production of opsonising murine antibodies such as IgG2a which is the
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Th 1 isotype that mediates optimal complement fixation and opsonisation 
(Arulanandam e/a/., 1999).
NK cells have been implicated as the major source of IFN-y during early 
Leishmania infection (Guevara-Mendoza et al, 1997). It is possible that IFN-y 
transcription during the first 24 hours can be attributed to activated NK cells which 
are down-regulated after 7 days and are then presumably replaced by pathogen- 
specific T cells.
Migration inhibitory factor (MIF) may be an important regulatory molecule in 
the induction of nitric oxide. It activates murine macrophages to express NOS and to 
produce high levels of NO in vitro (Cunha et al, 1993).
1.4.5 CD8  ^T cells
A role for CD8^ cytotoxic T cells in the control of cutaneous leishmaniasis has 
been suggested (Fong & Mosmann, 1990). This may be due to direct cytotoxicity or 
through cytokine production such as IFN-y. CD8^ T cells produce IFN-y as well as 
TNF-a, both of which are important in activating macrophages to kill Leishmania. 
Further evidence for CD8^ T cell involvement stems fi'om the fact that a leishmanial 
antigen, gp42 (M-2), is processed in the macrophage cytoplasm and is presented to 
CD8^ T cells via the classical pathway of MHC class I presentation (Kima et al,
1997). It has yet to be determined how gp42 traverses the parasitophorous vacuole 
to enter the cytosol of the host cell, although it is conceivable that some leishmanial 
antigens would be able to access the MHC class I presentation pathway and 
preferentially activate CD8^  T cells.
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1.4.6 Reactive nitrogen intermediates (RNIs)
NO is involved in a variety of biological activities including endothelium- 
related vascular relaxation, platelet aggregation, neurotransmission and macrophage 
killing of tumour cells (Macmicking et al, 1997). NO is very unstable and reacts with 
itself, water and oxygen to generate products collectively known as reactive nitrogen 
intermediates (RNIs) and finally the stable end products nitrite (NO2 ) and nitrate 
(NO3 ).
Macrophages activated in vitro by IFN-y or TNF-a, in the presence of 
Hpopolysaccharide (LPS), or by a combination of both cytokines, developed potent 
leishmanicidal activity and was correlated with the production of NO (Liew et al,
1990). The mechanism by which NO is cytotoxic is unknown. It may be similar to 
biochemical mechanisms identified in mammalian cells, e.g. loss of enzymatic function 
due to nitrosylation of catalytic iron - it therefore blocks cellular respiration by 
complexing with the iron in electron transport proteins. Recently, it has been shown 
that NO can inhibit the papain-like CP of P. falciparum, which is involved in 
haemoglobin degradation (Olson et al,. 1999). This effect is likely to be attributed to 
nitrosylation of the Cys-25 catalytic residue. Alternatively, reaction of the superoxide 
anion with nitric oxide can form peroxynitrite. Protonated peroxynitrite undergoes 
homolytic fission to yield highly toxic oxidant products such as the hydroxyl ion.
iNOS activity is crucial for the control of Leishmania persisting in 
immuno competent hosts after resolution of the primary infection (Stenger et al,
1996). There is Hfe-long expression of iNOS at the original skin lesion, and in the 
draining lymph node of long-term infected mice (Stenger et al, 1996). The host 
immune response will produce cytokines that can induce NOS, such as IFN-y, TNF-a 
and MIF but can also inhibit iNOS production via IL-4, TGF-P and IL-10 (Bogdan &
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RoUinghoff, 1998). This phenomenon is consistent with the sophisticated interplay 
characteristic of important biological systems.
1.4.7 Reactive oxygen intermediates (ROIs)
Within the lysosomes of the macrophage, a variety of hydrolases such as 
lysozyme, phosphoUpase Ai and proteases can participate in the destruction of the 
entrapped organism. Besides the oxygen-independent lysosomal hydrolases, 
macrophage lysosomes contain oxygen-dependent enzymes that can produce ROIs 
such as the superoxide radical (O2 ), hydrogen peroxide (H2O2), singlet oxygen CO2) 
and the highly reactive hydroxy radical (GIT).
These products and others are produced from the respiratory burst that 
accompanies the increased oxygen consumption and ATP generation needed for 
phagocytosis. However, it is well documented that Leishmania parasites are able to 
resist inactivation by the highly reactive oxygen radicals due to the presence of a 
dense glycocalyx and LPG molecules on the surface of the parasite. However, it has 
been recently reported that LPG is not a virulence factor in L. mexicana infeciton 
(Ilg, 2000) and it is more likely that the GIPL's are essential in protecting against the 
respiratory burst (McConville & Menon, 2000).
1.4.8 Parasite dose
It is not only the presence of cytokines that promote the Th 1/Th 2 paradigm 
in leishmaniasis but the contribution of several factors together including parasite 
dose. There is a suggestion that the resulting immune response to L. major is 
independent of infection route, strain of host or parasite (Menon & Bretscher, 1998), 
However, a recent study has reported that antigen dose can determine T helper subset
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development by regulation of the CD40 ligand (CD40L) through high-dose antigen 
inducing Thl development by up-regulation of CD40L, w^hereas low -^dose antigen 
stimulation fails to induce CD40L and promotes Th 2 development (Ruedl et al,
2000).
1.4.9 Parasitophorous vacuoles
L. mexicana amastigotes exist Avithin macrophages inside a parasitophorous 
vacuole (PV) (Alexander & Vickerman, 1975), a large fluid-filled vesicle that 
harbours many parasites and has been characterised as a late stage endosome (Russell 
et al, 1992). The PV intersects readily with the endocytic pathway of the 
macrophage and so is potentially exposed to degradative activities of the lysosomal 
contents such as the cathepsins B, C and L. However, it appears that following 
targeted fusion of the PV with endosomes, antigens derived from amastigotes become 
trapped in a compartment which either lacks the MHC molecules or does not allow 
the transport of the MHC-peptide complexes to the cell membrane (Bogdan & 
RoUinghoff, 1998).
Amastigotes of L. mexicana and other species (X. amazonensis, pifanoi and 
donovani) are not free in the PVs but are tightly bound to the membrane of the 
organelles via the posterior pole (Antoine et u/., 1998) Furthermore, PVs of X. 
mexicana tend to be large and one of the main factors involved in formation of these 
is the secretion of proteophosphoglycan from intracellular amastigotes (Peters et al,
1997). This particular species of Leishmania can also endocytose macromolecular 
materials via two independent routes (Schaible et al, 1999). Data suggests that X. 
mexicana PVs accumulate material by exploiting the cellular recycling machinery or 
through the host cell's organic anion transporter.
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Endocytosis of certain host molecules in the PVs, such as MHC molecules, 
would be advantageous to the parasite and could limit antigen presentation of parasite 
antigens. Indeed, internalisation of MHC molecules seems to be a selective process as 
neither lysosomal-associated membrane protein (LAMP) or macrosialin have been 
detected within parasites (Antoine et ai, 1998).
1.4.10 Antigen presentation
Peptide fragments derived from extracellular proteins usually bind to MHC 
class II molecules whereas MHC class I molecules associate with endogenously 
synthesised peptides generated in the cell cytosol. Macrophages express only low 
levels of MHC class II molecules until stimulated to do so by IFN-y. Expression is 
antagonised by IL-10 which is physiologically important in Leishmania infection 
(Abbas et al, 1996).
Parasitised macrophages are thought to be an essential source of antigens for 
the stimulation of Leishmania-%pQc\^c CD4^ T cells. However, analysis of 
amastigotes suggests that they avoid antigen presentation by their host cell by limiting 
the release of potential antigens (Russell et al, 1992). Once within the macrophage, 
Leishmania amastigote antigens are sequestered from the MHC class II pathway of 
antigen presentation by targeted fusion of the PV with certain endocytic 
compartments (Kima e ta l, 1996). Thus a do wn-regulation of parasite antigen 
presentation via the MHC class II pathway occurs and evidence indicates that the 
Leishmania-mSQQtQÔ. macrophage becomes refractory to cytokine (IFNry) activation. 
Hence the parasite niche becomes relatively obscured from immunological view 
allowing persistence of parasites and optimising for transmission and perpetuation of 
the life-cycle (McMahon-Pratt et al, 1998).
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Inhibition of MHC class II presentation cannot be attributed to unavailability 
of MHC class II molecules on the surface of infected cells (Antoine et al, 1998) nor 
is it likely that inhibition of antigen presentation by infected parasites is due to 
extensive phagocytosis of parasites since experiments using particulate materials do 
not affect antigen presentation (Fruth et al, 1993).
It is therefore important to determine the impact of Leishmania infection on 
the fate of the chaperone molecule, invariant chain (li), as this molecule plays a 
fundamental role in antigen presentation (Antoine et al, 1998). The invariant chain 
may be required for proper folding of class II molecules. Also, the presence of 
invariant chain can effectively block the peptide-binding cleft of the MHC molecule 
thereby preventing binding of any endogenous peptides that may be present in the 
endoplasmic reticulum. Under normal conditions, the PV-associated class II 
molecules are devoid ofli. Incubation o ff. amazonensis-mÎQcXQd macrophages with 
CP inhibitors leads to the detection ofli in > 60% of PVs (Antoine et al, 1998). 
Possibly, protease inhibitors block PV-associated enzymes that in normal conditions 
eliminate the li chains.
1.4.11 CPs in immuno-modulation
It is thought that MHC class II molecules are internalised by amastigotes and 
degraded within megasomes by CPs of parasite origin - endocytosis and degradation 
of MHC class molecules by L. amazonensis could be a means of circumventing the 
host’s immune system (De Souza Leao et al, 1995). A role for CPs in li degradation 
is also consistent with a number of other studies using proteinase inhibitors on intact 
antigen presenting cells (Bennet et al, 1992). Leishmanial CPs may therefore play an 
important role in induction of immunological polarity.
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Beyrodt et a l (1997) found that mice immunised with a purified CP, p30, 
were protected against infection by L. amazonensis. Subsequent cytokine analysis of 
T cell supernatants stimulated with p30 indicated that Th 1 is the subset involved in 
the lymphoproliferative responses to the antigen. The cytokines IFN-y and IL-2 were 
secreted while IL-4, IL-5 and IL-10 were absent suggesting a protective Th 1 
response.
Studies with L. mexicana mutants lacking CP genes, cpb (Acpb) or both cpa ( 
which encoded the Type II CP) and cpb {Acpa/cpb) have shown that the Th 1/ Th 2 
profile can be altered by the deletion of the cpb genes (Alexander et al, 1998). 
Immunological analysis of antibody isotype during infection and splenocyte IFN-y and 
IL-4 production, following stimulation with Leishmania antigen, indicated that there 
was a significant shift fi’om a predominantly Th 2-associated response in mice 
inoculated with wild-type Leishmania to a Th 1 response in mice infected with Acpb 
or Acpa/cpb mutants. In addition, the null mutants produced some protection against 
subsequent challenges and this also implicates leishmanial CPs in modulation of the 
immune response providing strong encouragement that CP-deficient L. mexicana are 
candidate attenuated live vaccines.
CPs are also found extracellularly in the tissue presumably as a result of 
macrophage rupture and appear to persist in lesion tissue, where they may damage 
host cells and the extracellular matrix since it has been found that cathepsin B and L 
can also degrade connective tissue such as collagen (Ilg et al, 1994).
The CPs may be potentiating Th 2 responses by increasing IL-4 production 
since it has been hypothesised that some proteolytic enzymes, produced in large 
quantity by many helminth parasites, are triggers of cytokines that induce a Th 2 
response (Pearce et al, 1991). Thus, leishmanial CPs may promote disease
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exacerbation by promoting a Th 2 polarisation. This, however, may be a species- 
specific phenomenon. For example, results suggest that whereas IL-4-driven Th 2 
lymphocyte expansion is necessary for disease progression and inhibition of a 
protective response in cutaneous infection caused by L. mexicana, such a role for Th 
2 cells in visceral leishmaniasis caused by L. donovani cannot be demonstrated 
(Satoskar et al, 1995). This clearly has implications for the CPs and their effects on 
the host immune response in different species.
1.5 ANTI-LEISHMANIAL VACCINES
Since drug therapy to the host is usually very toxic and there exists the chance 
that drug resistance can form, control of leishmaniasis would ideally be vaccine-based. 
In recent years, the search for a safe and effective Leishmania vaccine has intensified 
with the identification of protective protein immunogens which could be cloned and 
produced in large scale (Rivier et al, 1999). However, the outcome of vaccination 
against Leishmania infections is critically dependent on the nature of the adjuvant, the 
site of vaccination, the strain of mice used for the experimentation and the form of 
antigen used (Rivier et al, 1999). Transition fi’om mouse models to clinically useful 
vaccines is also a challenge.
1.5.1 Attenuated parasite vaccines
Attenuated organisms can infect the recipient and stimulate an immune 
response but they do not generally cause disease (Titus et al, 1995). Parasites can be 
attenuated by simply growing them in animals or in prolonged or repeated culture or 
under unusual conditions until suitable mutants are obtained (Gorczynski, 1989).
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More recently, targeted gene disruption has also been used for attenuation of parasites 
(Alexander et al, 1998).
Live parasite vaccines have several advantages over killed vaccines (Abbas et 
al, 1994). With a live vaccine, the attenuated parasites multiply within the body so 
that a sufficient dose of antigen can be delivered in one injection of low dose.
Normally, live replicating micro-organisms are needed to induce long-lasting 
immunological memory due to infected cells stimulating production of cytotoxic and 
helper T lymphocytes and thek associated memory cells (Titus et al, 1995). The 
drawback of live vaccines includes the risk that the parasite may, through genetic 
mutation, either lose its potency (so that the vaccine is ineffective) or worse stiU, 
regain its pathogenicity.
Dihydrofolate reductase-thymidylate synthase {dhfr-ts) is an essential 
metabolic gene and targeted disruption of this to yield dhfr-ts null mutants of L. 
major have been generated (Titus et al, 1995). These attenuated parasites were 
capable of eliciting substantial resistance to a subsequent challenge with virulent L. 
major when injected into the most susceptible mouse strain and ultimately were 
incapable of causing disease.
As already discussed, the CPs of L. mexicana may play a role in host 
immunomodulation and CP-deficient mutants have attenuated virulence for mice and 
potentiate a Th 1 type response as opposed to the normally susceptible Th 2 response 
seen in wild type infections (Alexander et al, 1998). Infection with these attenuated 
organisms resulted in a significant reduction in parasite-specific antibody titres, which 
resembles the immunologic status of humans at the resistant end of the disease 
spectrum. The increase of IFN-y, decrease in IL-4 and absence of lesion formation is
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in stark contrast to that seen in wild type infection and suggests that CP-deficient 
parasites may be good candidate live vaccines.
1.5.2 Subunit vaccines
The aim of subunit vaccines is to stimulate the immune response with a 
specific component of the parasite, while avoiding giving other components that cause 
unwanted or dangerous side effects. Once the gene that contains the information 
needed to make such an immunogenic protein of a microbe has been identified, this 
opens the way for its manufacture using recombinant DNA technology and protein 
purification.
gp63 was the first polypeptide fi'om Leishmania shown to mediate protection 
against cutaneous leishmaniasis when immunised as a liposome formulation (Russell 
and Alexander, 1988). Protection with this antigen was recently shown to be more 
effective in the presence of IL-12 as an adjuvant (Aebischer et al, 2000).
IL-12 as already detailed, is efficacious in stimulating a Th-1 response. Its 
efficacy for eliciting a protective immune response in the murine Leishmania model 
has been demonstrated repeatedly (Afonso et al, 1994; Scott et al, 1993). When 
C57BL/6 mice were immunised with a recombinant CP (misfolded CPB2.8) and IL- 
12, they only developed small lesions and healing occurred uniformly in all animals 
(Aebischer et al, 2000). Cured mice did not show any recurrence of disease for over 
a year. Conversely, \vithout IL-12, the proteinase afforded no protection to challenge 
with L. mexicana and in this respect, similar results have been reported, for 
immunisation with a proteinase fi'om L. amazonensis, where the enzyme enhanced 
parasite growth in the footpads and draining lymph nodes of mice infected with L. 
pifanoi (Soong et al, 1995).
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Therefore, it is apparent that choice of adjuvant is important in overall 
efficiency of subunit vaccination and should be considered carefully as one that would 
preferentially stimulate Th 1 helper cells.
1.5.3 DNA vaccines
DNA vaccines consist of a bacterial plasmid with a strong viral promoter, the 
gene of interest and a polyadenylation/transcription terrnination sequence (Donnelly et 
al, 1997) Plasmid is grown in bacteria, purified, dissolved in a saline solution and 
then simply injected into the host. The DNA plasmid is taken up by the host cells 
where the encoded protein is synthesised. Since the plasmid is without an origin of 
replication that is functional in eukaryotic cells, the plasmid can neither replicate in the 
mammalian host nor integrate within the chromosomal DNA of the animal. Because 
DNA vaccines result in expression of antigens in situ, presentation of antigenically 
relevant epitopes to the immune system may be more readily attainable than with 
subunit vaccination.
Immunisation of BALB/c mice with a plasmid encoding gp63 of L. major 
induced a helper T cell response with a dominant Th 1 phenotype. Significant 
amounts of IL-2 and IFN-y were produced but no IL-4, when spleen and lymph node 
cells from immunised mice were cultured with L  major antigens in vitro (Xu & Liew, 
1995).
Vaccination with DNA encoding the immunodominant LACK ( Leishmania 
homologue of receptor of activated C kinase) parasite antigen confers protective 
immunity to mice infected with L. major. Control of disease progression and parasite 
burden in mice vaccinated with LACK DNA was associated with enhancement of 
antigen-specific IFN-y production (Gurunathan et al, 1997). It is possible that
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vaccination with DNA induces protection to L. major by a somewhat different 
mechanism than vaccination with protein plus adjuvant since DNA vaccination is 
particularly useful for the production of cytotoxic T cells. However, what is 
encouraging for vaccine development is the way m which it is possible to induce a 
protective immune response against Leishmania by several modes of vaccination. 
Whether this can be applied to the level of human Leishmania infection remains to be 
seen.
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CHAPTER 2
Materials and Methods
2.1 MATERIALS
All materials used in this study were purchased from Sigma-Aldrich, unless 
stated otherwise,
2.1.1 Culturing ofZ. mexicana promastigotes
L. mexicana MNYC/BZ/62/M379 promastigotes were grown in sterilised 
HOMEM medium supplemented with 10% (v/v) heat-inactivated foetal calf serum 
(HI-FCS) and 50 pg/ml neomycin (Gibco-BRL) at 25°C. Parasite cultures (Tables 1 
& 2) were grown until stationary phase which occurred 8-10 days after seeding with 
parasites to 1 x lOVml. The parasites were considered to have reached stationary 
phase when the cell density, measured using an improved Neubauer 
haemocytometer, had dropped by 10 % from the previous day (Mallinson & 
Coombs, 1989). At this point, providing low sub-passage promastigotes were used, 
the culture contained a high level of metacyclic-like promastigotes (>50 %), 
determined by the majority of promastigotes being motile (Mallinson & Coombs, 
1986).
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Genetic manipulation Denoted Phenotype during in vitro and in vivo 
infection
None Wild-type
(WT)
Infects macrophages in vitro and produces 
rapidly growing, non-healing lesions in 
BALB/c mice (Mottram et al, 1996).
Deletion of cpb array A,cpb (N53 
in cytokine 
data)
Reduced inactivity to macrophages in vitro 
by 80 % and produces slow-growing lesions 
in BALB/c mice (Mottram et al, 1996).
Deletion of cpb array; re­
integration of metacyclic 
CPB2 with native 
(metacyclic) promoter
GL165 Unknown
Deletion of cpb array; re­
integration of amastigote 
CPB2.8 with native 
(amastigote) promoter
GL166 Unknown
Deletion of cpb array; re­
integration of metacyclic 
CPB2 with chimaeric 
(amastigote) promoter
GL167 Unknown
Deletion of cpb array; re­
integration of amastigote 
CPB2.8 with chimaeric 
(metacyclic) promoter
GL168 Unknown
Deletion of cpb array; re­
expression of cpb array 
using a cosmid shuttle 
vector
GL263 Unknown
Table 1: Construction ofZ. mexicana single null parasite mutants
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Genetic manipulation Denoted Phenotype during in vitro and in vivo 
infection
Deletion of cpa and cpb 
genes
Acpb/cpa Rate of infectivity to macrophages in vitro 
is similar to Acpb (Mottram et al, 1996) 
but did not produce lesions in mice 
(Alexander et flt/., 1998).
Deletion of cpa and cpb 
genes; re-integration of 
metacyclic CPB2 with 
native promoter
GL438 Unknown
Deletion of cpa and cpb 
genes; re-integration of 
amastigote CPB2.8 with 
native promoter
GL439 Unknown
Table 2: Construction of L .mexicana double null CPB parasite mutants
2.1.2 Culturing ofZ. mexicana amastigotes
Growth in vitro of amastigote-like forms (axenic amastigotes) involved sub­
passage in Schneider’s Drosophila medium containing 20% (v/v) foetal calf serum at 
pH 5.5 and 32°C. The following antibiotics were added in combination, as 
appropriate, for maintenance of the drug-selectable markers in the CP-deficient 
mutants: hygromycin B at 50 pg/ml, phleomycin (Cayla, France) at 10 pg/ml, 
puromycin at 10 pg/ml or G418 (Geneticin) (Gibco-BRL) at 25 pg/ml. The 
amastigotes were washed three times in phosphate buffered saline (PBS) (0.07 M 
sodium chloride, 0.075 M disodium hydrogen orthophosphate and 0.05 M sodium 
dihydrogen orthophosphate, pH 7.4), before infection of mice.
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2.2 IMMUNOLOGICAL MATERIALS
Lipopolysaccharide (LPS) (from Salmonella abortus equi) and IFN-y were 
purchased from Sigma-Aldrich and Calbiochem, respectively. LPS was diluted with 
endotoxin-free water (Sigma-Aldrich) to make a stock solution of 2 mg/ml and stored 
frozen at -20°C. IFN-y was also diluted with endotoxin-free water to yield a stock 
solution of 1000 U/ml and immediately aliquoted before storage at -20°C.
Recombinant IL-12 (a kind gift from Prof. Phil Scott, University of 
Pennsylvania) was diluted with sterile PBS to a stock solution of 2.5 p,g/ml and 
aliquoted before storage at -20°C.
2.3 BIOCHEMICAL METHODS
2.3.1 Media composition for growth of bacterial cultures
Luria-Bertani (LB) medium was used to culture E. coli M15pREP4 expression 
strain transformed with pGLlSO (pGLlSO encodes a N-terminally Hise-tagged pro­
form of CPB2.8 lacking the C-terminal extension (His6-CPB2.8ACTE)). 10 g sodium 
chloride, 5 g yeast extract (Difco) and 10 g bacto-tryptone (Oxoid) were dissolved in 
1 litre of double-distilled, deionised water (dddHzO) and the pH adjusted to 7.2. The 
medium was then autoclaved at 126°C for 30 minutes and allowed to cool before 
inoculation with the E. coli strain detailed above.
2.3.2 Determination of protein concentration
Protein concentration was determined using the BioRad Protein assay kit, based 
on the method of Bradford (1976). Bovine gamma globulin was used as the relative
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protein standard. For each set of samples, a standard curve was constructed using 
0.05 - 0.5 mg/ml protein, and absorbances read at 620 nm.
2.3.3 Dialysis of protein samples
Visking tubing was boiled in 10 mM sodium bicarbonate pH 8.0, 1 mM EDTA 
for 15 min to remove chemical contaminants. It was then rinsed and boiled in 
dddHiO for a further 10 min, before storage in 100 % (v/v) ethanol. The tubing was 
rinsed thoroughly in dddH20 before dialysis was carried out at 4°C, overnight, at a 
minimum ratio of 1:100 (sample: dialysis buffer). The composition of the dialysis 
buffer depended on the next stage of the experiment; each buffer will be described in 
the relevant results chapters.
2.3.4 Protein sample preparation for PAGE
Samples were prepared by 1:1 dilution with LaemmH sample buffer (125 mM 
Tris/HCI, pH 6.8, 4% (w/v) SDS, 5% (v/v) 2-mercaptoethanol, 20% (v/v) glycerol 
and 0.2% (w/v) Pyronin Y). Samples were then boiled for 5 min unless the samples 
were to be analysed for proteolytic activity using gelatin SDS-PAGE.
2.3.5 Concentration of protein samples for SDS-PAGE
For SDS-PAGE involving dilute protein samples, or those which contained 
potentially interfering material (e.g. guanidine hydrochloride), trichloroacetic acid 
(TCA) precipitation was carried out (Hames, 1990). Typically, samples were diluted 
to 100 pi before adding 100 pi of 10% (w/v) TCA and vortexing. The samples were 
then frozen at -20°C for 1 hour before centrifiiging at 10,000 g in a bench top 
centrifiige at room temperature for 15 min. The supernatant was removed and the
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pellet washed with 100 pi of ice cold acetone to remove any precipitated salt. The 
pellet was left to dry before resuspending in Laemmli sample buffer.
2.3.6 SDS-PAGE
L. mexicana native and recombinant proteins were evaluated using the 
discontinuous SDS-PAGE system as described by Laemmli (1970). 10% (w/v) mini 
acrylamide resolving gels (0.75 mm thickness), were cast, loaded and run using the 
Bio-Rad Mini-Protean II dual slab cell system. Gibco Benchmark Protein Ladder 
molecular weight markers were routinely run on polyacrylamide gels so that estimates 
of protein molecular weights could be made. Following electrophoresis, gels were 
stained overnight in Coomassie Blue stain (0.1% (w/v) Coomassie Blue R-250, 7% 
(v/v) acetic acid, 40% (v/v) methanol) and then de-stained vrith 7% (v/v) acetic acid 
and 40% (v/v) methanol until the background of the gel was clear.
2.3.7 Analysis of proteinase activity using gelatin SDS-PAGE
Gels were prepared as above except with co-polymerisation of 0.2% (w/v) 
gelatin (fi'om porcine skin) in the resolving gel as a substrate for proteinases. After 
electrophoresis, the gels were immersed for 30 min in 30 ml of 2.5% (v/v) Triton X- 
100, at 37°C, to remove SDS and allow proteolytic activity to be restored. Proteinase 
activity was developed by washing the gels for 30 seconds in tap H2O and then 
immersing the gels in incubation buffer (0.1 M sodium acetate, pH 5.5 containing 1 
mM dithiothreitol (DTT)) for 2 hours at 37°C. The bands were visualised by 
subsequent staining in Coomassie Blue stain for 1 hour before de-staining as detailed 
in section 2.3.6.
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2.3.8 Analysis of proteinase activity using fluorogenic substrates
Proteolytic activity of CPs was assessed by running standard SDS-PAGE gels 
as above and after washing in dddH20, incubating the gels in 0.1 M sodium acetate, 
pH 5.5, containing 1 mM DTT and a fluorogenic substrate, Suc-Leu-Tyr- (Suc-LY) 
and/or Bz-Phe-Val-Arg- (BzFVR) amino 4-methyl coumarin at a final concentration 
of 25 pM. The incubation buffer was warmed to 37°C before addition of the 
substrate and gels were shaken for 10 min before the activity bands were visualised 
using a UV transilluminator (UVP Inc.).
2.3.9 Immunoblotting
Proteins, after resolution by SDS-PAGE, were transferred to and immobilised 
on a matrix for subsequent immunological detection (Towbin et aL, 1979). Proteins 
were transferred on to 0.45 pm polyvinylidene difluoride (PVDF) membranes at 100 
V for 45 minutes using Bio-Rad Trans-Blot electrophoretic transfer apparatus in 
transfer buffer (25 mM Tris, 190 mM glycine, pH 8.2, 0.02% (w/v) SDS, 20% (v/v) 
methanol). The non-fixative stain, Ponceau S, was used to determine efficiency of 
transfer to the nitrocellulose and to allow identification of molecular weight markers.
After transfer, the membrane was blocked with wash buffer (0.1% Tween 20 
(v/v), 0.1% (w/v) gelatin, 20 mM Tris/HCI, pH 7.6, containing 137 mM NaCl) plus 
5% (w/v) non-fat milk (Marvel) (designated blocking buffer) overnight at 4°C. The 
overnight blocking buffer was decanted and the membrane was incubated for 4 hours 
at 4°C in anti-seiaim relevant to the particular experiment, at the dilutions given in 
Table 3.
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Sample being analysed Primary
Ab
dilution
Source of primary Ab Secondary Ab- 
HRP dilution
CPB2.8ACTE 1:2000 rabbit anti-CPB2.8ACTE 
(enzyme was purified from 
Nf-agarose column)
1:2000 
(purchased from 
SAPU, Carluke)
L. mexicana Wild Type 1:5000 Serum from Z. mexicana- 
infected mice
1:10,000
L. infantum Wild Type 1:2000 Serum from Z. infantum- 
infected dogs
1:50,000
Table 3: Dilutions of anti-sera and secondary antibodies used for Western
blotting
The membrane was washed three times for 10 min with wash buffer, and then 
incubated in the appropriate secondary antibody conjugated to horseradish peroxidase 
(HRP), at the given dilution, for 1 hour at room temperature. Following a further 
wash step, the membrane was developed using enhanced chemiluminescence western 
blotting reagents as described by the manufecturer (Amersham Pharmacia).
2.3.10 Enzyme assay using a peptidyl p-nitroanilide substrate
Proteinase activity was quantitated by measuring hydrolysis of the peptidyl-p- 
nitroanilide substrate, Bz-Pro-Phe-Arg Nan (BzPFR-Nan) (0.1 mM),
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spectrophotometrically at 37°C in 0.1 M sodium phosphate buffer, pH 6.0, containing 
10 mM DTT. The molar extinction coefficient of 4-nitroaniiine was taken to be 9500 
M'^cm'  ^at 405 nm. 5 pi of enzyme solution was added to 95 pi of buffer, incubated 
at 37°C for 10 min and absorbance was read at 405 nm. The activity of the enzyme 
was then calculated according to the following equation.
Aa/ 10 min x 1000 x i  = activity of enzyme in mmol.min.mf^
9.5 X 10^  vol. assayed 100
in pi
where Aa/ 10 min = change in absorbance over 10 min at 405 nm,
9.5 X 10^  = molar extinction coefficient of 4-nitroaniline.
2.3.11 Active site titration of CPB2.8ACTE
The method of Barrett and Kirschke (1981) was used for active site titration 
using /7'an5-epoxysuccinyl-L-leucylamido-(4-guanidino)-butane (E-64). Briefly, pure, 
dry E-64 was dissolved in dddHzO to give a stock solution of 1 mM and stored at - 
20°C. Working solutions of 1-10 pM concentration were prepared as required. 25 pi 
of enzyme solution (CPB2.8ACTE in PBS, pH 6.0) was added to 25 pi of 1-10 pM of 
E-64 and incubated at 37°C for 30 min, with gentle agitation. 10 pi of this reaction 
mixture was added to the buffer solution containing substrate, BzPFR-Nan. A linear 
plot of activity against E-64 molarity reaches zero activity at the molarity of the 
enzyme solution. Some of the inhibited enzyme was also tested for CP activity by 
gelatin SDS-PAGE. Excess E-64 was removed by overnight dialysis against PBS, pH 
6.0, at 4°C,
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2.4 OTHER METHODS
Details of other methods are given in Chapters 3-6 as appropriate.
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CHAPTER 3
Purification and activation of recombinant CPB2.8ACTE 
expressed in Escherichia coli
3.1 INTRODUCTION
The difficulty of obtaining quantities of pure enzyme from the relatively small 
amounts of parasite material that are easily available has limited research in the past 
but recent advances in molecular technology mean that it is now possible to express 
cloned parasite genes in heterologous systems such as Escherichia coli. This 
provides for a source of easily purifiable protein which can be utilised for kinetic and 
immunological studies, X-ray crystallography and general characterisation with 
regard to the protein's structure and function. There are several general 
considerations when embarking on the production of recombinant proteins.
3.1.1 Inclusion bodies
One frequent outcome of the expression of recombinant genes in E. coli is the 
accumulation of insoluble aggregated protein in inclusion bodies (Chaudhuri, 1998). 
This phenomenon occurs because although the recombinant enzyme possesses the 
correct amino acid sequence, it may not fold into the native structure. Moreover, the 
natural conformation of the recombinant enzyme may require modification by 
proteinases or glycosyl transferases, which are lacking in E. coli but present in other
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expression systems such as yeast expression systems, which are eukaryotic 
(Chaudhuri, 1998).
Fermentation temperature is a major factor affecting formation of inclusion 
bodies; growth at a lower temperature may result in soluble protein rather than 
aggregation into an insoluble complex (Cardamone et ai, 1995). Other important 
factors include the way in which stimulation of expression of recombinant protein is 
carried out such as choice of medium for bacterial growth and subsequent protein 
production (Chaudhuri, 1998). The over-expressed protein is the predominant 
constituent of inclusion bodies and may accumulate in these refractile bodies at levels 
of greater than 25% of total cell protein.
The production of recombinant proteins as inclusion bodies, although 
frequently considered a disadvantage, has a number of advantages; increased levels of 
protein can accumulate and it may facilitate the isolation of proteinase-sensitive 
proteins since inclusion bodies are resistant to proteinases (Marston, 1986). The 
main disadvantage is that the protein requires refolding into its native state. This can 
be difficult to achieve satisfactorily so that overall productivity of active protein can 
be poor (Chaudhuri, 1998).
Recovery of the desired product requires the inclusion bodies to be solubilised 
and the protein denatured in chaotropic solvents such as concentrated urea or 
guanidine hydrochloride (Marston, 1986). During inclusion body formation, it is very 
likely that incorrect disulphide bonds have been formed and these must be disrupted 
using reducing agents such as dithiothreitol or p-mercaptoethanol, usually in the 
presence of EDTA (Chaudhuri, 1998). By maintaining these conditions in the
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refolding buffer, formation of incorrect disulphide bridges is minimised. Refolding is 
stimulated by removal of dénaturant, for example by dialysis (Cardamone et al,
1995). This can lead to the recovery of a correctly folded and biologically active 
protein product but the yield varies considerably with the protein being used.
3.1.2 Washing of inclusion bodies
It is necessary to recover the inclusion bodies away from the soluble cell 
components and other cell contaminants. Recovery of recombinant protein during 
renaturation, has been reported to be much higher when carried out with purer 
protein preparations, since contaminants such as components of bacterial cell walls 
can interfere with protein folding (Cardamone et at., 1995). Analysis of inclusion 
bodies of E. coli has indicated that all contain some contaminants m common, 
irrespective of the cloned gene, promoter, plasmid vector, fermentation regimen or 
media composition used (Hartley & Kane, 1988). These contaminants include 
subunits of RNA polymerase, plasmid DNA, a combination of outer membrane 
proteins and more importantly, bacterial proteinases (Hartley & Kane, 1988).
The inclusion bodies can be washed to aid recovery of the desired protein.
The addition of Triton X-100 and p-octyl glucoside removes contaminating 
proteinase activity and so this should prevent any degradation of the recombinant 
proteins duimg inclusion body extraction (Babbit et al., 1990). The addition of low 
concentrations of urea buffer solubilises E. coli membrane proteins in the presence of 
EDTA, Tris/HCI and Triton X-100 but does not solubilise the inclusion bodies. This
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leaves the recombinant protein intact while potential membrane contaminants are 
removed.
When the recombinant enzyme is to be used for immunological studies, the 
removal of lipopolysaccaride (LPS) is essential and an important aim of purification. 
However, the use of specific chromatographic steps coupled with the use of pyrogen- 
fi'ee water and maintenance of equipment in a pyrogen-fi'ee state usually reduces the 
level of LPS to an acceptably low level (Marston, 1986).
3.1.3 Renaturation of the recombinant protein
There are several theories which explain the process of protein refolding and 
one such model suggests that refolding follows a hierarchical process in which simple 
structures are formed first, giving rise to a stable framework of secondary structures 
(Cardamone et al., 1995). Secondary structure of proteins is formed at an early stage 
in the folding process providing a scaffolding on which the remaining parts of the 
polypeptide chain can arrange themselves into a dense and low solvent-accessible 
surfrce area (Jaenicke, 1991). Tertiary structure is then assembled by eliminating 
water from the hydrophobic core as a consequence of salt linkages occurring 
between acidic and basic residues, hydrophobic aggregation of the aliphatic and 
aromatic amino acids, and hydrogen bonding between polar and charged amino acids. 
As a rule, the 3-D structure of a protein is fully determined by its amino acid 
sequence and the solvent environment; it occupies the state of minimum energy while 
disulphide bonds stabilise rather than determine the spatial arrangement of the 
polypeptide backbone (Jaenicke, 1991).
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The formation of protein disulphides can proceed either by enzymatic catalysis 
or by uncatalysed thiol-disulphide exchange (Wetlaufer, 1984). The non-enzymatic 
system employs thiol-disulphide exchange reactions between proteins and low 
molecular weight thiols and/or disulphides e.g. glutathione (Creighton, 1984). 
Methods for renaturation are generally very slow, give low yields and are protein- 
specific. Effective renaturation requires the removal of the denaturing buffer under 
conditions where the major fraction of the desired protein can refold into the active, 
native conformation. Chelating agents such as EDTA are also added to remove trace 
metals capable of catalysing oxidation and to prevent side reactions that may lead to 
the eventual irreversible covalent inactivation of the protein (Cardamone ei al.,
1995). Temperature must also be controlled, as temperatures greater than 25°C can 
encourage aggregation.
Protein concentration is extremely important and dilution of the protein must 
be such that intramolecular interactions occur in preference to intermolecular 
interactions. Reduced proteins have a strong tendency to aggregate thus oxidative 
renaturation must be carried out in low protein concentrations (Wetlaufer, 1984). 
With protein concentration in mind, it is important to consider that the refolding 
process has a parallel reaction. The folding intermediates have a tendency to 
aggregate rather than to refold as the exposed hydrophobic patches interact 
(Chaudhuri, 1998). Thus, renaturing protein molecules in isolation from each other 
reduces aggregation and this is the principle of dilution facilitating effective 
renaturation.
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3.1.4 Renaturation of CPs
The probability of polypeptide chains possessing many cysteine residues 
folding properly is very low and so obtaining the correct configuration constitutes a 
significant challenge in recovering the native conformation of the protein firom the 
solubilised inclusion bodies (Kuhelj et al., 1995). There is a complication to 
successful refolding of CPs in that, by definition, they have at least one fi-ee cysteine 
residue but also disulphide bridges (Taylor et al., 1992). It has been found that any 
refolding regime that produces activatable pro-papain or papain must produce three 
disulphide bridges fi’om the correct pairs of cysteines and leave the active site cysteine 
in a non-oxidised form able to take part in catalysis (Taylor et al., 1992).
3.1.5 Aims
The production of pure, active, recombinant CPB2.8ACTE was the main 
objective of the work reported in this chapter but the system was also to be optimised 
for purification of other leishmanial CPs including CPA and CPC of L. mexicana. 
Purification of an L. infantum CPB with the full C-terminal domam was also an aim.
3.2 MATERIALS AND METHODS
3.2.1 Growth of large-scale expression cultures of Z. coli
10 ml of Luria-Bertani broth containing 100 pg/ml ampicillin and 25 pg/ml 
kanamycin was inoculated with a single colony of E. coli M15pREP4 containing the 
expression plasmid pQE-30 and grown at 37°C overnight with vigorous shaking.
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200 ml of LB-broth (100 pg/ml ampicillin and 25 pg/ml kanamycin) was then 
inoculated 1:20 with the overnight culture and grovm at 37°C with vigorous shaking 
until the Aeoo reached 0.7 - 0.9.
IPTG was then added to a final concentration of 0.5 mM and growth of the 
culture continued for 4-5 hours. The cells were harvested by centrifugation at 4000 g 
for 10 min and the cell pellet stored at -20°C until further use.
3.2.2 Isolation and solubilisation of inclusion bodies
The bacterial pellet was re-suspended in 10 ml 50 mM Tris/HCI, pH 8.0, 
containing 5 mM EDTA (designated wash buffer) and 5% (w/v) sucrose. The 
suspension was firozen and thawed twice and subjected to sonication (6x30 seconds, 
30 W, Jencons High Intensity Ultraprocessor). After centrifugation at 6000 g for 10 
min, the inclusion body pellet was washed once in wash buffer containing 0.1%
Triton X-100 and twice in wash buffer containing 2 M urea. The pellet was finally 
re-suspended in 10 ml dddH2 0  before centrifugation once more at 6000 g for 10 min 
to obtain the purified inclusion bodies. These were solubilised directly in 8 M urea,
0.1 M Tris/HCI, pH 8.0, 10 mM DTT at 37°C with vigorous shaking for 1 hour 
followed by centrifiigation at 6000 g for 10 min to remove any material that had been 
incompletely solubilised. The clarified supernatant was used as the source of 
recombinant enzyme to be renatured.
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3.2.3 Refolding of CPB2.8ACTE
Fully denatured and reduced CPB2.8ACTE was diluted with 8 M urea, 0.1 M 
Tris/HCl, pH 8.0, 5 mM EDTA to a final protein concentration of 0.1 - 0.5 mg/ml. 
Dialysis of the resultant solution was then carried out for 15 hours against 100 vol. of 
a suitable buffer. In the experiment where the effect of redox reagents was studied, 
0.1 M Tris/HCl, pH 7.0, 5 mM EDTA and various combinations of cystine/cysteine 
and glutathione (reduced and oxidised) were used as the buffer. The influence of pH 
on refolding was assessed by using 0.1 M Tris/HCl (pH 7-9), 0.1 M sodium acetate 
pH 6.0 and 0.1 M histidine buffer, pH 6.0; all solutions contained 5 mM EDTA and 5 
mM cysteine.
In all cases, the redox reagent(s) were removed subsequently by dialysis for 2 
hours against 100 vol. of 20 mM Tris/HCl, pH 7.0, 5 mM EDTA prior to further 
purification by ion exchange chromatography.
3.2.4 Ion exchange chromatography of CPB2.8ACTE
After refolding of CPB2.8ACTE, the enzyme solution was transferred to 
polypropylene tubes and centrifuged at 6000 g for 10 min to remove any precipitated 
protein. The supernatant was then filtered through a 0.22 pm syringe filter (Gelman 
Sciences) before the sample was applied to a Mono Q HR 5/5 anion exchange 
column (Pharmacia) equilibrated with 20 mM Tris/HCl, pH 7.0, 5 mM EDTA, at a 
flow rate of 1 ml/min. After washing the column with equilibration buffer, protein 
was eluted with a 0-1 M NaCl gradient in the equilibration buffer. The fi*actions
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containing enzyme activity towards gelatin and BzPFR-Nan were pooled and stored 
at 4°C overnight, for activation to the fully active form.
3,2.5 Activation/processing of CPB2.8ACTE
The pooled fractions were assayed for protein content and diluted accordingly 
with activation buffer to 0.1 - 0.5 mg/ml before activation. The activation protocol 
was based on suggestions made for activation of cruzipain by Prof. J. H. McKerrow 
(University of California, USA). Activation buffer consisted of 0.9 M NaCl, 0.1 M 
sodium acetate, 2 mM EDTA and 10 mM DTT, pH 5.0. The pooled ion exchange 
fractions were added to the activation buffer, before activation of the enzyme was left 
to proceed at 37°C for 8 hours, while gently agitating on a shaker. At 4 hours, 10 
mM DTT was added to ensure that the enzyme was reduced during the processing 
step. After activation was complete, the sample was again centrifuged at 6000 g for 
10 min to remove any precipitated protein.
The volume of the enzyme solution (40-60 ml) was then reduced by transferring 
the activated enzyme solution to dialysis tubing. PEG 8000 flakes were added to the 
outside of dialysis membrane containing the activated enzyme solution and were left 
for several hour s at 4°C, to allow concentration of the enzyme to a volume of 
approximately 4 ml. This sample was then ftirther concentrated and desalted using a 
lOK Amicon Centricon system involving several 20-30 min centrifugation steps at 
4000 g, at 4°C.
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3.2.6 Purification of CPB2.8ACTE using nickel-agarose affinity 
chromatography
The pellet from a 500 ml culture of E. coli expressing CPB2.8ACTE was 
frozen and thawed before being re-suspended in 6 M guanidine hydrochloride, 0.1 M 
sodium phosphate, 0.01 M Tris/HCl, pH 8.0 (Buffer A) at 5 ml per gram wet weight 
of cells. The cells were stirred at room temperature for 1 hour and centrifuged at 
6000 g for 15 min at 4°C. The supernatant, containing solubilised inclusion bodies 
was loaded on to a 4 ml nickel-nitriloacetic acid (N?^-NTA) column, which had 
previously been equilibrated in Buffer A, at a flow rate of 10-15 ml/hour.
The column was then washed with 10 column volumes of buffer A and 5 
column volumes of buffer B (see Table 4). Buffers C - E were used to elute the 
recombinant protein and a final washing step was employed to remove any protein 
that had not been eluted using buffer F (Table 4).
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Buffer Components
A 6 M guanidine hydrochloride, 0.1 M sodium phosphate, 0.01 M 
Tris/HCl, pH 8.0
B 8 M urea, 0.1 M sodium phosphate, 0.01 M Tris/HCl, pH 8.0
C Buffer B at pH 6.5
D Buffer B at pH 5.9
E Buffer B at pH 4.5
F 6 M guanidine hydrochloride and 0.2 M acetic acid, pH 4.2
Table 4: Buffers used for nickel-agarose purification of CPB2.8ACTE
Fractions containing purified protein were pooled and stored on ice before 
immediate dialysis into refolding buffer.
3.2.7 Generation of polyclonal anti-serum to pro-CPB2.8ACTE
Polyclonal anti-serum raised in New Zealand White rabbits against his-tagged 
pro-form of CPB2.8ACTE was carried out in the animal facility at the University of 
Glasgow, 300 pg of nickel-agarose-purified enzyme (buffer E, Table 4) was dialysed 
into PBS, pH 7.0, and homogenised with Freund's Complete Adjuvant (FCA) for the 
first inoculation. 200 pg of enzyme was homogenised with Freund's Incomplete 
Adjuvant (FIA) for the three subsequent boosts. Anti-serum was collected five days 
after the final boost.
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3.3 RESULTS
3.3.1 Over-expression of CPB2.8ACTE in E, coli
CPB2.8ACTE was over-expressed in E. coli as a pro-protein without the C-
terminal extension or pre-region but with a poly-histidine tag at the N-terminus 
(Sanderson et al, 2000). The C-terminus is not essential for activation or correct 
intracellular trafficking of CPBs and so is not required for production of the 
recombinant, mature enzyme (Mottram et al, 1996). Indeed inclusion of the C- 
terminal domain may cause complications in the refolding process of the recombinant 
enzyme since the C-terminal extension contains a predominance of hydrophobic 
amino acid residues which theoretically increases the chances of aggregation rather 
than renaturation during the refolding process. Attempts at purifying an L. infantum 
CPB with its C-terminal extension confirmed this, since the solubilised protein had to 
be diluted even further before dialysis compared with the dilutions used for 
CPB2.8ACTE.
The poly-histidine tag allows for recombinant proteins such as CPB2.8ACTE 
to be bound to a nickel-agarose affinity column and then eluted by lowering of the pH 
of the column buffer - this results in the positively charged histidine side chain being 
incapable of binding to the nickel ions. This technique has been used for purification 
of several other parasite enzymes including an aldolase fi*om P. falciparum (Dobeli et 
al, 1990), and a methionine y-lyase from Trichomonas vaginalis (McKie et al,
1998). These studies exemplified the potential of this approach for obtaining parasite 
proteins for study.
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3.3.2 Time of culture growth before induction
Escherichia coli M15pREP4 incorporating the plasmid pQE-30 containing 
CPB2.8ACTE was grown to an Aeoo of 0.63, 0.91 or 1.21 before induction with 1.0 
mM IPTG for 4 hours. The amount of CPB2.8ACTE produced in each case was very 
similar (Figure 3.3.1). When assays were performed with the p-nitroanilide substrate, 
BzPFR-Nan, it was found that cells grovm to an Aéoo of 0.91 before induction yielded 
more proteinase activity after dialysis of the solubilised inclusion bodies (4.0 
nmoles.min.mg. protein ' ) con^ared with cells grown to an A^ oo of 0.61 or 1.22 (2.7 
and 3.3 nmoles.min.mg.protein ' respectively).
Bacterial cells in batch culture tend to grow in a sigmoidian fashion with log 
phase representing the point between an Aeoo of 0.6 - 0.9 and higher values probably 
indicative of stationary phase. During log phase, cells ai e most productive and have 
an abundant source of nutrients. One complication of high-density growth and 
expression with E. coli when glucose is the carbon source, is the accumulation of 
acetate to toxic concentrations. Acetate can begin to inhibit protein production by 
being assimilated when glucose sufficiently limits growth. Since acetate is taken up in 
its protonated form, the resulting pH rise may disrupt metabolism. This is difficult to 
avoid in batch fermentation (Swartz, 1996). However, the choice of LB medium 
prevents such an increase in acetate concentration as glucose is not the carbon 
source.
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Figure 3.3.1 10 % SDS-PAGE stained with 
Coomassie Blue showing variation of pre­
induction time and production of CPB2.8ACTE 
Lane 1, E. coli at A^ggOf 0.63; 
lane 3, E. coli at A^g of 0.91 ; 
lane 5, E. coli at A^g of 1.21; 
lanes 2, 4 and 6, 4 h post-induction.
56
Chapter 3
3.3.3 Time of culture growth after induction
After the culture had been grown to an Aeoo of 0.8, the cells were induced 
with 1.0 mM IPTG for 1, 2, 3, 4 or 5 hours and expression of the recombinant 
protein was monitored. The maximal amount of protein was produced after 4 to 5 
hours induction (Figure 3.3.2.). The enzyme activity, however, was not increased in 
parallel. This could be visualised using gelatin SDS-PAGE (Figure 3.3.3). There 
was a decrease in activity towards gelatin as more enzyme was over-expressed, 
suggesting that it was sequestered as an inactive form within inclusion bodies. For 
purification purposes, the accumulation of CPB2.8ACTE within inclusion bodies is 
far fi-om ideal, due to problems with refolding. However, it was easier to obtain a 
higher yield of over-expressed enzyme using this method and the risk of proteolysis 
was reduced. Thus 4 hours was chosen as the standard for subsequent work.
3.3.4 IPTG concentration
Production of CPB2.8ACTE utilising IPTG at final concentrations of 0.1, 0.5 
and 1.0 mM resulted in similar amounts of recombinant protein as assessed by SDS- 
PAGE (Figure 3.3.4). The inclusion body phase was isolated fi'om cells that had been 
induced with these concentrations of IPTG. Dialysed inclusion body samples from 
each concentration of IPTG were analysed by gelatin SDS-PAGE (Figure 3.3.5) and 
BzPFR-Nan. Cells induced with 1.0 mM IPTG appeared to contain more active 
enzyme as assessed by gelatin SDS-PAGE, but activity towards BzPFR-Nan was 
very similar although cells induced with 0.1 mM IPTG gave slightly less activity than
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Figure 3.3.2 Coomassie-stained 12 % SDS-PAGE showing 
over-expression of CPB2.8ACTE in E. coli.
Cells were induced with 1.0 mM IPTG and, at 
hourly time points, 1 ml aliquots of culture were centrifuged at 
10000 g for 15 min and the cell pellet re-suspended in 100 pi 
of sample buffer. Lanes were loaded with equivalent volumes. 
Lane 1, E. coli pre-induction; lane 2, 1 h post-induction; lanes 
3-6 represent post-induction at 2, 3, 4 and 5 h respectively.
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Figure 3.3.3 Coomassie-stained 10 % gelatin 
SDS-PAGE gel of over-expressed CPB2.8ACTE in 
E. coli.
Lane 1, lysate of stationary phase promastigote cph 
null mutant L. mexicana, re-expressing gene 2.8; 
lane 2, E. coli pre-induction; lanes 3-7 represent 
samples taken 1-5 h post-induction, respectively.
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Figure 3.3.4 Coomassie-stained 10% SDS-PAGE 
showing induction of CPB2.8ACTE with varying 
concentrations of IPTG.
Lanes 1, 3 and 5, pre-induced E. coli\ 
lane 2, E. coli 4 h post-induction with 0.1 mM IPTG; 
lane 4, E. coli 4 h post-induction with 0.5 mM IPTG; 
lane 6, E. coli 4 h post-induction with 1.0 mM IPTG.
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Figure 3.3.5 10 % gelatin SDS-PAGE comparing 
activity from cultures induced with different 
concentrations of IPTG. The inclusion body phase was 
isolated, solubilised and dialysed overnight. The gel 
shows activity from the post-dialysis sample.
Lane 1, wild-type, stationary phase, promastigote 
parasite lysate;
lane 2, cells induced with 0.1 mM IPTG; 
lane 3, cells induced with 0.5 mM IPTG; 
lane 4, cells induced with 1.0 mM IPTG.
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those cells induced with 0.5 and 1.0 mM IPTG (data not shown). A concentration of 
0.5 mM was used routinely for all subsequent recombinant protein expression.
3.3.5 Washing of inclusion bodies
Inclusion body-derived CPB2.8ACTE was purified away Ifom the intrinsic 
factors associated wdth inclusion bodies prior to solubilisation and refolding. Since 
inclusion bodies are slightly denser than the cell debris, they can be separated by 
differential centrifiigation. Contaminating proteins were removed by washing not 
only in sucrose but also in moderate chaotrope, 2 M urea, which is known to 
solubilise contaminants but leave the inclusion bodies insoluble. Proteinases are also 
removed in this way, which is beneficial as they could degrade the recombinant 
product. The effects of the washes were assessed by SDS-PAGE (Figure 3.3.6a) and 
this confirmed that there was a minimal loss of the recombinant protein in the wash 
solutions during the isolation of the inclusion bodies. However, there was removal of 
contaminating proteins which may interfere with refolding. Western blot analysis 
(Figure 3.3.6b) confirmed that there was a minimal loss in recovery of CPB2.8ACTE 
during the washing procedure.
3.3.6 Solubilisation of inclusion bodies
Disulphide bonds may form in an oxidising microenvironment within the 
inclusion bodies. If intramolecular or intermolecular disulphide bonds in the 
recombinant protein in inclusion bodies are incorrect, then disruption of these is an 
essential component in the recovery of the correctly folded, active protein. The
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F igure  3.3.6a Coomassie-stained 12 % SDS-PAGE to monitor 
solubilisation o f incluson bodies during washing stages.
Lane 1, sucrose wash; lane 2, Triton X-100 wash; lanes 3 and 4,
2 M urea washes; lane 5, H^O wash. All lanes were loaded with an 
equal volume o f  supernatant from the wash steps.
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F igure  3.3.6b W estern blot monitoring solubilisation o f  inclusion 
bodies during washing stages. The blot was probed with antibody 
to pro-m ature CPB2.8ACTE.
Lane 1, sucrose wash; lane 2, Triton X-100 wash; lane 3, second 2 
M urea wash; lane 4, H jO wash. All lanes were loaded with an 
equal volume o f  inclusion body pellet from the wash steps.
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addition of DTT allows reduction of interchain disulphide bonds by thio 1-disulphide 
exchange and increased solubilisation of aggregated protein. Since the reaction is 
favoured by an alkaline pH, Tris buffer is the preferred option.
Recovery of active, mature enzyme was compared between inclusion bodies 
solubilised in the presence of DTT and without by assessing activity to gelatin gels 
(Figure 3.3.7). As can be seen from Figure 3.3.7 (compare lanes 2 in A and B), there 
was no difference between gelatinase activity of the second dialysate, whether or not 
DTT was omitted during the solubilisation of the inclusion bodies. However, there 
was clearly a difference in the activity profile of the eluant from the ion exchange 
chromatography step, as active enzyme was eluted more quickly, when no DTT was 
used to solubilise inclusion bodies (Figure 3.3.7). Furthermore, when active fractions 
from each run were pooled and activated, the inclusion bodies solubilised with DTT 
resulted in mature enzyme with a higher specific activity (18 nmoles.min.mg.protem') 
than enzyme from inclusion bodies not solubilised with DTT (13 
nmoles.min.mg.protein '). The solubilisation conditions of Kuhelj et ai (1995), 
which includes solubilisation of inclusion bodies with 10 mM DTT, were therefore 
deemed the most efficient in solubilisation of CPB2.8ACTE.
3.3.7 Refolding of CPB2.8ACTE
A study of the optimum conditions for maximal recovery of enzyme activity 
and protein yield was carried out for the refolding step.
Renaturation, that is refolding and re-oxidation, of the protein was performed 
by slowly removing the denaturing agent by dialysis in glass vessels, since refolding
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F igure 3.3.7. 10% gelatin SDS-PAGE analysis o f  eluants from ion exchange 
chromatography o f dialysed inclusion bodies solubilised with or without DTT.
Lanes 1 and 13, wild type, stationary phase promastigote parasite lysate; lane 2, load
(2nd dialysate); lane 3, flow-through; lane 4, wash (pre-gradient);
lanes 5-13 represent fractions eluted from the Mono Q column with a 0-1 M NaCl
gradient.
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experiments carried out in plastic containers have given poor yields in some instances 
(Creighton, 1984), I tested to see if this was important with CPB2.8ACTE. There 
was no difference in activity of the refolded enzyme (data not shown) but after 
subsequent freeze-thaw of the refolded samples there was a marked increase in 
protein precipitate from the sample dialysed in plastic containers with no visible 
change in the enzyme dialysed in the glass containers. Thus, glass containers were 
used routinely for subsequent experiments.
pH 7 was used by Kuhelj et at. (1995) to isolate pro-cathepsin B but it has 
been reported that higher pH values may facilitate oxido-shuffling, the process 
whereby refolding occurs. Most common alkyl thiols have proton ionisation pKa 
values in the range of 8-10 and disulphide exchange reactions can therefore proceed 
rapidly under mildly alkaline conditions or neutral conditions (Wetlaufer, 1984). This 
process results in correct exchange of disulphide bonds and therefore refolding of the 
enzyme to an active state.
Altering the pH of the dialysis buffers fi-om pH 7 was attempted to increase 
enzyme activity and protein recovery. Since CPB2.8ACTE is possibly activated in 
the lysosomes of the parasite in vivo, it was hypothesised that lowering the pH of the 
dialysis buffer fi-om pH 7 to pH 6 would increase conversion of the pro-mature form 
to the active, mature state. However, the different buffers used (sodium acetate, pH 
6.0; histidine buffer, pH 6.0) did not improve yield nor activity of enzyme and indeed 
an increase in protein precipitation occurred during the dialysis step. When the 
solubilised inclusion bodies were dialysed at pH 6 rather than pH 7, there was an 
apparent loss in activity towards gelatin (Figure 3.3.8, lane 2). However, since there
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Figure 3.3 .8  10 %  gelatin SD S-PA G E com paring
pH  6 and pH  7 during dialysis o f  solubilised inclusion bodies.
Lane 1, stationary phase, prom astigote parasite lysate {cpb null re­
expressing gene 2.8); lane 2, inclusion bodies d ialysed at pH  6; lane 3, 
inclusion bodies dialysed at pH  7.0. Lanes 2 and 4 w ere loaded w ith 
equal volum es o f  supernatant from  the centrifuged dialysate.
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was a considerable amount of precipitate in the former dialysis, it may be that the 
apparent loss in activity was in fact due to less enzyme in the supernatant as more of 
it had precipitated.
Increasing the pH of the refolding buffers from pH 7 to pH 8 did not result in 
an increase in mature enzyme activity towards gelatin SDS-PAGE gels although there 
was a small increase in activity of the pro-mature enzyme (Figure 3.3.9). However, 
there was no difference in specific activity between the two samples (data not 
shown). Thus pH 7 was chosen as the optimum pH for refolding of this particular 
protein. Since the enzyme is ultimately associated with lysosomal organelles which 
are acidic, one may expect that the enzyme would be adapted for these conditions.
Reduced proteins have a strong tendency to aggregate, thus oxidative 
renaturation must be carried out at low protein concentrations. Typically, the protein 
concentration was estimated to be 1.0 mg/ml by the BioRad protein assay after 
solubilisation m 8 M urea and this sample was therefore diluted 8 to 10-fold with 8 M 
urea to an approximate concentration of 0.1 - 0.125 mg/ml before dialysis. Omission 
of this dilution step led to increased aggregation resulting in losses in yield and a 
subsequent decrease in enzyme activity.
The dialysis was carried out at room temperature and at 4°C to compare 
temperature effects on the refolding process. It was found that the protein did 
renature at room temperature as seen by activity on gelatin SDS-PAGE gels (results 
not shown) but there was a small amount of precipitation whereas there was none 
with dialysis at 4°C. This is in agreement with Kuhelj et aL (1995), who reported a 
50% decrease in enzyme activity if refolding was carried out at room temperature.
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Figure 3.3.9 Coomassie-stained 10 % gelatin 
SDS-PAGE gel comparing proteinase activity of 
solubilised inclusion bodies, dialysed at pH 7 or 
pH 8.
Lane 1, stationary phase promastigote parasite lysate 
of cpb null re-expressing gene 2.8; lane 2, dialysed 
inclusion bodies at pH 7; lane 3, dialysed inclusion bodies 
at pH 8.
Lanes 2 and 3 were loaded with equal volumes.
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Reformation of disulphide bonds occurs under oxidising conditions and increased 
yields of active, recombinant CPs are normally obtained by maintaining the correct 
redox potential using oxidised thiol compounds and reducing agents such as DTT. 
The effects of two different redox reagents upon refolding were examined. Cysteine 
was tried as this had been used previously in the refolding of human pro-cathepsin B 
(Kuhelj et a l, 1995). However CPB2.8ACTE is cathepsin L-like, so glutathione (a 
mixture of 90 % reduced and 10 % oxidised) was incorporated into the renaturation 
buffer instead of cysteine as this mixture of glutathione had been used previously in 
refolding of human cathepsin L (Menard et aL, 1998).
Activity towards gelatin was recovered from inclusion bodies dialysed with 
glutathione and gave a similar enzyme activity profile (Figure 3.3.10) as that of the 
enzyme refolded with cysteine (after purification using ion exchange 
chromatography). That is, the pro-mature, intermediate form of the enzyme was able 
to completely activate to the mature form, shown by the slow mobility band being 
processed to the faster mobility band. The purity of the two protein preparations was 
almost identical (Figure 3.3.11) and the final specific activity of the enzyme refolded 
with cysteine (408 nmoles.min.mg.protein ' ) was slightly greater than that refolded 
with glutathione (352 noles.min.mg.protein ' ). Although glutathione can therefore 
be used to refold inclusion bodies containing CPB2.8ACTE and produce activatable 
enzyme, it was no better improvement in terms of activity and yield, than using 
cysteine as the thiol reagent. Thus, cysteine was routinely used subsequently.
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Figure 3.3.10 10 % gelatin SDS-PAGE comparing activation 
of pooled ion exchange fractions.
Lane 1, solubilised inclusion bodies refolded with glutathione. This dialysate 
was purified by ion exchange chromatography and gelatin gel activity is due 
to the pooled fractions from the ion exchange purification; 
lane 2, sample described in lane 1, after activation;
lane 3, solubilised inclusion bodies refolded with cysteine. This dialysate was 
purified by ion exchange chromatography and gelatin gel activity is due to the 
pooled fractions from the ion exchange purification; 
lane 4, sample described in lane 3, after activation.
Lanes were loaded with equivalent volumes.
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Figure 3.3.11 Coomassie-stained 12 % SDS-PAGE 
comparing activated enzymes obtained after refolding in 
the presence of glutathione and cysteine.
Lane 1, glutathione-refolded sample; lane 2, cysteine- 
refolded sample. Lanes were loaded with equivalent 
protein concentrations.
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3.3.8 Nickel-agarose purification of CPB2.8ACTE
Affinity chromatography represents one of the most rapid, efficient and 
convenient means of generating pure protein. Inclusion bodies were solubilised by re- 
suspending in 8 M urea, 0.1 M sodium phosphate, 0.01 M Tris/HCl, pH 8.0 and 
vigorously shaking for 1 hour at 37°C. These were then clarified by centrifugation to 
remove any particulate material before application to the nickel-agarose column. The 
recombinant enzyme consistently eluted in buffer E (8 M urea, 0.1 M sodium 
phosphate, 0.01 M Tris/HCl, pH 4.5). According to the QIAgen protocol, monomers 
usually elute at pH 5.9 while multimers, aggregates and proteins with two 6xHis tags 
tend to elute at pH 4.5. A small amount of CPB2.8ACTE did elute at pH 5.9 but the 
majority (> 90%) eluted at pH 4.5 (Figure 3.3.12). This is surprising, since the 
enzyme is expected to exist as a monomer and therefore would be expected to elute 
at the higher pH. It may be that conditions on the column itself could produce a 
steric change in the conformation of the protein resulting in aggregation and a greater 
affinity to the column than usual. The subsequent problems encountered in 
attempting to activate the enzyme are consistent with the presence of un-natural 
enzyme aggregates.
Using the protocol devised by Kuhelj et al (1995), which I used for 
solubilisation of the protein prior to the affinity chromatography, contaminating 
proteins are removed prior to purification and so there is less chance of aggregation 
with other proteins. The problem with the nickel-agarose procedure is the 
incompatibility of the nickel agarose resin with the thiol-containing chemicals such as 
DTT or p-mercaptoethanol (p-ME) used for the solubilisation process of the method
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Figure 3.3.12 Coomasie-stained 10 % SDS-PAGE showing 
purification of CPB2.8ACTE using nickel-agarose chromatography 
under denaturing conditions.
Lane 1, load (solubilised inclusion bodies);
lane 2, column flow-through;
lane 3, column wash with buffer B;
lane 4, wash with buffer C, pH 6.5;
lane 5, wash with buffer C, pH 6.5;
lane 6, wash with buffer D, pH 5.9;
lane 7, wash with buffer D, pH 5.9;
lane 8, CPB2.8ACTE eluant with buffer E, pH 4.5.
Lanes were loaded with equivalent volumes.
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documented by Kuhelj et a l (1995). Attempts to solubilise the inclusion bodies using 
this procedure but without the presence of a reducing agent resulted in less 
solubilisation of the recombinant enzyme (Figure 3,3.13a). It was found that for 
maximal recovery of CPB2.8ACTE from inclusion bodies, they should be solubilised 
in precisely the conditions utilised by Kuhelj ei al (1995); 8 M urea, 10 mM DTT 
and 0.1 M Tris/HCl, pH 8.0. Furthermore, when the inclusion bodies (solubilised 
without the presence of a reducing agent) were purified using the nickel-agarose 
column, the enzyme could still not be frilly activated (Figure 3.3.13b). Although, the 
nickel-agarose purified enzyme displayed gelatinase activity, it did not activate to the 
frilly active, mature form shown in Figure 3.3.10 (lane 2). Instead, the protein 
remained as the higher mobility form, shown in Figure 3.3.10, (lane 1). This 
intermediate form was known to have 7 amino acids of the pro-region still attached, 
analysed by N-terminal sequencing (Sanderson et al, 2000) and although the enzyme 
was proteolytically active towards gelatin, activity to BzPFR-Nan was low (Table 5). 
So, this form of purification was deemed to be inefficient for recovery of frilly active 
recombinant proteinase since all attempts to convert the pro-form to fully active 
enzyme were unsuccessful. The possible reasons for this are discussed in section 3.4.
Nickel-agarose affinity chromatography was, however, successful in providing 
extremely pure pro-enzyme for generation of polyclonal anti-serum (Figure 3.3.14).
3.3.9 Ion  exchange  c h ro m a to g ra p h y
Since nickel-agarose was incompatible with the solubilisation process used 
and enzyme that was purified using nickel-agarose chronmtography could not be fully
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Figure 3.3.13a Coomassie-stained 10 % SDS-PAGE showing 
different solubilisation conditions attempted. Inclusion bodies were 
solubilised in a number of different buffers.
Lane 1, 8 M urea with Tris/HCl, pH 8.0;
lane 2, 0.1 M Tris/HCl, pH 8.0 with 10 mM DTT;
lane 3, 8 M urea with 10 mM DTT and Tris/HCl, pH 8.0;
lane 4, 8 M urea with 10 mM DTT.
Lanes were loaded with equivalent volumes from clarified supernatants.
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Pro-mature 
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Figure 3.3.13b 10 % gelatin SDS-PAGE showing gelatinase activity 
from nickel-agarose purified CPB2.8ACTE. Inclusion bodies were solubilised 
in two different buffers (without DTT), affinity-purified then refolded.
Lane 1, inclusion bodies solubilised in 8 M urea, 0.1 M sodium 
phosphate and 0.01 M Tris/HCl, pH 8.0;
lane 2. inclusion bodies solubilised in 8 M urea and Tris/HCl, pH 8.0
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Figure 3.3.14 Silver-stained 10 % SDS-PAGE gel showing 
purity of CPB2.8ACTE obtained from nickel-agarose 
chromatography.
Lane 1, molecular weight markers;
lane 2, His^-tagged CPB2.8ACTE pro-mature enzyme.
77
Chapter 3
activated, the refolded enzyme sample was fiirther purified using a Mono Q anion 
exchange column. Importantly, this step was found to be essential for full activation 
of the enzyme to be achieved. Analysis of the eluted samples by gelatin SDS-PAGE 
and BzPFR-Nan assays showed that the enzyme in the Mono Q eluant was only 
partially active. There were two bands with activity towards gelatin (Figure 3.3.15) 
with the lower molecular mass band being the mature enzyme species and the other 
band being the intermediate pro-mature form. The specific activity towards BzPFR- 
Nan of the pooled sample (fi"actions 6 to 14) was typically about 40 
nmoles.min. mg .protein ,^ reflecting enhanced purification and some activation firom 
the Mono Q step (Table 5).
The rationale behind using the ion exchange step was to separate the 
intermediate and mature enzyme fi'om each other. Although there were consistently 
two separate, defined protein peaks (Figure 3.3.16), these did not correspond to 
intermediate and mature proteins (see Figure 3.3.15) and the two species could not 
be isolated fi'om each other as assessed using gelatin SDS-PAGE (Figure 3.3.15). 
However there was a significant difference in fi-actions eluted fi'om the Mono Q 
column and their ability to be activated thereafter. Fractions 8 to 14 (elution 
concentration o f400 - 700 mM NaCl) were able to be fuUy activated to the mature 
form but fi-actions 5 to 7 (250 - 350 mM) could not be suecessfiilly activated. 
However, if all of fractions 5 to 14 were pooled, it was possible to activate all the 
protein in the mixture to the fully active enzyme. Without the Mono Q step, the 
enzyme could not be fiiUy activated in this way - it appears that the ion exchange step 
was necessary for this step to occur.
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Figure 3.3.15 10 % gelatin SDS-PAGE and Western blot on 10 % SDS- 
PAGE showing Mono Q ion exchange purification of CPB2.8ACTE.
Lanes land 15 of gelatin gel , stationary phase promastigotes of L. 
mexicana cpb null mutant re-expressing gene 2.8; 
lane 2, refolded inclusion bodies (column load); lane 3, column flow­
through; lane 4, column wash (pre-NaCl gradient); lanes 5-14, NaCl 
gradient elution.
All lanes were loaded with equal volumes. Pro-region peptides are not 
apparent on the gelatin SDS-PAGE gels since they contain no activity 
towards gelatin. Fractions 5 to 14 were pooled for activation.
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Figure 3.3.16 FPLC /V28O elution profile of Mono Q ion exchange 
chromatography step used to purify refolded CPB2.8ACTE. The 
chromatograph shows the 0-1 M NaCl gradient as the straight line 
running from bottom left (0 M NaCl) to the top right of the figure 
(1 M NaCl). The elution profile shown is typical of those obtained, 
with two large protein peaks eluting at 250 mM (fraction 10) to 
400 mM NaCl (fraction 16). Fractions 5 to 14 were pooled for 
subsequent activation.
80
Chapter 3
3.3.11 Activation of CPB2.8ACTE
Complete activation of the enzyme, that is conversion of the pro-mature to 
the mature form, usually occurs as an autocatalytic step for cathepsins (BCirschke et 
al, 1995).
The activation process in vivo is thought to occur at an acidic pH and the 
conditions I used in vitro were designed to mimic these. High salt concentration was 
thought to be essential for the activation process. Addition of NaCl to the activation 
buffer resulted in a dramatic increase in activation and a resultant 12-fold increase in 
specific activity towards the substrate BzPFR-Nan (Table 5). The increase in specific 
activity correlated with conversion of the pro-mature form on gelatin SDS-PAGE 
(slower mobility species, lane 1, Figure 3.3.10) to fully active, mature enzyme (lane 2, 
Figure 3.3.10). This single band of activity also migrated on SDS-PAGE as a single 
band with some low molecular mass pro-region peptides (Figure 3.3.17, lane 4).
Activation of CPB2.8ACTE requires a lowering of pH and this is similar to 
other cysteine proteinases (Eakin et al, 1993). Attempts to activate at neutral pH 
resulted in a loss of activity and incomplete conversion of pro-enzyme to mature 
enzyme (Figure 3.3.18, lanes 2 and 3). However, if the pH was lowered to pH 5.5, 
conversion on gelatin SDS-PAGE and by Western blotting could be visualised of the 
pro-enzyme being processed to the fully active, mature enzyme (Figure 3.3.18, lanes 
4 and 5).
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Table 5. Purification summary (from 100 ml culture)
Purification
step
Total
protein
(mg)
Activity* 
(nmoles.min.ml^ )
Specific Activity 
(nmoles.min.mg. 
protein'*)
Purification
factor
Post-dialysis 23 3 13 1
Post - Mono Q 7 8 39 3
Post - 
acidification
2.5 50 455 36
Using micro-titre plate stopped assay with BzPFR-Nan as substrate
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Figure 3.3.17 Coomassie-stained 10 % SDS-PAGE showing 
processing steps required for purification of CPB2.8ACTE. 
Lane 1, E. coli pre-induction; lane 2, 4 h post-induction; 
lane 3, pooled Mono Q fractions; lane 4, pooled Mono Q 
fractions post-activation; lane 5, post-activated CPB2.8ACTE 
after Centricon 10 concentration.
Lanes 1 and 2 were loaded with an equal volume of culture. 
Lanes 3, 4 and 5 were loaded with equal volumes.
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Figure 3.3.18 10 % gelatin SDS-PAGE showing requirement for 
acidification for activation from the pro-mature to the mature form.
Lane 1, stationary phase promastigote parasite lysate of cpb null 
expressing gene 2.8;
lane 2, pooled Mono Q fractions before activation with no acidification; 
lane 3, pooled Mono Q fractions after activation with no acidification; 
lane 4, pooled Mono Q fractions before activation with acidification; 
lane 5, pooled Mono Q fractions after activation with acidification.
Lanes 2, 3, 4 and 5 were loaded with equivalent volumes.
The sample in lanes 2 and 3 were from another protein preparation which 
was more concentrated, compared to the sample in lanes 4 and 5.
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3.3.12 Purification of a L. infantum CPB containing a C-terminal extension
Purification of a recombinant leishmanial CPB with its C-terminal extension 
using the published protocol, was attempted but proved to be difficult. Due to time 
constraints, the inclusion bodies were only solubilised and dialysed (Figure 3.3.19) 
although there was a clear difference in protein yield and activity after dialysis 
compared to dialysed CPB2.8ACTE. Overnight dialysis resulted in extremely high 
levels of protein precipitation and most of the recombinant protein was found as 
precipitated protein (Figure 3.3.19). After overnight dialysis, the supernatant 
displayed no activity to gelatin SDS-PAGE gels (data not shown), even though some 
processing of the protein had occurred during the dialysis stage (Figure 3.3.19).
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Figure 3.3.19 Coomassie-stained 12 % SDS-PAGE gel showing 
processing and precipitation of L. infantum CPBCTE during refolding 
stage at designated time-points.
Lane 1, solubilised inclusion bodies, 1 h after start of dialysis; 
lane 2, solubilised inclusion bodies, 3 h after start of dialysis; 
lane 3, solubilised inclusion bodies, 6 h after start of dialysis; 
lane 4, supernatant of solubilised inclusion bodies, 20 h after dialysis; 
lane 5, pellet of solubilised inclusion bodies, 20 h after dialysis.
For lanes 1 to 3, the dialysate was completely soluble and there was no 
evidence of precipitation even after centrifugation. For lanes 4 and 5, 
the sample was centrifuged at 6000 g for 10 min and supernatant loaded. 
The resultant pellet was re-suspended in sample buffer and loaded as for 
the supernatant. Lanes were loaded with equivalent volumes.
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3.4 DISCUSSION
A CP of L. mexicana, CPB2.8ACTE, has been successfully over-expressed in 
E, coli. This has enabled further characterisation of the enzyme's pivotal role in 
immune evasion and also facilitates high-throughput screening using substrate and 
inhibitor libraries. A novel procedure has been developed for the purifieation and 
activation of leishmanial CPB isoenzymes over-expressed in E. coli.
CPB2.8ACTE was expressed as a Hise-tag fusion protein for efficient 
purification using nickel-agarose resin. Purified pro-enzyme was obtained using this 
method and employed in the production of specific anti-serum. However, the 
preparation had very low enzyme activity and all attempts to convert the pro-form to 
mature, fully active enzyme were unsuccessful. There are several possible reasons for 
this.
As inclusion bodies are formed fi'om the accumulation of incorrectly folded 
recombinant protein and the presence of other protein contaminants, lipids and 
polysaccharides, it is likely that the protein was eluting as an aggregated form, even 
after solubilisation with dénaturant, as a reducing agent was not present. It has been 
reported (Kuhelj et al, 1995) that for complete disruption of aggregates within 
inclusion bodies during solubilisation, it is essential to have a small amount of 
reducing agent such as DTT or p-ME present to allow complete separation of 
disulphide bonds. However, the nickel-agarose column would be reduced by the 
presence of DTT or p-ME and therefore fail to purify the enzyme, and so it was 
necessary that the enzyme was solubilised in dénaturant without reductant, in advance 
of attempted affinity purification using nickel-agarose. It is possible that the
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misfolded disulphide bonds formed in the inclusion bodies were not being completely 
disrupted by the solubilisation conditions and so the protein continued to exist as 
aggregates rather than monomers. This would account for the elution at pH 4.5.
Such purification of the misfolded enzyme, would result in enzyme that could not be 
fully activated since the protein would still contain incorrectly formed disulphides. 
Furthermore, it is known that an oxidative protein cross-linking reaction can be 
mediated by a nickel-peptide complex (Fancy era/., 1996). This reaction was 
dependent on nickel, the Hise-tag and oxidant. The bead-bound nickel atoms support 
the oxidative cross-linking reaction and it could be that without the presence of a 
reductant in the solubilisation procedure, irreversible oxidation and cross-linking 
would take place. Again, this would explain the elution of CPB2.8ACTE at pH 4.5, 
consistent with elution of aggregated forms. Full activation of the enzyme would 
therefore not be possible.
A number of possible hypotheses exist which could explain the role of the 
Mono Q step in the purification of CPB2.8ACTE. The rationale behind using ion 
exchange chromatography is that the required protein is bound while contaminating 
proteins are washed through the column and then the protein of interest is specifically 
eluted. It is possible that the interaction with the column may be sterically favouring 
a form which facilitates subsequent activation, whereas previously the protein was in 
a non-activatable form. In essence, the bound pro-region may be moved to a position 
which makes it easier for cleavage by the mature enzyme.
Another possibility for the Mono Q step enabling subsequent activation could 
be due to the positively charged resin competing with and thereby removing some
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positively charged pro-region peptides associating with the mature enzyme, which 
had been hydrolysed but were still bound. Spontaneous activation of human pro- 
cathepsin L also followed purification on Mono Q resin or incubation with negatively 
charged dextran sulphate (Mason & Massey, 1992), which was thought to induce a 
small conformational change in the positively charged pro-region. Subsequent 
acidification during the activation step could loosen the structure and increase the 
mobility of the pro-segment allowing for dissociation of such pro-region peptides 
resulting in an increase in enzyme activity. A similar mechanism has been 
demonstrated for rat pro-cathepsin B (Cygler et al, 1996).
It has been reported that pro-enzyme activation seems to proceed faster than 
proteolytic processing, suggesting that the mechanism involves two steps: pro­
enzyme activation followed by cleavage to yield the mature enzyme (Mach et al, 
1994). Whether this may be the case for cathepsin L-like enzymes is unknown, 
although evidence for cathepsin L-like proteins suggests that proenzyme 
concentration is important in the rate of processing, indicating the existence of 
bimolecular and unimolecular steps in the mechanism of processing (Menard et al, 
1998). Little is known of zymogen processing in Leishmania parasites. However, an 
active variant of cruzipain, the major CP fi’om T. cruzi, revealed that the proteolytic 
cleavage of the C-terminal extension domain is independent of cruzipain activity, 
possibly due to a bacterial proteinase (Eakin et al, 1993).
High salt concentration was shown to be essential for the activation process 
and the rationale behind this was that cleavage of the pro-region firom the mature 
enzyme would proceed optimally if non-specific interactions were prevented. The
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presence of chloride ions has also been documented as essential for activation to 
occur in a dipeptidyl arylamidase from the pituitary (McDonald, et al., 1966). This 
enzyme, which also contained thiol groups that are essential for activity, showed an 
absolute requirement for chloride ions in the activation medium. It is possible that 
the clipped pro-region may still be associated with the partially active enzyme after 
ion exchange and the presence of halide can help trigger the dissociation of the pro- 
region peptides from the mature enzyme. With human pro-cathepsin L, the enzyme 
undergoes activation at pH 5.5 in the presence of negatively charged surfaces 
(Menard et al., 1998). This is very similar to the situation I found with 
CPB2.8ACTE, although pro-cathepsin L does not appear to go via intermediate 
forms during processing .
Low pH was shown to aid activation. It is possible that lowering the pH 
causes protonation of some acidic groups with a concomitant weakening of salt 
bridges and/or hydrogen bonds between the pro-segment and the mature enzyme 
(Vemet et al., 1995). Furthermore, it has been postulated that the role of acidic pH 
is to loosen the structure and allow the peptides to dissociate from the mature 
enzyme (Cygler et al, 1996). The binding of the remaining peptides become 
progressively less tight, eventually leading to the peptide falling off the enzyme. 
Mature, active enzyme is then able to degrade the detached pro-region to small 
peptides which can subsequently be removed by concentrating the 23 kDa protein 
through a molecular weight cut off membrane of 10 kDa. This resulted in enzyme 
that was considered pure.
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Analyses of CPB2.8ACTE and another recombinant parasite CP derived from 
inclusion bodies, cruzipain from T. cruzi (Eakin et al, 1992), revealed similar kinetic 
parameters, conJBrming the recovery of significant enzyme activity following refolding 
from inclusion bodies. However, there was a difference in the processing of the two 
recombinant enzymes as the sites of cleavage were quite different (Sanderson et al, 
2000).
Recent attempts at purification and activation of a recombinant CP from 
Toxocara canis, Tc-cpz-1, proved unsuccessful (Falcone et a l, 2000). The enzyme 
was poorly soluble and enzymatically inactive, so attempts to purify the enzyme using 
E. coli as the recombinant ceU, were abandoned. However, the problem may be due 
to the enzyme being generated as the recombinant, mature form. It is possible that 
the mature enzyme could be purified and refolded using oui" published protocol but 
the enzyme would be incorrectly folded since the pro-region of most CPs is needed 
for correct folding of the mature enzyme (Taylor et al, 1992). The method we have 
developed for purification of CPB2.8ACTE could be used for the purification of 
other recombinant parasite CPs m E. coli but only when produced as pro-mature 
constructs. Alternatively, the pro-region of the mature enzyme could be added 
exogenously to the mature enzyme, during the refolding stage as has been 
demonstrated for the refolding of subtilisin (Zhu et al, 1989).
Purification of a L. infantum CPB with its C-terminal extension was an aim of 
this study but using the published protocol, this was largely unsuccessful. The 
presence of the C-termmal extension, resulted in greater aggregation during the 
refolding step and subsequent precipitation with a resultant loss in yield of the
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recombinant CP. This was probably due to the approximate 50 % increase in 
cysteine residues, which would increase the occurrence of incorrectly positioned 
disulphide bridges and result in misfolding of the protein. Purification of the L. 
mexicana CPB2.8 with its C-terminal extension has been attempted before but this 
resulted in misfolded protein (Wolfram et al, 1995), although a different method of 
refolding was used from the method discussed in this chapter. Due to time 
constraints, this work was unable to be completed although the procedure for 
purifying this recombinant CPB with its C-terminal extension, would need to be 
modified from that discussed, due to the hydrophobic nature of the C-terminal 
extension.
Purification of the individual CPB isoenzymes from the array makes possible a 
range of investigations of this important class of parasite, not previously possible due 
to difficulties in purification and the presence of multiple isoforms in the parasite. 
Detailed structural analysis of CPB2.8ACTE should provide further insights into its 
function, which may facilitate the design of specific inhibitors to this enzyme. 
Purification of the enzyme has allowed initial characterisation of the enzyme’s role in 
the host-parasite interaction and highUghted its potential as part of a subunit vaccine 
against L. mexicana.
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C H A P T E R  4
Study on the vaccine potential of recombinant CPB
4.1 INTRODUCTION
Cutaneous leishmaniasis is perhaps one of the best parasite targets for 
vaccine development since long-term immunity is induced in the majority of 
people following natural infection (Alexander et al., 1998). There is also a history 
of successful vaccination by live parasite inoculation (Titus et al, 1995). 
Unfortunately, the increasing prevalence of immuno-suppression makes the use of 
a live vaccine less likely as this could be virulent in such individuals (Stenger et 
al., 1996). It is believed that the development of a vaccine against leishmaniasis 
should incorporate defined antigens fi'om the amastigote stage of the parasite 
since it is this form of the parasite which is responsible for the disease in the 
human host. The development of a subunit vaccine against L. mexicana should 
provide an interesting challenge in terms of choice of both antigen and adjuvant 
and these must be carefully considered in their usage for stimulation of a 
protective immune response.
Adjuvants are thought to work by slowing the release of antigen, targeting 
antigen to antigen presenting cells (APCs) such as macrophages and by directly 
activating macrophages (Warren, 1986). The adjuvant, alum, was included in the 
first recombinant and peptide malaria vaccines tested in humans (Patarroyo, 1988) 
and at present is one of the few adjuvants hcensed for human use. More recently,
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alum has been shown to increase the biological half-life of IL-12, when the two 
are co-administered during vaccine studies against HIV infection (Jankovic et al, 
1997). Increasing the biological half-life of IL-12 in vivo may result in a more 
persistent induction oflFN-y thereby leading to a more potent helper effect on Th 
1 -dependent antibody isotypes. Despite this, alum without the addition of 
immuno-potentiators is not an ideal adjuvant for all applications due to its inability 
to induce a Th 1 immune response.
Protective immunity to murine cutaneous leishmaniasis is dependent upon 
the development of an IL-12 - driven CD4^ Thl-type response and the subsequent 
production of IFN-y (Liew & O’ Donnell, 1993). In turn, this cytokine induces 
up-regulation of macrophage iNGS and NO production, which is microbicidal for 
the parasite (Liew and O’ Donnell, 1993). Thus, injection of exogenous IL-12 
with known parasite molecules should potentiate a Th 1-driven immune response 
and protect against subsequent Leishmania infection.
IL-12, a cytokine produced from phagocytes and other antigen presenting cells, 
has been shovm to induce an IFN-y driven Th 1 response when administered with 
soluble leishmanial antigen and can protect against infection with L. major in the 
susceptible BALB/c mouse model (Afonso et al, 1994). Furthermore, low 
concentrations of IL-12 and low amounts of soluble protein can stimulate 
increased IFN-y production and profoundly up-regulate the synthesis of the 
complement-fixing antibody subclasses (IgG2a, IgG2b and IgG3) in vivo 
(Germann et al, 1995). More recently, administration of IL-12 and several 
recombinant leishmanial antigens was found to protect against infection with L. 
mexicana (Aebischer et al, 2000).
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It has been demonstrated that recombinant IL-12 (IL-12) can be an 
effective Th 1-inducing adjuvant in combination with protein antigens; effective 
vaccination against L. major infection in susceptible strains was achieved using 
IL-12 with soluble leishmanial antigen (SLA) (Afonso et al, 1994 ) and 
subsequently, with a recombinant leishmanial protein (LACK) (Gurunathan et al, 
1997).
L. mexicana produces non-healing lesions in most mouse strains and has 
the ability to substantially down-regulate the immune response, often resulting in 
lesions metastasising to the viscera (Roberts e? a/., 1990). Studies in IL-4 
knockout mice have demonstrated that non-healing lesion development is 
dependent on the presence of this cytokine (Satoskar et al, 1995). Since CP 
activity has been shown to stimulate IL-4 production (Travis et al, 1995), the 
many active CPs of this Leishmania species may direct the immune response to an 
IL-4 driven Th 2-type response.
It has recently been shown that immunisation with an inactive recombinant 
CP and recombinant IL-12, conferred protection to a normally lethal infection 
with L. mexicana infection in C57BL/6 mice (Aebischer et al, 2000). This mouse 
strain has intermediate susceptibility to L. mexicana (Roberts et al, 1990) and 
this vaccine did not, however confer protection to the BALB/c mouse strain. 
However, intraperitoneal immunisation with an active, native CP from Z. major 
and Freund's complete adjuvant (FCA) was also found to promote protection to 
Z. major infection in susceptible BALB/c mice (Rafati et al., 2000). These results 
provide encouragement that parasite CPs both in their active and inactive form 
will mediate protection against Leishmania infection, when administered as a 
vaccine. However, the above studies were also not ideal as ultimately for quality
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control, recombinant antigen will have to be used in human vaccines without FCA 
as the adjuvant cannot be used in humans (Bomford , 1989). Therefore, we 
studied the vaccine potential of both active and E-64 - inactivated recombinant 
CPB2.8ACTE adjuvanted with IL-12 to assess protection against wild-type L. 
mexicana infection in three different mouse strains. These mice vary in their 
susceptibility to L. mexicana infection (Roberts et al, 1990) although all develop 
large primary lesions.
4.2 METHODS
4.2.1 Assessment of lipopolysaccharide by E-toxate assay
The level of endotoxin in a preparation of pure CPB2.8 ACTE was assessed 
using the E-toxate assay (Sigma). All glassware was soaked overnight in a 1% 
(v/v) bleach (Domestos) solution, scrubbed and rinsed vigorously several times 
with dddHiO. The glassware was then autoclaved for 1 hour before heating in an 
oven at 175°C, for a minimum of 3 hours.
The pH of the enzyme preparation was adjusted from pH 5.5 to pH 6.0 with 
endotoxin-free NaOH (Sigma) and boiled for 5 minutes to remove proteinase 
activity which interferes with the assay. The enzyme sample was added to the E- 
toxate working solution and the tubes mixed gently before incubation for 1 hour 
at 37°C. Positive controls contained EPS standard and negative controls 
contained enzyme buffer alone.
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4.2.2 Vaccination with CPB2.8ACTE plus IL-12 and challenge infection with
L. mexicana
Age matched female C57BL/6, BALB/c and CBA mice were maintained in 
the animal facility of the University of Glasgow and used at 8-16 weeks of age.
Murine recombinant IL-12 was kindly provided by Prof. Phil Scott, 
University of Pennsylvania, USA. This was diluted to yield 2.5 pg/ml in PBS and 
a 200 pi injection was given subcutaneously at the tailbase, between 30 and 60 
minutes before administration of the active or inactive CP (5 pg) or saline control 
at the same site and route. Separate administration of antigen and adjuvant was 
taken as a precautionary step since the active enzyme may have proteolytically 
cleaved IL-12.
The immunisation schedule was: 15 mice, each of 3 different strains 
(C57BL/6, CBA and BALB/c), were divided into 3 groups of 5 (A - C). Group 
A were injected with active enzyme plus IL-12; group B were injected with E-64 
inactivated enzyme (as described in section 2.3.11, chapter 2) plus IL-12; group C 
were injected with PBS, pH 7.4, as a control.
Mice were immunised twice, two weeks apart, using 200 pi of adjuvant plus 
200 pi of purified CPB2.8ACTE (or saline).
L. mexicana promastigotes were harvested from late log phase culture by 
centrifiigation at 700 g for 15 min at 4°C and washed twice with PBS, pH 7.4. 
Parasite pellets were re-suspended to 1 x 10 /^ml and 200 pi aliquots used to infect 
mice 2 weeks after the second set of immunisations. Mice were infected into a 
shaven i*ump.
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4.2.3 Measurement of lesion volume
The course of infection was monitored by weekly measurement of the
shaven rump using a slide gauge micrometer. Lesion volume was measured in
this study according to the calculations described by Honigberg (1961).
They found that the volume of the protruding portion of the lesion represented
one half of a spheroid. Thus, the formula used was
4/3 7t X 1/2 X w/2 X h 
2
where 1 = length, w = width and h ^ height. Thus volumes were calculated using 
0.5236 X 1X h X w.
4.2.4 Detection of Lc/s/r/M««ifl-specific antibodies by ELISA
Peripheral blood was obtained after five months (and seven months for CBA 
mice) from infected animals by tail bleeding into heparinised capillary tubes. All 
plasma samples were stored at -20°C before analysis for specific Ab content.
Leishmania-&i^&c\ûc IgGl and JgG2a end-point titres were measured by 
ELISA. Each well of an Immulon-1 microtitre plate (Dynatech Laboratories, 
Billingshurst, UK) was coated with 2 pg of soluble leishmanial antigen (SLA) 
(fteeze/thawed wild-type promastigotes in PBS, pH 9.0, were centrifuged at 
10,000 g for 15 min and the supernatant was utilised as SLA) by overnight 
incubation. Following incubation of serial dilutions of plasma samples for 1 h at 
37°C, bound Abs were detected by incubation with either rat anti-mouse IgGl- 
HRP conjugate (diluted 1/20,000) or rat anti-mouse IgG2a-HRP conjugate 
(Southern Biology Associates, Birmingham, USA). Binding of conjugate was 
visualised with tetramethylbenzidine (0.06 mg/ml) in 0.1 M sodium acetate buffer,
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pH 5.5, containing 0.04 % H2O2. The colour reaction was stopped by adding 10 
% (v/v) sulphuric acid, and the absorbance was measured at 450 nm. Results 
were expressed as end-point dilutions in which the end-point was defined as the 
final plasma concentration that yielded an absorbance higher than a negative 
control plasma sample included in the assay.
4.2.5 Splenocyte responses
Spleens were aseptically removed at appropriate times post-infection, as 
detailed for individual groups to be analysed. Cell suspensions were prepared by 
gently teasing apart the tissue in RPMI 1640 supplemented with 2 mM L- 
glutamine, 100 U/ml penicillin, 100 pg/ml streptomycin, 50 p,M |3-ME and 10 % 
(v/v) HI-FCS (Life Technologies, Paisley, UK). This was designated complete 
medium. Following centrifugation at 200 g for 10 min at 4°C, cells were re­
suspended in 5 ml of Boyle’s solution (0.17 M Tris/HCl, pH 7.2 and 0.16 M 
ammonium chloride) at 37°C for 2 min to deplete red blood cells. Spleen cells 
were then eentrifuged at 200 g for 10 min at 4°C, resuspended, washed and 
resuspended in 2 ml of complete medium. Viable cells were enumerated by trypan 
blue exclusion, and the suspensions were adjusted to 5 x 10^  cells/ml. Aliquots of 
the cell suspension (100 p,l) were added to 96-well, flat-bottomed tissue culture 
plates (Costar, Cambridge, USA), and 100 p,l aliquots of concanavalin A (Con A) 
(5 pg/ml), SLA (10 p,g/ml) or recombinant CPB2.8ACTE (5 pg/ml) were added. 
Cultures were then incubated in 5 % C02/95% air for 72 h at 37°C. Supernatants 
were collected at this time and fi'ozen at -20°C until cytokine quantification was 
performed.
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4.2.6 IFN-y, IL 4, IL-10 and IL-12 assays
IFN-y and IL-4 production by stimulated T cells (stimulated by Leishmania 
antigen or Con A) and non-stimulated cells (complete RPMI) from mice infected 
with wild-type parasites were measured by capture ELISA, while IL-10 and IL-12 
(from thioglycollate-elicited macrophages) was also measured in this way. The 
wells of Immulon-1 microtitre plates (Dynatech Laboratories) were coated with 
capture Ab at 2 |ig/ml (IFN-y, R4-6A2 (PharMingen, San Diego, USA)); IL-4,
1 IB 11 (Genzyme, Cambridge, UK) in PBS, pH 9.0 by overnight incubation at 
4°C (Antibodies to IL-10 and IL-12 were a kind gift from Prof. Phil Scott). Wells 
were then washed three times with PBS, pH 7.4/0.05 % Tween-20 (wash bufter) 
and blocked by incubation by 10 % (v/v) FCS for 1 h at 37°C. The culture 
supernatants and appropriate recombinant standards (rIFN-y, rIL-10 and rIL-12, 
PharMingen; IL-4, Genzyme) were then added to individual wells. For standard 
curves, rIFN-y, IL-10 and IL-12 (0-1,250 pg/ml) and rIL-4 (0-625 pg/ml) were 
used. Following incubations at 37°C for 2 h, the wells were washed three times 
with wash buffer, and then biotinylated rat anti-mouse IFN-y (XMG1.2, 
PharMingen; 1 (Xg/ml) or biotinylated rat anti-mouse IL-4 (Genzyme; 1 p,g/ml) 
was added and incubated for 1 h at 37°C.
For the detection of bound biotinylated rat Ab, 100 p.1 of streptavidin- 
alkaline phophatase conjugate (diluted 1/1000, PharMingen) was added to each 
well for 45 min at 37°C, and following further washing, binding was visualised 
with substrate consisting of p-nitrophenyl phosphate (1 mg/ml. Sigma) in glycine 
buffer (0.1 M, pH 10.4). The absorbance was subsequently measured at 405 nm 
on a Titertek Multiscan Plate Reader. All assays were conducted in triplicate.
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4.2.7 Statistics
Comparisons between groups of mice were made with a Mann-Whitney U 
test for measurement of antibody titres. For comparison of lesion volume and 
cytokine production between groups of mice, the Student’s t test was used. P 
values of <0.05 were considered significant.
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4.3 RESULTS
4.3.1 Lipopolysaccharide (LPS) content of recombinant CPB2.8ACTE
The LPS content of recombinant CPB2.8ACTE was determined using the 
E-toxate assay and found to be < 1 ng LPS/mg protein. This was considered to 
be a significantly low level of LPS which would not influence the experimental 
results and the level of LPS correlates well with production of recombinant 
protein from E. coli  ^used in other immunological studies (Skeiky et al, 1998; 
Aebischer et al, 2000).
4.3.2 Protection of BALB/c mice against L. mexicana infection
The control mice, injected only with saline developed non-healing lesions 
which were significantly swollen in the shaven rump (Figure 4.3.1). In contrast, 
immunisation with either active or inactive CPB2.8ACTE plus IL-12 adjuvant 
delayed the onset of lesion formation for three weeks and thereafter resulted in 
lesions significantly smaller than those of the control group (p< 0.05). In two 
mice immimised vWth the active and inactive CPB, complete healing of the 
lesion was observed. There was no significant difference in protection mediated 
by the active or inactive CP.
4.3.3 Protection of CS7BL/6 mice against L. mexicana infection
The control mice, injected with PBS alone, developed progressive lesions 
(Figure 4.3.2). The lesions differed from the lesions observed in PBS-immunised 
BALB/c mice (Figure 4.3.1). The lesions were characterised by a visibly wet
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Figure 4.3.1 Cutaneous lesion growth of/.. 
mexicana in non-vaccinated (PBS) BALB/c 
mice or vaccinated with CPB2.8ACTE (active or 
inactive), 1 mo before challenge with 2x10^  
wild-type promastigotes. Mice (5 per group) 
were vaccinated on two occasions, two weeks 
apart with 5 ^g proteinase, 30 min after 
administration of IL-12. Control mice were 
inoculated in a similar manner with PBS alone. 
Data represent mean values of 5 mice per 
group with error bars corresponding to mean +/- 
SEM. Control mice had significantly higher 
lesion volumes than both groups of CPB- 
vaccinated mice (p< 0.05). There was no 
significant difference between the two CPB- 
immunised groups.
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Figure 4.3.2 Cutaneous lesion growth of L. 
mexicana  in non-vaccinated (PBS) C57BL/6 mice 
or vaccinated with CPB2.8ACTE (active or inactive), 
1 mo before challenge with 2 x 1 0 ^  wild-type 
promastigotes. Mice (5 per group) were vaccinated 
on two occasions, two weeks apart, with 5 ^g 
proteinase, 30 min after administration of IL-12. 
Control mice were inoculated in a similar manner 
with PBS alone. Data represent mean values of 5 
mice per group with error bars corresponding to 
mean +/- SEM. Control mice displayed significantly 
larger lesion volumes than active CPB-immunised 
mice (p< 0.05) and inactive CPB-immunised mice 
(p< 0.02). There was no significant difference 
between the two CPB-immunised groups.
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ulcer at the site of infection- Of the five mice analysed, one did not develop a 
lesion at all. Those mice vaccinated with the active or inactive CP and IL-12 
showed a similar degree of protection as occurred in the CPB-vaccinated BALB/c 
mice, although healing was seen in three mice immunised with the inactive CPB 
and two mice immunised with active CPB, with significantly smaller and less 
severe lesions occuring than in the control mice. The immunisation of active CP 
and IL-12 or inactive CP and IL-12 resulted in no significant difiference in terms 
of lesion volume.
4.3.4 Protection of CBA mice against L. mexicana infection
The control CBA mice, vaccinated with saline alone, developed non-healing 
lesions (Figure 4.3.3). The lesions were similar in appearance to those in the 
BALB/c mice, although the lesions were slower growing. One of the five mice 
did not develop a lesion. Immunisation of mice with active or inactive CP plus 
IL-12 adjuvant delayed the onset of lesion formation by two weeks and those 
lesions that did form subsequently were significantly smaller than those seen in the 
PBS-immunised mice (p< 0.001). One mouse fi-om each group of vaccinated 
mice did not develop any lesions. Again, the activity of the enzyme was 
unimportant in conferring protection against wild-type L  mexicana infection.
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Figure 4.3.3 Cutaneous lesion growth of L. mexicana 
in non-vaccinated (PBS) CBA mice or vaccinated with 
CPB2.8ACTE (active or inactive), 1 mo before 
challenge with 2x10^  wild-type promastigotes. Mice 
(5 per group) were vaccinated on two occasions, two 
weeks apart, with 5 ^g proteinase, 30 min after 
administration of IL-12, Control mice were inoculated 
in a similar manner with PBS alone. Data represent 
mean values of 5 mice per group with error bars 
corresponding to mean +/- SEM. Control mice had 
significantly larger lesions than both groups of CPB- 
immunised mice (p< 0.001). There was no significant 
difference between the CPB-immunised groups.
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4.3.5 Analysis of Ze/s/rwa«/fl-specific antibodies in vaccinated BALB/c mice
As IL-4 and IFN-y direct immunoglobulin class switching for IgGl and
IgG2a, respectively (Finkelman et al, 1990), we measured production of these 
antibody isotypes specific for Leishmania to provide an indirect but physiological 
in vivo assessment of the pattern of cytokine production.
After 5 months, control mice injected with saline alone, displayed high 
antibody titres of the IgGl subclass with much lower IgG2a titres, as is 
characteristic of infections with wild-type L. mexicana (Figure 4.3.4). The level 
of IgGl was significantly decreased in active and inactive CPB plus IL-12- 
vaccinated mice and there was a distinct and significant increase in the 
IgG2a/IgGl ratio (p <0.05), although the IgG2a antibody titre was not 
significantly different fi-om control mice.
4.3.6 Analysis of Leishmania-sptcxTic antibodies in vaccinated C57BL/6 mice
Mice vaccinated with inactive CPB and IL-12 displayed very low levels of 
IgGl. This was significantly lower than that observed in control mice (p <0.05) 
although it was not significantly different fi-om that of the active CP-vaccinated 
mice (Figure 4.3.5). Active CPB-immunised mice had comparable levels of IgGl 
to that of the control mice and there was no signifcant difference between these 
two groups. The level of IgG2a was similar for all groups studied and there was 
no significant difference between the groups. The increase in the IgG2a/IgGl 
ratio was not apparent in the CPB/IL-12-vaccinated mice compared with the 
change in ratio observed in the CPB/IL-12-vaccinated BALB/c mice.
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Figure 4.3.4. Analysis of plasma IgGl and 
lgG2a levels in vaccinated BALB/c mice 5 mo 
after infection with wild type stationary phase L. 
mexicana  promastigotes. Values represent 
mean end-point dilutions +/- SEM (n=4). 
lgG2a was not significantly different between 
the three groups but IgGl was significantly 
lower in the CPB-immunised mice compared 
to the saline control mice (p< 0.05).
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Figure 4.3.5 Analysis of plasma IgGl and lgG2a 
levels in vaccinated C57BL/6 mice 5 mo after 
infection vwth wild-type stationary phaseL. mexicana 
promastigotes. Values represent mean end-point 
dilutions +/- SEM (n=5). Inactive CPB-immunised 
mice displayed significantly lower levels of IgGl than 
control mice (p< 0.05) but there vas no significant 
difference compared to active-CPB immunised mice. 
For lgG2a production, there vas no significant 
difference betveen the groups analysed.
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4.3.7 Analysis of ZmA/wflwia-specific antibodies in vaccinated CBA mice
Control mice had significantly higher levels of IgGl than the mice 
immunised with inactive CP and IL-12 (p <0.05) (Figure 4.3.6). In contrast, 
levels of IgGl were not significantly different between control mice and mice 
immunised with the active CP plus IL-12. There was no significant difference in 
levels of IgG2a isotypes in any of the groups analysed. The increase in the 
IgG2a/IgGl ratio was not apparent in the CPB/IL-12-vaccinated mice compared 
with the change in ratio observed in the CPB/IL-12-vaccinated BALB/c mice and 
was similar to that observed in the CPB/IL-12-immunised C57BL/6 mice.
At 7 months post-infection, the IgGl titres for control mice were 
significantly higher compared with control mice at 5 months post-infection (p< 
0.05) (Figure 4.3.7). Control saline-injected mice had a significantly higher level 
of IgGl than both the groups of mice immunised with the active or inactive CPB 
(p< 0.05 for both). However, there was no significant difference between IgG2a 
levels in any groups of mice, as IgG2a was high in saline-injected mice. The 
increase in IgGl in mice analysed at 7 months compared with 5 months post­
infection, resulted in a decrease in the IgG2a /IgGl ratio in the saline-infected 
groups (1:3) compared with 5 months post-infection (1:2).
4.3.8 IFN-y production by stimulated splenocytes from BALB/c vaccinated 
mice
IFN-y production fi^ om splenocytes isolated from vaccinated BALB/c mice 
seven months post-infection and stimulated with SLA (10 pg protein /ml), 
recombinant CPB2.8ACTE (5 pg/ml) and Con A (5 pg/ml) are shown in Figures 
4.3.8, 4.3.9 and 4.3.10, respectively.
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Figure 4.3.6 Analysis of plasma IgGl and lgG2a levels in 
vaccinated CBA mice 5 mo after infection with wild type 
stationary phase L mexicana promastigotes. Values 
represent mean end-point dilutions +/- SEM (n=5).
Control mice had significantly higher levels of IgGl than 
mice immunised with inactive CPB/IL-12 (p< 0.05) but 
displayed no significant difference between mice 
immunised with active CPB/IL-12. There was no 
significant difference in lgG2a production between all the 
groups of mice studied.
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Figure 4.3.7 Analysis of plasma IgGl and lgG2a 
levels in vaccinated CBA mice 7 mo after infection 
with wild type stationary phase L. mexicana 
promastigotes. Values represent mean end-point 
dilutions +/- SEM (n=5). The level of IgGl was 
significantly higher in control mice compared to 
groups of mice immunised with active or inactive 
CPB/IL-12 (p< 0.05). lgG2a levels vere not 
significantly different betveen the groups of mice 
analysed.
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Figure 4.3.8 IFN-y production by cultured 
splenocytes removed from CPB-immunised and 
control (PBS) BALB/c mice, 7 mo post-infection with 
wild-type stationary phase L mexicana 
promastigotes. Cytokine analysis was performed on 
soluble leishmanial antigen-stimulated (10 pg 
protein/ml) cultures with non-stimulated cultures used 
as controls. Bars represent SEM (n=4). Splenocytes 
from active and inactive CPB-immunised mice 
produced significantly higher levels of IFISPy than 
control mice (p< 0.02; p< 0.001 respectively). There 
was no significant difference in IFN-y levels between 
the two groups of CPB-immunised mice.
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Figure 4.3.9 IFN-y production by cultured 
splenocytes removed from CPB-immunised and 
control (PBS) BALB/c mice 7 mo post-infection with 
wild-type stationary phase L. mexicana 
promastigotes. Cytokine analysis was performed on 
CPB2.8ACTE -stimulated (5 pg/ml) cultures. Non- 
stimulated cultures were used as controls. Bars 
represent SEM (n=4).
Mice immunised with inactive CPB/IL-12 had 
significantly higher levels of IFN-y than background 
(p< 0.05). Mice immunised with acti\^ CPB/IL-12 or 
injected with PBS did not produce levels of IFN-y that 
were significantly different from background.
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Figure 4.3.10 IFN-y production by cultured 
splenocytes removed from CPB-immunised 
and control (PBS) BALB/c mice, 7 mo post­
infection with wild-type stationary phase L 
mexicana promastigotes. Cytokine analysis 
was performed on Con A (5 pg/ml)-stimulated 
cultures. Bars represent SEM (n=4). All 
groups produced significantly higher levels 
than background (p< 0.01) but were not 
significantly different from each other.
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Splenocytes from CPB-vaccinated mice, incubated with SLA produced 
significantly increased levels of IFN-y compared with control mice (active CPB, p 
<0.02; inactive CPB, p <0.001) (Figure 4.3.8). There was no significant 
difference in splenocyte IFN-y production between the active and inactive CPB- 
vaccinated mice.
When splenocytes were stimulated with recombinant CPB2.8ACTE (Figure 
4.3.9), only the inactive CPB-immunised mice produced levels of IFN-y that were 
significantly greater from the background levels (p <0.05). Control mice injected 
3vith saline produced no detectable IFN-y in response to recombinant enzyme 
stimulation. The level of IFN-y produced from inactive CPB-vaccinated mice that 
were stimulated with SLA and CPB2.8ACTE was also different, with significantly 
more IFN-y being produced by the former antigen stimulus (p <0.02).
Con A stimulation increased IFN-y production to significantly greater levels 
than background in all splenocyte cultures tested (p <0.01) (Figure 4.3.10), with 
there being no significant difference between IFN-y production by any of the 
groups studied.
4.3.9 IL-4 production by stimulated splenocytes from vaccinated BALB/c 
mice
While splenocytes from control mice injected with saline failed to produce a 
significant antigen-induced increase in IFN-y production, there was a marked and 
highly significant increase in IL-4 production over background levels (p <0.001), 
when splenocytes were stimulated with SLA (Figure 4.3.11) but not when 
stimulated with CPB2.8ACTE (Figure 4.3.12). In contrast, CPB-immunised mice
116
Chapter 4
- 1 □ SLA
60 -
T
m Medium
2
40 -
2 0 -
0
T
1 r
CPB+IL-12 CPB(E-64)+IL-12 
Vaccinated group
PBS
Figure 4.3.11 IL-4 production by cultured 
splenocytes removed from CPB and control (PBS) 
BALB/c mice, 7 mo post-infection with wild-t^e 
stationary phase L mexicana promastigotes. 
Cytokine analysis was performed on SLA- 
stimulated (10 pg/ml) cultures with non-stimulated 
cultures used as controls. Bars represent SEM 
(n=4). Control (PBS) mice produced significantly 
higher levels of IL-4 compared with background 
(p< 0.001) while both CPB-immunised groups did 
not.
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Figure 4.3.12 IL-4 production by cultured 
splenocytes removed from CPB-vaccinated and 
control (PBS) BALB/c mice, 7 mo post-infection 
with wild-type stationary phase L mexicana 
promastigotes. Cytokine analysis was performed 
on CPB2.8ACTE-stimulated (5 pg/ml) cultures with 
non-stimulated cultures used as confrols. Bars 
represent SEM (n=4). CPB-stimulated cultures did 
not produce significantly higher levels of IL-4 
compared with background in all groups studied.
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did not produce levels of IL-4 that were significantly different from background 
levels when stimulated with SLA or recombinant enzyme (Figures 4.3.11 and 
4.3.12). Con A-induced splenocyte IL-4 production was significantly greater (p 
<0.01) than background levels for all groups of immunised mice (Figure 4.3.13).
4.3.10 IFN-y production by stimulated splenocytes from C57BL/6 vaccinated 
mice
IFN-y production from splenocytes isolated from C57BL/6 mice seven 
months post-infection and stimulated with SLA (10 pg protein/ml), recombinant 
CPB2.8ACTE (5 pg/ml) and Con A (5 pg/ml) is shown in Figures 4.3.14, 4.3.15, 
and Figure 4.3.16, respectively.
Stimulation with the SLA preparation, significantly increased IFN-y 
production in comparison with background levels in mice vaccinated with active 
(p <0.0001) and inactive (p <0.01) CPB (Figure 4.3.14). In contrast, there was 
no significant increase with splenocytes from control mice, when stimulated with 
SLA. There was no significant difference in IFN-y production between 
splenocytes from active and inactive CPB-immunised mice when stimulated with 
SLA.
When splenocytes were stimulated with recombinant CPB enzyme, the level 
of IFN-y production in all groups of mice was very low and not significantly 
different from background levels (Figure 4.3.15).
Con A stimulation increased IFN-y production to substantially greater levels 
than background in aU splenocyte cultures tested (Figure 4.3.16) (p< 0.01) but 
there was no significant difference between the groups studied.
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Figure 4.3.13 IL-4 production by cultured 
splenocytes removed from CPB-vaccinated and 
control (PBS) BALB/c mice, 7 mo post-infection 
with wild-type stationary phase L mexicana 
promastigotes. Cytokine analysis was performed 
on Con A-stimulated (5 pg/ml) cultures. Bars 
represent SEM (n=4). All Con A-stimulated 
cultures produced significantly higher levels of IL-4 
compared with background (p< 0.01) but were not 
significantly different from each other.
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Figure 4.3.14 IFN-y production by cultured 
splenocytes removed from CPB-vaccinated and 
control (PBS) C57BL/6 nice, 7 mo post-infection 
with wild-type stationary phase L. mexicana 
promastigotes. Cytokine analysis was performed on 
SLA (10 pg/ml)-stimulated cultures. Background 
levels are shown for comparison. Bars represent 
SEM (n=5). Mice immunised with active CPB and 
inactive CPB produced significantly higher levels of 
IL-4 (p< 0.0001; p< 0.01 respectively) than 
background while control mice did not. There was 
no significant difference in splenocyte production of 
IL-4 between the two CPB-immunised groups.
121
Chapter 4
2
£u_
■ CPB2.8a CTE
□ Medium
CPB+IL-12 CPB(E-64)+IL-12 
Vaccinated group
PBS
Figure 4.3.15 IFN-y production by cultured 
splenocytes removed from CPB-vaccinated and 
control (PBS) C67BL/6 mice, 7 mo post­
infection with wild-type stationary phase L  
mexicana promastigotes. Cytokine analysis 
was performed on CPB2.8ACTE (5 pg/ml) - 
stimulated cultures. Bars represent SEM (n=4). 
Splenocyte production of IL-4 was not 
significantly higher than background levels, in all 
groups studied.
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Figure 4.3.16 IFN-y production by cultured 
splenocytes removed from CPB-vaccinated 
and control (PBS) C57BL/6 mice, 7 mo post­
infection with wild-type stationary phase L  
mexicana promastigotes. Cytokine analysis 
was performed on Con A (5 pg/ml) - 
stimulated cultures. Bars represent SEM 
(n=4). All groups produced significantly 
higher levels of IFN-y than background levels 
(p< 0.01) but there was no significant 
difference between the groups analysed.
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4.3.11 IL-4 production by stimulated splenocytes from C57BL/6 vaccinated
mice
While splenocytes from control C57BL/6 mice showed no antigen-induced 
increase in IFN-y, there was a marked increase in IL-4 production, when 
stimulated with SLA (p <0.01) (Figure 4.3,17). However, CPB-vaccinated mice 
did not exhibit a significant increase in IL-4 production compared with 
background levels (Figure 4.3.17) nor did they respond to stimulation with 
recombinant enzyme, in terms of IL-4 production (Figure 4.3.18). Moreover, 
control mice did not produce a significantly different level of IL-4 compared to 
background levels when stimulated with CPB2.8ACTE (Figure 4.3.18).
Con A polyclonal stimulation did produce much greater levels of IL-4 than 
background levels, in all groups of mice tested (p <0.0001) (Figure 4.3.19). 
Splenocytes from mice immunised with active CPB/IL-12 had significantly higher 
levels of IL-4 than splenocytes from mice immunised with inactive CPB/IL-12 (p< 
0.01) but no greater than control mice.
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Figure 4.3.17 IL-4 production by cultured 
splenocytes removed from CPB-vaccinated 
and control (PBS) C57BL/6 mice, 7 mo post­
infection with wild-type stationary phase 
L. mexicana promastigotes. Cytokine analysis 
was performed on SLA (5 pg/mi) -stimulated 
cultures. Bars represent SEM (n=5). Control 
(PBS) mice produced significantly higher levels 
of IL-4 than background levels (p< 0.01) 
whereas CPB-immunised mice did not.
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Figure 4.3.18 IL-4 production by cultured 
splenocytes removed from CPB-vaccinated 
and control (PBS) C57BL/6 mice, 7 mo post­
infection with wild-type stationary phase L  
mexicana promastigotes. Cytoldne analysis 
was performed on CPB2.8ACTE (10 pg/ml) - 
stimulated cultures. Bars represent SEM 
(n=5). Splenocyte production of IL-4 from all 
groups was not significantly higher than 
background levels.
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Figure 4.3.19 IL-4 production by cultured 
splenocytes removed from CPB-vaccinated and 
control (PBS) C57BL/6 mice, 7 mo post-infection 
with wild-type stationary phase L mexicana 
promastigotes. Cytokine analysis was performed 
on Con A (5 pg/ml)-stimulated cultures. Bars 
represent SEM (n=4). All groups produced 
significantly high levels of IL-4 compared with 
background levels (p< 0.0001). Active CPB- 
immunised mice had significantly higher levels of 
IL-4 than inactive CPB-immunised mice (p< 0.01) 
but were not significantly different from control 
mice.
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4.4 DISCUSSION
It is well documented that a protective immune response against cutaneous 
leishmaniasis is associated with a type 1 response and IFN-y production (Heinzel 
et al, 1989). Therefore, successful vaccination requires administration of defined 
antigens together with an adjuvant that preferentially stimulates the expansion of 
IFN-y secreting Lew/ïwîflnm-specific Th 1 cells.
Previous studies have shown that CPB2.8 is a potential T cell immunogen 
and is capable of eliciting a protective Th 1 cell line with concurrent production of 
IFN-y (Wolfi’am et al, 1995). It is therefore very encouraging for future vaccine 
strategies that the immunisation of all three mouse strains of mice with 
CPB2.8ACTE and IL-12 significantly protected against L  mexicana infection. In 
each of the mouse strains tested, development of parasite lesions was significantly 
reduced in volume in the CPB-immunised mice compared with control mice, 
which developed much larger lesions. Furthermore, some of the vaccinated 
animals healed and others failed to develop lesions.
The argument that IL-12 alone, is the factor required for protection against 
Leishmania rather than the mixture of antigen and adjuvant has been dispelled m 
several studies since IL-12 on its own is not enough to protect mice against 
leishmanial infection (Aebischere/tï/., 2000; Afonso 1994). This in part 
may be due to the very short half-life of three hours when injected into rodents 
(Kenney et al., 1999). This may provide a limited window of opportunity to 
vaccinate when the conditions are right to promote a Th 1 response.
Furthermore, administration of IL-12 alone to naive mice has been shown to 
induce the expression of IL-10 (Melby et al, 1996), a cytokine capable of 
exacerbating Leishmania infection (Suffia et al, 2000).
128
Chapter 4
BALB/c mice are particularly susceptible to infection with Leishmania and 
a previous vaccine study incorporating CP as the protective antigen has been 
unsuccessful at protecting this mouse strain against Leishmania pifanoi (Soong et 
al, 1995). It was therefore encouraging to see that the enzyme administered 
with IL-12 afforded a large degree of protection against infection in this strain. 
Indeed, not only were lesions significantly smaller in vaccinated animals but some 
healed completely. Strong protection was also seen in C57BL/6 mice in this 
study. On the other hand, Aebischer et al (2000), using inactive, misfolded 
CPB2.8 and recombinant IL-12 was also able to partially protect C57BL/6 mice 
but not BALB/c or CBA mice. It is likely that the different immunisation 
protocol between the two groups, were responsible for the observed phenotypes. 
Several differences relating to the antigen itself are apparent. Aebischer et a l 
(2000) immunised mice with hah* the dose of enzyme used in our study but it is 
unlikely that the difference between the two doses would be sufficient to allow for 
protection in C57BL/6 and not in BALB/c or CBA mice. It is more feasible that 
the nature of the proteinase used by Aebischer for immunisation was the 
determining fector. Due to the known proteolytic capability of CPB2.8ACTE, a 
precautionary step was taken in my experiments whereby IL-12 was injected a 
short time before immunising with CPB2.8ACTE. In contrast, Aebischer (2000) 
immunised with native CPB and IL-12 concurrently. Presumably, the native CPB 
was proteolyticaUy active and could have degraded IL-12 at the site of 
inoculation. The effect of this could be to partially inhibit the Th 1-potentiating 
effects of IL-12 so that BALB/c and CBA mice were not protected against 
Leishmania infection. Alternatively, the inactive, misfolded CPB used for 
immunisation in the Aebischer (2000) study would be structurally different fi-om
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the native CPB molecule. Thus, antigen processing and epitope selection could 
be different from native antigen, with consequences for the developing immune 
response (Abbas et al, 1994).
Another study involving purification of a native CP from L. amazonensis 
and vaccination with this enzyme did confer protection to infection with 
L. amazonensis^ in BALB/c mice (Beyrodt et al, 1997) but the choice of 
adjuvant, FCA, could not be used for human vaccine trials. However, the purified 
proteinase did elicit IFN-y and IL-2 from splenocytes harvested from vaccinated 
mice and so this enzyme could afford protection to L. amazonensis infection. Our 
results agree with those of Beyrodt et al (1997) m that the purified CP was 
protective against the respective leishmanial infection and could elicit IFN-y 
production from splenocytes removed from vaccinated mice. However, IL-2 was 
not measured m this study but m future, this should be performed.
An examination of the humoral and cellular immune responses of BALB/c 
mice following vaccination with CP and infection is consistent with CPB2.8ACTE 
and recombinant IL-12 partially protecting against wild-type L  mexicana 
infection by promoting a Th 1 response. The level of IgGl and IgG2a isotypes in 
control PBS-immunised mice was very similar to that seen by Alexander et a l 
(1998) with high IgGl titres and low levels of IgG2a. However, immunisation 
with active or inactive CPB2.8ACTE and IL-12 significantly decreased IgGl, 
suggesting more of a developing Th 1 response. The observation that there was 
no increase in IgG2a production in CPB-vaccinated mice is interesting since 
Aebischer et a l (2000) found that mice vaccinated with CPB and IL-12 produced 
IgG2a titres against parasite lysate that were ten times higher than in non­
vaccinated animals. IL-12 is known to up-regulate IgG2a antibody production
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by production of IFN-y (Trinchieri, 1995). Consequently, we may have expected 
elevated IgG2a levels from the CPB/IL-12 vaccinated mice in this study, since 
these mice were strongly protected against Leishmania infection and were shown 
to produce splenocyte IFN-y compared to controls, in response to SLA 
stimulation. Injection of a CP frrom the house dust mite, has been shown to 
stimulate IgE production (Gough et al, 1999) and it is possible that injection of 
CPB2.8ACTE may have resulted in such an increase in IgE with subsequent 
antibody isotype switching fi*om IgG2a to IgE (Finkelman et al, 1990).
Detection of IgE was to be carried out by collaborators at the University of 
Strathclyde.
The direct evidence for a change in T helper cell phenotype following 
vaccination during L. mexicana infection was visualised by analysis of splenocyte 
production of IFN-y and IL-4. Control mice exhibited high IL-4 and virtually no 
IFN-y production when stimulated with parasite lysate, indicative of a Th 2 
response as previously seen in wild-type L. mexicana infected BALB/c mice 
(Alexander et al, 1998). In contrast, mice immunised with CPB and IL-12 
displayed significantly higher IFN-y and lower IL-4 levels upon stimulation with 
parasite lysate, indicative of a protective Th 1-type response (Alexander et al, 
1998).
Collectively, the data indicate that CPB2.8ACTE plus recombinant IL-12 
can switch the Th 2 response normally seen in Leishmania infection to a 
protective Th 1 response. This agrees with several studies performed using 
Leishmania antigen and recombinant IL-12 as a protective combination in 
establishing a Th 1 phenotype and protecting against Leishmania infection ( 
Afonso et al, 1994; Aebischer et al, 2000 ). The results also indicate that a
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leishmanial CP is potentially usefiil as a protective antigen, as seen with other 
systems (Soong et al, 1995; Rafati et al, 2000).
However, the question remains as to what effect the enzyme activity of the 
CPs per se have on the outcome of Leishmania infection. Vaccination with active 
and inhibited enzymes plus IL-12, exhibited equally protective effects, in terms of 
reduction in lesion size, decreasing IgGl production and increasing IFN-y 
production with concomitant reduction of IL-4. IFN-y production from 
splenocytes stimulated with active CP has been recently reported in a vaccine 
study against L. major infection (Rafati et al, 2000) and so we may have 
expected IFN-y production from the two CPB-immunised groups, when 
stimulated with recombinant CPB2.8ACTE. When splenocytes from both 
BALB/c and C57BL/6 strains of mice were re-stimulated with CPB2.8ACTE, 
there was no IL-4 production in any of the groups (active or inactive CPB- 
immunised or control) assessed. In contrast, IFN-y production from splenocytes 
removed from mice immunised with CPB was demonstrated in the BALB/c 
mouse strain and correlates well with the results from Rafati et ah (2000). 
Splenocytes from CPB-immunised C57BL/6 mice did not produce IFN-y in 
response to CPB2.8ACTE but the enzyme used to re-stimulate these cells was 
from a different protein preparation than that used to stimulate the BALB/c mice. 
Although the enzyme was used at a similar protein concentration, the refolding 
process may have yielded a slightly different conformation of enzyme (since 
refolding is never exactly the same each time for a particular protein), which may 
not have stimulated the splenocytes as well as the first batch of enzyme.
The humoral and cellular immune response in C57BL/6 vaccinated mice
was not as clearly defined as that observed in BALB/c mice although protection
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was seen in both active and inactive CPB-vaccinated mice. As with CPB- 
vaccinated BALB/c mice, the level of protection confen*ed was no different when 
active or inactive proteinase was used to immunise mice. Antibody titres were 
much lower in C57BL/6 vaccinated mice and this may be attributed to the rate of 
parasite growth at the five month time-point of infection. By this time-point, all 
groups of the BALB/c mice had a greater mean lesion volume than all the groups 
of C57BL/6 mice and so the latter strain may not have been exposed to as many 
parasite antigens as the former and as a consequence had not produced as much 
antibody as the BALB/c vaccinated mice. The level of IgG2a was similar in all 
groups of C57BL/6 vaccinated mice and the level of IgGl was reduced in control 
mice compared with BALB/c control mice. The general antibody titre for both 
groups of C57BL/6-vaccinated mice was low and only the active CPB-vaccinated 
mice had a significantly lower IgGl titre than the control immunised mice. These 
results are very different fi’om those reported by Aebischer et al (2000), who 
found that C57BL/6 mice vaccinated with misfolded CPB2.8 and IL-12 presented 
higher IgG2a titres than PBS control mice. However, the infecting parasite dose 
was doubled in these experiments and so exposure to lysed parasite material and 
therefore antigens would be quicker in those vaccinated mice compared with our 
study.
Analysis of the cytokine responses suggest that there was a developing Th 1 
response in the C57BL/6 mice. CPB-vaccinated mice displayed significantly 
higher IFN-y levels and lower IL-4 levels than control mice which presented 
typically low levels of IFN-y and high levels of IL-4 when stimulated with SLA. 
These results correlate well with those of Aebischer and colleagues (2000), in
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terms of IFN-y production, who also found that CPB and IL-12 vaccinated mice 
produced high levels of IFN-y compared to PBS control mice.
The apparent contrast in antibody and cytokine results may be due to the 
fact that antibody analysis was for a time-point at five months post-infection, 
while the cytokine values were analysed at seven months post-infection. By seven 
months, the progression in lesion development is more disparate than was seen at 
five months post-infection and the cytokine data confirm this conclusion. In 
retrospect, it would have been interesting had the antibody analysis been 
measured nearer the time of splenocyte preparation.
CBA mice displayed a similar development in lesion progression and 
antibody iso type levels to the C57BL/6 vaccinated mice. The inactive CPB- 
vaccinated group of mice displayed levels of IgGl which were significantly lower 
than control mice but there was no significant difference in IgGl production 
between control and active CPB-vaccinated mice. Again, this may be due to the 
tailbleeds being taken at five months post-infection, when the course of infection 
was not as well established as seven months post-infection. Tailbleeds were 
therefore taken at seven months post-infection and the IgGl titre was markedly 
higher in the control mice than in either of the CPB-vaccinated mice which 
indicated more of a progressive infection compared to the CPB-immunised mice. 
However, there was no significant difference between the control and CPB- 
immunised mice in terms of IgG2a production.
CPB2.8ACTE used in this study can be readily produced from bacteria in 
large amounts and in highly purified form. Its use as an antigen suitable for 
immunisation against L. mexicana infection has been shown in this study and 
others (Aebischer et ai, 2000) but administration of this protein requires a more
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suitable adjuvant since IL-12 is presently not considered a safe adjuvant for use in 
humans because of significant side effects (Atkins et al, 1997).
Results fi-om a collaborating laboratory have shown that IL-12 is needed for 
protection against L. mexicana infection using CPB2.8ACTE as the antigen, since 
active or inactive enzyme alone, was not enough to protect mice against infection 
with this parasite. This correlates well with other studies when antigen alone did 
not confer protection against Leishmania infection and the presence of IL-12 was 
found to be essential (Kenney et al, 1999; Aebischer et al, 2000 ). In fact, 
Kenney et al (1999) reported exacerbation of disease compared with control 
mice, when IL-12 was excluded firom the immunisation regimen, which included 
freeze/thawed promastigote lysates. In this study, one group of mice (C57BL/6, 
inactive CPB-immunised mice without IL-12) at the University of Strathclyde, 
displayed a significant level of disease exacerbation, greater than that of the 
control group, immunised with PBS. One reason that CPB alone may not 
promote a protective immune response is probably due to the fact that transcripts 
encoding the IL-12 receptor p-chain are selectively inhibited by soluble antigen 
but are enhanced by IL-12 co-administration (Galbiati et al, 1998). Moreover, 
soluble protein antigen appears to be selectively presented in vitro by B cells, 
which may favour Th 2 development as they fail to secrete IL-12 (Guery et al,
1997). Furthermore, one may expect that injection of a cysteine proteinase in 
vivo would result in an increase in IL-4 production and therefore disease 
exacerbation, since injection of papain has been shown to increase mRNA for IL- 
4, one hour after injection (Finkelman & Urban, 1992). It is possible that the 
recombinant enzyme was not as active as that of native papain, since it has been 
shown that active CPB2.8ACTE was only 30 % active (Sanderson et al, 2000)
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whereas we may expect all the papain (native) molecules to be approximately 100 
% active. Analysis of mRNA for IL-4 is now being investigated at the University 
of Strathclyde to see if there is an increase in mRNA production after injection of 
active and inactive CPB2.8ACTE in mice.
Ultimately, the success of a CP vaccine will be dependent on how it is 
adjuvanted. A number of different adjuvants have been tested with purified CPs 
including FCA (Rafati et al, 2000) but this is incompatible with human use.
Other adjuvants that could be tested include IL-18. IL-18 has been shown to 
induce IFN-y production and up-regulate IL-12 receptor expression on the 
macrophage cell surface (Eberl et al, 2000). IL-18 has been used successfully to 
protect mice against pulmonary and disseminated infection with Cryptococcus 
by inducing IFN-y production (Kawakami et a/., 1997). However, 
IL-18 has not yet been tested for therapeutic use in humans, so its value in human 
use as a vaccine is not known.
A parasite CP jftom E. histolytica has been shown to possess high affinity 
for liposomes and yet remain active (Jacobs et al, 1998). Liposome formulations 
are currently being investigated for purposes of vaccination and some success has 
been already achieved in immunisation against Leishmania infection using the 
surface metalloproteinase, gp63, with liposomes (Russell & Alexander, 1988). 
Administration of CPB2.8ACTE as a liposome formulation would target the 
active enzyme to the host macrophage population, since phagocytosis of such 
molecules would occur, resulting in MHC class II presentation of parasite 
molecules to the host immune system. This may also reduce the potentially 
aggravating effects of injecting an active CP into the mammalian host.
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Research in this exciting area is currently being explored in a collaborating 
laboratoiy.
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CHAPTER 5
The effects of recombinant CPB2.8ACTE on macrophage function
5.1 INTRODUCTION
Leishmania parasites can survive within the hostile environment of a 
macrophage and are able to resist or circumvent or inhibit the microbicidal 
response by ways which include scavenging oxygen radicals generated during the 
respiratory burst (Chan et al, 1989) and suppressing N0S2 expression and NO 
production (Proudfoot et al, 1996). If the macrophage is in a fully activated state, 
normally under the influence of IFN-y, there will be an increase in nitric oxide and 
IL-12 production and subsequent killing of the parasite with a concomitant 
increase m antigen presentation of parasite molecules (Liew & O’ Donnell, 1993). 
Presentation of parasite antigens by class II MHC molecules on antigen- 
presenting cells causes expansion of the protective IFN-y producing Th 1 subset 
and has been thought to be essential for control of infection (Liew & O’ Donnell, 
1993).
The switch of CD4+ T cell differentiation from Th 2 to a Th 1 -type profile 
was seen when a cathepsin B inhibitor was used during experimental Leishmania 
infection. This suggested that alteration in antigen processing could modulate the 
polarity of T helper cell differentiation (Maekawa et al, 1998). Parasite viability 
was not directly affected by the inhibitors. Inhibition of MHC class II 
presentation is one possible mechanism by which the leishmanial CPs could
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potentially influence the generation of a protective immune response. For 
example, it has been shown in studies using L. amazonensis that MHC class II 
molecules are internalised and degraded by CPs of parasite origin although it is 
unknown how the parasites do this. This seems an important means of preventing 
antigen presentation and thus promoting parasite survival (De Souza Leao et al,
1995).
Generally in Leishmania infection, macrophage inflammatory functions are 
down-regulated and they produce significant levels of the regulatory cytokine, IL- 
10, which inhibits T cells and anti-microbial functions of macrophages by down- 
modulating macrophage leishmanicidal activity (Barrai et al, 1993). IL-10 is also 
an antagonist of IFN-y production and activity and so antigen-induced production 
of this cytokine is of particular interest since IL-10 production correlates with the 
degree of pathology (Bogdan and Rollinghoff, 1998). Furthermore, it is known 
that another Th 2-type cytokine, TGF-p, is produced during leishmanial infection 
and this too has a part to play in disease exacerbation by down-regulating IL-12 
expression and activity (Bogdan & Rollinghoff, 1998). TGF-p is the most potent 
known suppressor of NOS expression in mouse macrophages and does this by 
destabilising NOS mRNA, retarding synthesis of the protein and accelerating its 
degradation (Vodovotz et al, 1993).
A non-healing response against L. mexicana may come about for several 
reasons including inhibition of MHC presentation, down-regulation of IL-12 or 
induction of IL-4. CPs have been shown to influence MHC (De Souza Leao et 
al, 1995) and IL-4 production (Finkelman & Urban, 1992) and there is indirect 
evidence they could influence macrophage cytokine production (Maekawa et al,
1998). We therefore studied whether CPB2.8ACTE had the potential to influence
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cytokine production from activated peritoneal exudate cells, in particular IL-10, 
IL-12 and also nitric oxide output. Any significant alteration in production of one 
of these important immune mediators could conceivably influence the balance 
between a Th 1- or Th 2-type response and determine the fate of the parasite.
5.2 METHODS
5.2.1 Harvesting of peritoneal exudate cells from BALB/c mice
Age-matched adult female BALB/c mice were used in all experiments unless 
otherwise stated. 1 ml of sterile, 4% (w/v) thioglycoUate was injected into the 
peritoneum of mice 4 days before use, to elicit inflammatory macrophages.
RPMI-1640 (Gibco-BRL) was supplemented with 10 % (v/v) FCS, 2 mM 
L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (the resulting 
solution was designated complete RPMI). The mice were sacrificed using CO2 
and 5 ml of pre-chilled complete RPMI was injected into the peritoneal cavity 
using a 25 gauge needle. The peritoneum was massaged for approximately 5 
minutes before the medium was withdrawn yielding 3-4 ml of PECs suspension at 
a cell density of IxlOVml. 200 pi aliquots were added to each well of a flat- 
bottomed tissue plate (Costar) in triplicate and all cells were incubated overnight 
at 32°C in 95% air/5% CO2 to allow the macrophages to adhere. The plates were 
then washed in complete RPMI to remove any non-adherent cells.
5.2.2 Incubation of PECs with CPB2.8ACTE
The adherent cells (designated macrophages) were incubated in complete 
RPMI with various components (Table 6) at 32®C in 95% air/5% CO2 for 48
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hours to allow production of IL-10, IL-12 and NO2 . After 48 hours, 
supernatants were frozen and stored at -70°C before analysis for IL-10 and IL-12 
by ELISA as detailed in section 4.2.6, chapter 4. Antibodies for detection of IL- 
12 were a kind gift from Phil Scott, University of Pennsylvania. Antibodies for 
detection of IL-10, were purchased from Pharmingen. NO2 was measured by the 
Griess reaction. Macrophages were activated with LPS and IFN-y since ingestion 
of most microbes by macrophages elicits autocrine production of TNF-a and 
IFN-y (Macmicking et al, 1997). Addition of the recombinant enzyme (100 
ng/ml) to these activated macrophages would more closely resemble that of the 
situation in vivo.
Component
LPS (100 ng/ml)
LPS/IFN-y (50 U/ml)
LPS/IFN-y and CPB2.8ACTE (100 ng/ml)
LPS/IFN-y and CPB2.8ACTE and E-64 (10 pM)
LPS/IFN-y and boiled CPB2.8ACTE (100 ng/ml)
LPS/IFN-y and wild type lysate (100 ng protein/ml)
LPS/IFN-y and buffer (PBS, pH 6.0)
Table 6. Stimuli used to assess IL-10, IL-12 and NO2" production from
PECs
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PECs were incubated, in triplicate, with 100 pi of RPMI containing various 
stimuli shown in table 6. For activation of macrophages, cells were stimulated 
with LPS and IFN-y. To analyse the effect of active enzyme on activated 
macrophages, 100 ng/ml of CPB2.8ACTE was added to medium before addition 
of LPS and IFN-y. This concentration was used subsequently for all other 
macrophage experiments. To assess the importance of CP activity, CPB2.8ACTE 
was inhibited with E-64 (lOpM) and this concentration of E-64 was found to be 
the minimum amount that was sufficient to ablate all CP activity (result not 
shown). Recombinant enzyme was also boiled for 10 min to denature the CP. A 
lysate of wild-type L. mexicana promastigotes was also added to the activated 
macrophages to assess whether this could potentially affect IL-10 cytokine 
production. As a control, PBS was added at similar volumes as the enzyme to 
assess whether buffer could affect cytokine production.
5.2.3 Measurement of NO2 from macrophage supernatants
The production of nitric oxide by macrophages during incubation with 
CPB2.8ACTE was measured using the Griess reaction (modified fi-om Green et 
al, 1982) to detect the nitrite produced during nitric oxide degradation. Resident 
peritoneal macrophages are relatively resistant to activation by factors such as 
IFN-y, producing low levels of microbicidal effector mechanism molecules (Adam 
& Hamilton, 1992). In order to detect nitric oxide, it was necessary to use 
macrophages which had been primed for activation via elicitation with 
intraperitoneal injection with thioglycoUate broth. Injection of such broth into the 
peritoneum causes the migration of immature mononuclear phagocytes fi-om other 
tissues into the peritoneum. The granularity of the medium induces the
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macrophages present to phagocytose the particulate matter, thus imitating 
infection and promoting an inflammatory response within the peritoneum 
(Grattendick, 1999). Therefore the macrophages harvested after this procedure 
are ‘primed’ for activity and give an increased level of responsiveness after IFN- 
y/LPS stimulation.
The standard curve was prepared, using doubling dilutions in dddH20 in a 
flat-bottomed 96-well plate (Greiner Labortechnik) fi-om a 14 mM sodium nitrite 
stock with a maximum concentration of 250 pM. Stored supernatants were 
defrosted at room temperature before addition of 100 pi to the plate, in duplicate. 
1% (w/v) sulphanilamide in 5% (v/v) phosphoric acid was added to 0.01% (w/v) 
a-napthylamine in a 1:1 ratio and 100 pi was added to each well. The plate was 
incubated at room temperature for 5-10 minutes before the absorbance at 540 nm 
was measured using a Titertek Multiskan MCC/340 plate reader.
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5.3 RESULTS
5.3.1 Effect of CPB2.8ACTE on IL-12 and nitric oxide production
ThioglycoUate-eiicited PECs were stimulated with IFN-y and activated 
with LPS. This resulted in an expected increase in both IL-12 and nitric oxide 
production as can be seen in Figures 5.3.1 and 5.3.2. The enzyme in either its 
active or inactive form did not significantly affect activated macrophage 
production of these immuno-modulatory molecules. Enzyme buffer (PBS) also 
did not affect production of IL-12 or nitric oxide.
5.3.2 Effect of CPB2.8ACTE on production of IL-10
When PECs were stimulated with LPS and IFN-y, there was an expected 
increase in IL-10 production (Figure 5.3.3). When these activated macrophages 
were incubated with recombinant CPB2.8ACTE, there was a significant reduction 
in the level of IL-10 as can be seen in Figure 5.3.3 (p< 0.05). This occurred with 
both enzymatically active and E-64-inhibited enzyme. When activated 
macrophages were incubated with the same protein concentration of a wild-type 
parasite lysate, this also reduced the production of IL-10 in a manner similar to 
that of the enzyme. Enzyme buffer did not significantly alter IL-10 production 
fi-om activated macrophages.
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Figure 5.3.1 Effect of CPB2.8a CTE on nitrite production from 
LPS/IFN-y activated macrophages. Supernatants were assessed  
for nitrite levels using the Greiss reaction.
A denotes macrophages in RPMI media.
B - macrophages activated with 100 ng/ml LPS and 50 U/ml IFN- 
y (a m .)
C - a.m. plus CPB2.8a CTE,
D - a.m. plus CPB2.8a CTE (E-64).
E - a.m. plus CPB2.8a CTE (boiled).
F - a.m. plus PBS buffer.
Active enzyme, CPB (100 ng/ml), was either inactivated by E-64 
or boiled for 10 min. Results are presented as the means +/- SEM 
(n=7). The macrophages stimulated with conditions B-F were not 
significantly different from each other in nitrite production.
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Figure 5.3.2 Effect of CPB2.8a CTE on IL-12 production from 
LPS/IFN-y activated macrophages. Supernatants were 
assessed  for IL-12 production by ELISA.
A denotes macrophages in RPMI media.
B - macrophages activated with 100 ng/ml LPS and 50 U/ml IFN- 
Y (a.m.)
C - a.m. plus CPB2.8a CTE .
D - a.m. plus CPB2.8a CTE (boiled).
E - a.m. plus CPB2.8a CTE (E-64).
Active enzyme, CPB (100 ng/ml), was either inactivated by E-64 
or boiled for 10 min. Results are presented as the means +/- 
SEM (n=4). There was no significant difference in IL-12 
production between macrophages stimulated as in B-E.
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Figure 5.2.3 Effect of CPB2.Ba CTE on IL-10 
production from LPS/IFN-y activated macrophages. 
Supernatants were assessed for IL-10 production by 
ELISA.
A denotes macrophages in RPMI media.
B - macrophages activated with 100 ng/ml LPS and 50 
U/ml IFN -y (a.m.)
C - a.m. plus CPB2.8a CTE .
D - a.m. plus CPB2.8a CTE (E-64).
E - a.m. plus wild-type lysate.
F - a.m. plus PBS buffer.
Active enzyme, CPB (100 ng/ml), was either inactivated 
by E-64 or boiled for 10 min. Results are presented as 
the means +/- SEM (n=4). Macrophages stimulated with 
conditions C, D and E were significantly different from 
macrophages activated using condition B (p< 0.05).
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5.3 DISCUSSION
The role of the CPs in leishmanial infection is unknown although there is 
little question that they do play some part in the host-parasite relationship 
(Mottram et al, 1996). Several other CPs have been shown to actively degrade 
cytokines or indirectly inhibit/upregulate production of cytokines thereby affecting 
the host immune response (Calkins et al, 1998; Borger et al, 1999).
CPB2.8ACTE did not affect PEC synthesis of IL-12 or nitric oxide in 
vitro. These results confirm work done previously in this laboratory, albeit using 
a different in vitro system for analysing nitric oxide production Jfrom PECs 
infected with Leishmania parasite lines (Townson, 1999). This study analysed the 
infection of PECs with a CPB null mutant parasite {Acpb) and the results 
documented that the CPBs did not affect in vitro production of nitric oxide. The 
system used in my analysis of macrophage production of cytokines is similar to 
work done by Wang et al (1992) where soluble amoebic proteins and live 
amoebae were added to LPS and IFN-y treated PECs and the production of TNF- 
a  was monitored. The effects on TNF-a production were similar for the soluble 
amoebic protein or the live parasite and mirrors the results obtained in my study 
and that of Townson (1999), in terms of nitric oxide production. Both sets of data 
show that the PECs were unaffected in IL-12 and nitric oxide production when 
either infected with the Leishmania parasite single null (Acpb) mutant re­
expressing the proteinase, CPB2.8, or incubated with the recombinant enzyme, 
CPB2.8ACTE, itself.
The role of IL-10 in cutaneous leishmaniasis is well documented and is 
involved in leishmanial disease by inhibiting IFN-y production (Melby et al,
1996). The inhibitory effect of IL-10 on IFN-y production is mediated by loss of
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accessory cell function by suppression of IL-12 synthesis. It has recently been 
reported that a recombinant parasite molecule from L  infantum can elicit IL-10 
production by peripheral blood mononuclear cells of patients with visceral 
leishmaniasis (Sufifia et al, 2000), Therefore, CPB2.8ACTE could have a similar 
effect on production of IL-10 from PECs, even though these were isolated from 
naive mice rather than infected mice. From the results obtained, it was interesting 
to note that CPB2.8ACTE did not elicit production of IL-10 from activated 
macrophages but in contrast, reduced the generation of this cytokine.
Furthermore, enzyme activity is not necessary to induce this effect on IL-10 
production since active and inactive enzyme both significantly reduced levels of 
IL-10. This is significant as it has been reported that some parasite molecules 
which have no enzymatic activity nevertheless are able to exert their effect on host 
cells. For example, ES-62, an excretory-secretory product from 
Acanthaceilonema viteae^ can significantly affect B and T cell signal trai^duction 
(Deehan et a l, 1998). Theoretically, CPB2.8ACTE may act in a similar fashion 
by binding to macrophage receptors, or sterically affecting these receptor sites 
resulting in possible interference with various signal transduction mechanisms.
The in vitro system used here has clear limitations and the meehanism of 
action of the enzyme in the system is unknown. There are however, a number of 
possibilities such as those discussed below.
The localisation of CPB2.8ACTE is most likely to be within the lysosomes 
of the parasite, which resides within a parasitophorous vacuole within the 
macrophage. This localisation means that it is unlikely that the CPB enzymes 
could have a direct effect on cytokine production. However, work done by Ilg 
and colleagues (1994) showed that lesions contained extracellular CP activity,
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which was attributed to parasites which had lysed. The catalytically active 
proteinases could potentially interfere with the host cytokine network once 
outside the macrophage and in the extracellular milieu. It has been consistently 
shown that proteinases can degrade connective tissues such as laminin, fibronectin 
and collagen (Mort et al, 1981; Rooprai & McCormick, 1997) and in doing so, 
attract various cell types which could produce anti-inflammatory molecules such 
as IL-10 or TGF-p. Production of these two cytokines would then down-regulate 
the microbicidal potential of neighbouring macrophages and possibly allow 
parasite survival. Although this is not a defined role for the proteinase, it is 
possible that the CPs could transiently affect the macrophage activation state in 
this way, subsequently increasing parasite proliferation. However, the most likely 
function of parasite extra-corporeal cathepsin L-hke enzymes could be 
degradation of host tissues for parasite migration and following further hydrolysis 
utilisation as nutrients (Dalton et al, 1996).
A lysate of wild-type promastigotes was also tested for its ability to 
modulate IL-10 production, since it has been found that the soluble fraction of E. 
histolytica can increase TNF-a production fi:om LPS/IFN-y activated PECs 
(Wang et al, 1992). Indeed, the promastigote lysate was also found to reduce the 
level of IL-10 as did CPB2.8ACTE. It would have been of interest to determine 
whether a parasite lysate of the single null mutant, Ecpb, was also able to affect 
IL-10 production as this would rule out the possibility of CPB being an important 
factor in the decrease in IL-10 production. One may expect both the purified CP 
and the lysate to act in a similar fashion since they both possess CP activity 
although the lysate also contains a vast number of other parasite molecules and 
consequently far less CPB than in the recombinant enzyme experiment. The fact
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that the lysate and CPB2.8ACTE affected the macrophage similarly in terms of 
reducing IL-10 production is therefore not entirely surprising.
What is remarkable is that the enzyme and lysate reduced the level of IL- 
10 production from the activated macrophages at all, when they may have been 
expected to increase IL-10 production as it is produced by activated macrophages 
in much the same way as IL-12, in response to LPS and IFN-y. Suffia et al. 
(2000), using a recombinant L. infantum protein, LelF, found that incubation of 
this protein with PBMCs increased IL-10 production. The protein was therefore 
designated as a virulence factor. However, the systems used in the two 
experiments are completely different since this study utilised PECs (a 
predominance of macrophages although eosinophils and neutrophils are still 
present) from naive mice whereas Suffia et al. (2000) used purified peripheral 
blood mononuclear cells (PBMCs) from Leishmania-wÎQcXQà individuals. Further 
studies using bone-marrow derived macrophages would eliminate the possibility 
of other cells involved.
To further investigate if recombinant CPB2.8ACTE affected production of 
IL-10 from macrophages at the transcriptional level, a possible experiment could 
be to isolate the mRNA from macrophages and perform reverse transcriptase 
polymerase chain reaction (RT-PCR) for this cytokine. Moreover, proteinase 
could simply be added to IL-12 and tested for its ability to proteolytically cleave 
IL-12.
In addition to affecting macrophage cytokine production, the proteinases 
could also be involved in regulation of prostaglandin production. It is known that 
E. histolytica can alter the metabolism of arachidonic acid and therefore the 
production of important inflammatory molecules such as prostaglandin E2
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(PGE2) which down-regulates production of TNF-a and IL-12 (Wang & Chadee, 
1992). TNF-a is produced from macrophages which are stimulated by IFN-y and 
it acts in an autocrine manner to upregulate further production from the 
macrophage as well as synergising with IFN-y to activate macrophages to kill 
Leishmania parasites. It is important in Leishmania infection as it activates the 
macrophage to become inflammatory and therefore leishmanicidal (Liew & O’ 
Donnell, 1993) and so a decrease in this cytokine could alter the disease outcome. 
Other inflammatory mediators could be involved such as the prostaglandins and 
the leukotrienes, which are also known to be involved in Entamoeba infection 
(Wang & Chadee, 1992).
Leishmanial CPs appear to interfere with MHC class II molecules and their 
up-regulation by IFN-y (De Souza Leao et al, 1995). In this context, it is 
interesting to note that CPs secreted from the anaerobe Porphyromonas 
gingivalis are able to indirectly affect antigen presentation by directly cleaving 
IFN-y (Yun et al., 1999). L. mexicana CPs may act in a similar fashion. If this 
was the case, inactivation of IFN-y could potentially lead to proliferation of Th 2- 
type cells and mediate disease progression.
The major CP from T. cruzi, cruzipain has been shown to display 
kininogenase activity and can therefore affect vascular permeability (Del Nery et 
al, 1997). Cruzipain activates plasmatic pre-kallikrein with concurrent release of 
bradykinin and shares this property with another CP from a bacterium. 
Streptococcus pyogenes (Herwald et a l, 1996). Bradykinin stimulates an influx 
of macrophages from the circulation to the area of infection and helps perpetuate 
the infection as well as causing pain and swelling through release of 
prostaglandins. CPB2.8 shares high homology with cruzipain and therefore it is
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possible that CPB2.8 could also display kininogenase-like properties.
Furthermore, it is known that addition of serum to trypanosomal and leishmanial 
lysates can significantly increase CP activity and this has been attributed to a 
kininogen-like moiety (Lonsdale-Eccles et al, 1995). Experiments to elucidate 
whether this was the case for CPB2.8 would be easy to perform and would 
confirm whether CPB2.8 had kininogenase properties.
The house dust mite is known to contain a CP which also has a number of 
immunomodulatory properties and has been shown to cleave a number of cell 
surface proteins including CD23, the IgE receptor (Hewitt et a l, 1995) and 
CD25, a subunit of the IL-2 receptor (Schulz et al, 1998). The effect of this CP 
is to increase levels of circulating IgE and inhibit the ability of peripheral blood T 
cells to proliferate and secrete IFN-y. The resultant changes consequently bias the 
immune response towards the propagation of Th 2 cells and this is another 
possible way in which CPB2.8 could potentially affect the immune response once 
in the vascular system.
It has recently been found that a metacestode secreted product containing 
CP activity has the ability to deplete human CD4+ lymphocytes in vitro (Molinari 
et al, 2000). Although the leishmanial CPs are not secreted, parasite lesions have 
been shown to contain CP activity and could possibly behave in a similar manner.
Leishmanial CPs may therefore influence the host to promote infection by 
a number of mechanisms. However, these await further study.
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C H A P T E R  6
Re-integration of CPB into genetically attenuated 
L, mexicana:, analysis of disease phenotype in mice
6.1 INTRODUCTION
The activity of CPs in virulence and pathogenicity towards the mammalian 
host during infection by many pathogens is widely recognised (Carmona et al, 
1993; Travis et al, 1995; Engel et al, 1998). The L  mexicana cpb array is a 
tandemly repeated organisation of genes that may function as a mechanism to 
increase the transcript abundance of the highly expressed CPB isoenzymes. These 
CPs are recognised as virulence factors since gene deletion of the cpb array 
attenuates the organism in its ability to infect macrophages in vitro and in mice 
(Mottram et al, 1996). Re-expression of a single CP, CPB2.8, restored 
infectivity to macrophages to wüd type levels and, by inference, CP expression is 
therefore considered to be important in enabling the parasite to survive 
intracellularly.
However, the importance of the CPB isoenzymes for infectivity to a 
mammalian host has not been investigated fully. Individual isoenzymes differ in 
their substrate preferences (Mottram et al, 1997) and the first two genes of the 
cpb array, cpbl and cpb2 differ significantly firom the other genes m that they are 
transcribed predominantly in the metacyclic stage of the parasite and encode
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enzymes with a truncation in the C-terminal extension. These results suggest that 
the individual isoenzymes have distinct roles in the host-parasite interaction.
There are several experimental tools which can be used to investigate the 
roles of the leishmanial CPs as virulence factors. Gene knockout experiments can 
demonstrate whether a gene is essential. However, although a gene may be 
essential, there is no guarantee that it encodes a valid drug target (Barrett et al,
1999). Indeed, non-essential genes can encode drug targets as was demonstrated 
by Engel et al (1998). In this study, an inhibitor of cruzipain was shown to kill T. 
cruzi by preventing autocatalytic processing of the pro-mature enzyme to its 
active, mature form. This resulted in a subsequent increase in precursor 
molecules in the Golgi apparatus, which most likely prevented normal fimctioning 
of the Golgi complex and led to parasite death. Gene deletion experiments could 
not have predicted that this enzyme was indeed a valid drug target and so a 
combination of inhibitor studies and genetic manipulation should be utilised to 
study putative drug targets.
The ability to manipulate genes of trypanosomatids either through over­
expression of genes from episomal vectors or by gene deletion via targeted 
homologous recombination using drug-selectable markers has allowed the 
function of a major CP from T. cruzi, cruzipain, to be examined (Tomas et al.,
1997). This study showed how amplification of CP genes using a cosmid shuttle 
vector, resulted in elevated levels of CP activity and enhanced ability of the 
parasite to differentiate from the epimastigote to the metacyclic life-cycle stage.
In contrast, targeted gene deletion experiments have been successfully used to 
study CP function in L. mexicana, and infection of mice with double null
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{Ecpb/cpd) mutants has shown that these genetically attenuated mutants may be 
good vaccine candidates (Alexander et al, 1998).
Inhibitor studies using a group of inhibitors, the vinyl sulphones, have 
shown these compounds to be active against L. major (Selzer et ai, 1997) and T. 
cruzi (Engel et ai, 1998) and by interfering with parasite enzyme function, this 
should help to elucidate the potential roles these enzymes may play. However, 
the use of inhibitor studies also has one main disadvantage in aiding discovery of 
new drug targets. Targeted gene deletion prevents subsequent protein 
transcription and therefore loss of function of the particular protein but most 
pharmacological inhibitors do not result in a 100 % inhibition of target enzyme 
activity, when administered to living cells (Barrett et al, 1999).
However, this study will focus only on the use of genetic manipulation to 
study the potential role of the CPs in the host-parasite interaction. Generation of 
the Ecpb null mutant was produced by targeted gene deletion. This mutant was 
then manipulated for re-integration of two CPBs (see Table 7) into the parasite 
genome, rather than by re-expression of CP genes using a plasmid vector 
(Mottram et al, 1996). Re-integration of the CPB into the parasite chromosome 
has the advantage that antibiotic selection is not needed for enzyme re-expression 
whereas the latter technique used by Mottram et a l (1996) resulted in loss of 
CPB expression without antibiotic pressure in vivo.
Re-integration of an amastigote CP, CPB2.8, or a metacyclic CP, CPB2, 
into the single null mutant, Ecpb, with expression of the enzyme determined by a 
native or a chimaeric promoter should allow analysis of the importance of these 
two enzymes in vivo (see Table 7).
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Genetic manipulation Denoted Phenotype during in vitro and in vivo 
infection
None Wild-type
(WT)
Infects macrophages in vitro and produces 
rapidly growing, non-healing lesions in 
BALB/c mice (Mottram et al, 1996).
Deletion of cpb array àcpb (N53 
in cytokine 
data)
Reduced infectivity to macrophages in vitro 
by 80 % and produces slow-growing lesions 
in BALB/c mice (Mottram et al, 1996).
Deletion of cpb array; re­
integration of metacyclic 
CPB2 with native 
(metacyclic) promoter
GL165 Unknown
Deletion of cpb array; re­
integration of amastigote 
CPB2.8 with native 
(amastigote) promoter
GL166 Unknown
Deletion of cpb array; re­
integration of metacyclic 
CPB2 with chimaeric 
(amastigote) promoter
GL167 Unknown
Deletion of cpb array; re­
integration of amastigote 
CPB2.8 with chimaeric 
(metacyclic) promoter
GL168 Unknown
Deletion of cpb array; re­
expression of cpb array 
using a cosmid shuttle 
vector
GL263 Unknown
Table 7. Construction of mutants based on the Ecpb single null mutants of
L . mexicana
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Construction of chimaeric mutants was performed to analyse if the time of 
expression of the genes affects the effects the enzymes have on the host-parasite 
interaction.
The use of a cosmid shuttle vector to study parasite CP expression in 
vitro, has been used before (Tomas et al., 1997) and was used here to analyse re­
expression of the entire cpb array into the Ecpb null mutant (Table 7). The aim of 
re-expressing the entire cpb array as a cosmid vector was to assess whether over­
expression of the cpb array in the Ecpb null mutant could restore wild-type 
virulence levels in vivo and so whether the different genes of the array contribute 
individually in enabling the parasite to survive.
Re-integration of the CPB2.8 and CPB2 into double null {Acpb/cpa) 
mutants was also performed (see Table 8).
Experiments were set up using both promastigote and axenic amastigote 
forms of the parasites but the mice infected with promastigotes did not display 
lesions for several months and so data analysis was done only on mice infected 
with axenic amastigotes.
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Genetic manipulation Denoted Phenotype during in vitro and in vivo 
infection
Deletion of cpa and cpb 
genes
Acpb/cpa
(DN8in
cytokine
data)
Rate of infectivity to macrophages in vitro 
is similar to Acpb (Mottram et al., 1996) 
but did not produce lesions in mice 
(Alexander er a/., 1998).
Deletion of cpa and cpb 
genes; re-integration of 
metacyclic CPB2 with 
native promoter
GL438 Unknown
Deletion of cpa and cpb 
genes; re-integration of 
amastigote CPB2.8 with 
native promoter
GL439 Unknown
Table 8. Construction of mutants based on the Acpb/cpa mutants of
L, mexicana
6.2 MATERIALS AND METHODS
6.2.1 Generation of T. mexicana cpb mutant lines
L. mexicana parasites lacking the cpb and cpa genes have been generated 
by targeted gene disruption and the method for this has been described elsewhere 
(Mottram «/., 1996). A number of steps were required for CP re-integration 
into the Acpb null mutant and all steps were performed by Dr. D. Brooks 
(Wellcome Centre of Molecular Parasitology, University of Glasgow).
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Transfection of the cosmid vector pGL263 into amastigotes was 
performed by Dr. H. Denise (Wellcome Centre of Molecular Parasitology, 
University of Glasgow). pGL263 is a cosmid isolated from a cosmid libraiy of L. 
mexicana, generated by Dr. D.C. Barker (Cambridge University).
6.2.2 Infections
Age-matched female BALB/c mice were maintained in the animal facility 
at the University of Glasgow and used at 8 weeks of age. Groups were 
comprised of 5 mice and infected sub-cutaneously in the shaven rump with 5x10^ 
axenic amastigotes or stationary phase promastigotes of the various L. mexicana 
mutants described in tables 7 and 8.
The course of infection was monitored by weekly measurement of the 
shaven rump using a slide gauge micrometer and lesion volume was measured, as 
described in section 4.2.3, chapter 4.
Animals were tail-bled before infection with L. mexicana parasites and 
subsequently every two months for antibody isotype analysis, as described in 
section 4.2.4, chapter 4. At seven months post-infection, mice were sacrificed 
and spleens isolated for cytokine analysis. This was performed as described in 
section 4.2.5, chapter 4, and, as before, IL-4 and IFN-y were analysed by ELISA.
Lesions were removed from each mouse (by Mr. D. Laughland) and 
macerated in PSGEMKA buffer (PBS buffer plus 0.05 M glucose, 0.5 mM 
EDTA, 0.01 M MgCb.bHzO and 0.005% bovine serum albumin, pH 7.3) using a 
grinder, to remove host cell material. The resulting preparation was washed three 
times and re-suspended in PSGEMKA buffer, before parasite cell counts were 
performed. Lesion pellets were frozen at -70°C.
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6.2.3 Preparation of harvested lesion material for CP analysis
Frozen lesion pellets were used to prepare parasite lysates. Lysates were 
produced by thawing frozen parasite pellets and re-suspending in 0.25 M sucrose 
and 0.25 % Triton X-100. The resultant mixture was vortexed, frozen and 
thawed before centrifugation in a bench-top centrifuge at 10, 000 g for 15 min to 
clarify the lysate. The resulting supernatant from each mouse was assayed for 
protein content using the BioRad protein estimation kit. Supernatants were used 
for subsequent experiments to analyse CP content and activity by Western 
blotting and gelatin gels, respectively. These were performed as described in 
chapter 2.
Statistical analysis of the results was similar to that described in section 
4.2.7, chapter 4.
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6.3 RESULTS
6.3.1 Lesion growth in BALB/c mice infected with £. mexicana wild-type 
and Acpb single null mutant amastigotes
The two control lines for the experiments were the wild-type and single 
null mutant {Acpb), the line lacking both copies of the entire cpb array.
Cutaneous lesion growth was monitored for each mouse from the groups of mice 
infected and the mean values were plotted (see Figure 6.3.1 for wild-type and 
Acpb lines).
In Figure 6.3.1, all mice in the group infected by wüd-type L. mexicana 
amastigotes exhibited large, progressive lesions which required culling of the mice 
at week 21 due to the excessive lesion volume. The average lesion volume at this 
stage of the study was approximately 500 mm  ^which was significantly greater 
than that of mean lesion values seen in mice infected with Acpb L  mexicana, at 
week 21 (p< 0.01).
6.3.2 Lesion growth in BALB/c mice infected with L. mexicana GL165 
amastigotes
Re-integration of native CPB2 (GL165), a proteinase expressed 
predominantly by metacyclics, into the Acpb parasite line, produced enhanced 
lesion growth compared to the Acpb parasite line at week 27 (p< 0.05) although 
the mean lesion volumes were significantly smaller from week 14, than those 
lesion volumes observed in wild-type infected mice, until week 21 (p< 0.05) 
(Figure 6.3.2). GL165-infected mice produced lesion values that were
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Figure 6.3.1 Mean lesion growth in mice 
infected with L mexicana amastigotes. Mice 
were infected with wild-type and Acpb parasite 
lines. Data represent mean values of at least 4 
mice per group with error bars corresponding to 
SEMs. At week 21, mean lesion volume of mice 
infected with wild-type parasites was 
significantly higher than that of Acpb-infected 
mice (p< 0.01).
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Figure 6.3.2 Mean lesion growth in mice infected 
with L mexicana amastigotes. Mice were infected 
with the GL165 mutant line. Wild-type and Acpb 
controls are shown. Data represent mean lesion 
values of at least 4 mice per group with error bars 
corresponding to SEMs. By week 27, mean lesion 
volume of mice infected with the GL165 parasite line 
was significantly higher than mice infected with the 
Acpb line (p< 0.05) and significantly smaller than 
mice infected with wild-type parasites (p< 0.05), 
measured at week 21.
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significantly greater than those produced by Acpô-infected mice by week 12 of 
infection.
6.3.3 Lesion growth in BALB/c mice infected with X. mexicana GL166 
amastigotes
GL166, the Acpb mutant with re-integrated native CPB2.8, an amastigote 
specific proteinase, displayed a mean lesion volume that was significantly smaller 
than the mean lesion volume of wüd-type infected mice at week 21 (p< 0.05) but 
was not significantly different fi:om the mean lesion volume of the Acp6-infected 
mice (Figure 6.3.3).
6.3.4 Lesion growth in BALB/c mice infected with X. mexicana GL167 
amastigotes
Mice infected with Acpb mutants with re-integrated chimaeric CPB2 
(GL167), produced mean lesion volumes that were significantly higher than those 
observed in A6^6-infected mice at week 27 (p< 0.05) but were significantly 
smaller than mean lesion volumes produced by wüd-type infected mice at week 21 
(p< 0.05) (Figure 6.3.4). There was no significant difference m lesion volumes 
fi"om mice infected with chimaeric or native CPB2 (Figure 6.3.6),
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Figure 6.3.3 Mean lesion growth in mice 
infected with L mexicana amastigotes. Mice 
were infected with the GL166 mutant line. Wild- 
type and Acpb are shown. Data represent mean 
lesion values of at least 4 mice per group with 
error bars corresponding to SEMs. By week 27, 
mean lesion volume of mice infected with the 
GL166 parasite line was not significantly higher 
than Acpb-infected mice but was significantly 
lower than that of wild-type infected mice (p< 
0.05), measured at week 21.
166
Chapter 6
^  600
3 400
200
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28
GL167
Week of infection
Figure 6.3.4 Mean lesion growth in mice 
infected with L mexicana amastigotes. Mice 
were infected with the GL167 mutant line. Wild- 
type and Acpb controls are shown. Data 
represent mean lesion values of 5 mice per group 
with error bars corresponding to SEMs. By week 
27, mean lesion volume of mice infected with 
GL167 parasite line was significantly higher than 
that of Acpb-infected mice (p< 0.05) but 
significantly tower than that of wild-type infected 
mice (p< 0.05), at week 21.
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6.3.5 Lesion growth in BALB/c mice infected with L. mexicana GL168 
amastigotes
Mice infected with Acpb mutants with re-integrated chimaeric CPB2.8 
(GL168), produced mean lesion volumes that were significantly greater than those 
observed in Acpb-infected mice at week 27 (p< 0.05) but were significantly 
smaller than mean lesion volumes produced by wild-type infected mice at week 21 
(p< 0.05) (Figure 6.3.5). Re-integration of chimaeric CPB2.8 produced 
significantly greater lesion volumes at week 21 when compared with Acph- 
infected mice. This was markedly different firom mice infected with GL166 (re­
integration of native CPB2.8) whose lesion volumes were not significantly 
different firom the Acpb-infected mice. However, there was no significant 
difference in lesion growth between mice infected with GL166 or GL168 (Figure
6.3.6).
6.3.6 Comparison of mice infected with Acpb null mutants re-expressing 
different CPBs
By week 27, when all mice were culled for splenocyte examination, there 
was no significant difference in lesion volumes between any of the groups of mice 
infected with GL165, GL166, GL167 or GL168 L  mexicana amastigotes (Figure
6.3.6). However, by week 12 of infection, mice infected with the GL165 parasite 
line had significantly greater lesion volumes than the remaining groups (p< 0.05) 
until week 18, at which point they ceased to be significantly different fi*om mice 
infected with the other CPB re-integrated lines.
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Figure 6.3.5 Mean lesion growth in mice infected 
with L. mexicana amastigotes. Mice were infected 
with the GL168 mutant line. Wild-type and Acpb 
controls are shown. Data represent mean lesion 
values of 5 mice per group with error bars 
corresponding to SEMs. By week 27, mean lesion 
volume of mice infected with GL168 parasite line 
was significantly higher than Acpb-infected mice 
(p< 0.05) but at week 21 was significantly lower 
than that of wild-type infected mice (p< 0.05).
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Figure 6.3.6 Mean lesion growth in mice 
infected with L mexicana amastigote mutants 
re-integrated with CPBs. Data represent mean 
lesion values of at least 5 mice per group with 
error bars corresponding to SEMs. By week 27, 
there was no significant difference in mean 
lesion volume from mice infected with parasites 
re-integrating the different CPB enzymes.
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6.3.7 Lesion growth in BALB/c mice infected with L. mexicana double null 
mutant amastigotes
Mice infected with double null mutant {Acpb/cpa) L  mexicana amastigotes 
produced very small lesion volumes (<10 mm )^ after almost 8 months of infection 
(Figure 6.3.7). Mice infected with Acpb/cpa L. mexicana mutants re-integrated 
with CPB2 (GL438), produced lesions that were not significantly different, by 
week 33, in volume compared to mice infected with the Acpb/cpa-infected mice. 
Mice that were infected with GL439 L. mexicana mutants {Acpb/cpa re­
integrated with CPB2.8) produced no lesions in the time period shown.
6.3.8 Measurement of IgGl and IgC2a antibody titres in mice infected with 
wild-type, Acpb and GL165-168 L, mexicana axenic amastigotes
Figure 6.3,8 shows that wild-type L. wex/ca«a-infected mice displayed high 
levels of IgGl as expected, but surprisingly the other A. mexicana-mSQCtcd mice 
{Acpb, GLl65-168) had comparably high IgGl titres which were not significantly 
different to each other, except for the GLl66 group. GL166-infected mice 
presented antibody titres of the IgGl subclass that were significantly lower than 
the GLl67 infected group (p< 0.05).
Figure 6.3.8 also shows the antibody production of IgG2a fi-om L. 
mexicana-mfcctcd mice. As expected fi"om previous studies, wild-type infected 
mice produced significantly less IgG2a compared with the Acp6-infected mice (p< 
0.02) In fact, most groups of infected mice (GLl 65, GLl 67 and GLl 68) had 
significantly higher IgG2a plasma titres than the wild-type infected mice (p< 0.05 
for all mice compared). The exception was GLl66 which had comparable levels
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Figure 6.3.7 Mean lesion growth of L mexicana 
amastigotes in BALB/c mice. DN8 represents 
Acpb/cpa null mutant; GL438 represents Acpb/cpa 
null mutant re-integrated with CPB2; GL439 
indicates Acpb/cpa null mutant re-integrated with 
CPB2.8. There was no lesion formation in mice 
infected with GL439 in the time period shown. Data 
is shown as mean values of 5 mice per group with 
error bars corresponding to SEMs.
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Figure 6.3.8 Analysis of plasma IgGl and lgG2a 
levels in BALB/c mice 6 mo after infection with 
L  mexicana amastigotes of either wild-type (WT) 
(n=4), A cpb null (N53),
Acp6 null re-integrated with CPB2 (GLl 65) (n=4),
A cpb null re-integrated with CPB2.8 (GLl 66) (n=4),
A cpb null re-integrated with chimaeric CPB2 (GLl 67) 
or A cpb null re-integrated with chimaeric CPB2.8 
(GLl 68). Values represent mean end-point dilutions 
+/- SEM (n = 5 unless stated).
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of IgG2a to the wild-type infected mice and displayed no significant difference 
between the two groups.
6.3.9 Measurement of IgGl and IgG2a antibody titres in mice infected with 
Zr. mexicana DN8, GL438 and GL439 axenic amastigotes
Generally, the plasma antibody titres for all infected mice were very low as 
can be seen in Figure 6.3.9. The level of IgGl was very similar for all infected 
groups analysed and there was no significant difference in production of this 
antibody isotype. However, GL438 and GL439-infected mice both presented 
significantly higher IgG2a isotype levels than Ac/?Z>/Q9ûr-infected mice (p< 0,05 for 
both) although there was no significant difference between the two CPB re­
expressing lines.
6.3.10 IFN-y production from SLA-stimulated splenocytes from X. 
mexicana-mîecteà mice
Figure 6.3.10 shows the production of IFN-y fi'om ex vivo splenocytes 
stimulated with soluble parasite antigen from mice infected with various CP 
mutant and wild-type L  mexicana amastigotes. Wild-type infected mice 
produced very little IFN-y with no significant difference from background levels 
and was significantly lower in production of IFN-y compared with all other 
infected L. mexicana amastigote lines (Acp6, p< 0.001; GL165, p< 0.001;
GL167, p< 0.01; GL168, p< 0.01; GL263, p< 0.01). These groups had levels of 
IFN-y much higher than background levels (p< 0.05 for all mice). Furthermore, 
GL165-
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Figure 6.3.9 Plasma analysis of antibody 
isotype from BALB/c mice infected 6 mo with 
L mexicana amastigotes. DN8 line represents 
Acpb/cpa double null mutant; GL438,
Acpb/cpb double null mutant re-integrated with 
CPB2; GL439, Acpb/cpb double null mutant 
re-integrated with CPB2.8. Values represent 
mean end-point dilutions +/- SEM (n=5).
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Figure 6.3.10 IFN-y production by cultured 
splenocytes removed from L mexicana- 
infected BALB/c mice, 7 mo post-infection. 
Cytokine analysis was performed on SLA- 
stimulated (10 pg/ml) cultures with non­
stimulated cultures used as controls. Bars 
represent SEMs. ND denotes non-detection of 
cytokine by assay.
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infected mice produced significantly higher IFN-y than GL167-infected mice when 
splenocytes were re-stimulated with SLA (p< 0.02).
The GL166-infected mice produced no detectable cytokine (neither IFN-y 
nor IL-4) when stimulated polyclonally or with leishmanial antigen although 
cytokine standards were positive and suggested that the samples were in some 
way defective, rather than the assay itself.
6.3.11 IFN-y production from CPB2.8ACTE-stimuIated splenocytes 
removed from X. mexicana-infecieù mice
Of all the infected mice tested, only GL165 X. mexicana-mSecXeô. mice 
produced significantly high levels above background when stimulated with 
recombinant CPB2.8ACTE (p< 0.05) (Figure 6.3.11). Furthermore, GL165- 
infected mice displayed significantly higher IFN-y levels than mice infected with 
GL167 (p< 0.001), GL168 (p< 0.05) and wild-type X. mexicana (p< 0.001).
6.3.12 IFN-y production from Con A-stimulated splenocytes from X. 
mexicana-mfected mice
Con A-stimulated splenocytes firom all groups of infected mice exhibited 
much higher IFN-y levels than background levels (p< 0.0001) (Figure 6.3.12). 
However, there were differences in IFN-y production between several of the 
mutant lines analysed in response to Con A. GL167-infected mice produced 
significantly less IFN-y when splenocytes were polyclonally stimulated with Con 
A than the GL168, Acpb and wild-type infected mice (all groups, p< 0.02). The 
difference in IFN-y production was even more substantial between GL167 and
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Figure 6.3.11 IFN-y production by cultured 
splenocytes removed from L mexicana- 
infected BALB/c mice, 7 mo post-infection. 
Cytokine analysis was performed on 
CPB2.8ACTE-sfmulated (5 |jg/ml) cultures with 
non-stimulated cultures used as controls. Bars 
represent SEMs. ND denotes non-detection of 
cytokine by assay.
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Figure 6.3.12 IFN-y production by cultured 
splenocytes removed from L mexicana- 
infected BALB/c mice, 7 mo post-infectlon. 
Cytokine analysis was performed on Con A- 
stimulated (5 Mg/ml) cultures with non-stimulated 
cultures used as controls. Bars represent 
SEMs. ND denotes non-detection of cytokine 
by assay.
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GL165-iiifected mice with the latter group producing much higher levels in 
response to Con A (p< 0.0001). Splenocytes fromX. mexicana GL165 and 
GL168 amastigote-infected mice produced comparable levels of IFN-y with no 
significant difference between them although IFN-y was significantly higher than 
the other two groups tested (Acpb and wild-type, p< 0.001 for both).
6.3.13 IL-4 production from SLA-stimulated splenocytes from X. mexicana- 
infected mice
In aU groups analysed for IL-4 production fi:om splenocytes re-stimulated 
with SLA, only mice infected with GL165 and wild-type X. mexicana amastigotes 
produced significant levels of IL-4 above background levels (p< 0.05 and p< 0.01 
respectively) while the remaining groups did not (see Figure 6.3.13).
Wild-type X. mexicana-mÎQQXQà mice produced significantly higher levels 
of IL-4 than all other groups tested except for GL165-infected mice, where there 
was no significant difference. Wild-type splenocytes produced significantly higher 
IL-4 levels XhsnAcpb splenocytes (p< 0.02), GL167 (p< 0.05), and GL168 (p< 
0.02) infected mice. GL165-infected mice produced significantly higher amounts 
of IL-4 than Acp/>-infected mice (p< 0.01).
6.3.14 IL-4 production from CPB2.8ACTE-stimulated splenocytes from X. 
mexicana-miected mice
In all splenocyte cultures tested, levels of IL-4 produced were not 
significantly different from background levels when stimulated with recombinant 
CPB2.8ACTE (Figure 6.3.14).
80
Chapter 6
200
180 ~
160 -
140 -
120 -
100 -
3 80 -
60 —
40 —
20 -
0 —
□  SLA
I I Medium
a ND aaT I I I T
WT N53 GL165 GL166 GL167 GL168 
Parasite line
Figure 6.3.13 IL-4 production by cultured 
splenocytes removed from L mexicana infected 
BALB/c mice, 7 mo post-infection. Cytokine 
analysis was performed on SLA-stimulated (10 
pg/ml) cultures with non-stimulated cultures used 
as controls. Bars represent SEMs. ND denotes 
non-detection of cytokine by assay.
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Figure 6.3.14 IL-4 production by cultured 
splenocytes removed from L mexicana- 
infected BALB/c mice, 7 mo post-infection. 
Cytokine analysis was performed on 
CPB2.8ACTE-stimulated (5 pg/ml) cultures 
with non-stimulated cultures used as controls. 
Bars represent SEMs. ND denotes non­
detection of cytokine by assay.
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Con A stimulation of splenocytes from ail groups tested produced 
significantly higher levels of IL-4 than background cultures tested (p< 0.0001) 
and all groups analysed, had comparable levels of IL-4 to each other with no 
significant difference between them (see Figure 6.3.15).
6.3.15 Lesion growth in BALB/c mice infected with L, mexicana GL263 
amastigotes
Re-expression of the cpb array using a cosmid vector in the Acpb parasite 
line, at week 27 did not result in significantly greater lesion volumes compared 
with the A(^6-infrcted mice. However, at week 21, wild-type-infected mice 
produced progressive lesions which were significantly greater in volume than the 
GL263-infected mice (p< 0.02) (Figure 6.3.16).
6.3.16 Measurement of IgGl and IgG2a antibody titres in mice infected 
with L, mexicana GL263 amastigotes
Plasma IgGl was elevated for all three parasite lines in infected mice as 
can be seen in Figure 6.3.17 and there was no significant difference between the 
GL263-, wild-type- and Acp6-infected mice. GL263-infected mice displayed 
significantly lai ger IgG2a antibody titres than that of the wild-type infected mice 
(p< 0.02) which were very low. The level of IgG2a from GL263-mfected mice 
was comparable with that seen in the Acpb -infected mice and the IgGl/IgG2a 
ratio was much lower in the GL263-infected mice compared to the wüd-type- 
infected mice.
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Figure 6.3.15 IL-4 production by cultured 
splenocytes removed from L mexicana infected 
BALB/c mice, 7 mo post-infection. Cytokine 
analysis was performed on Con A-stimulated 
(5 pg/ml) cultures with non-stimulated cultures 
used as controls. Bars represent SEMs. ND 
denotes non-detection of cytokine by assay.
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Figure 6.3.16 Mean lesion growth in mice 
infected with L mexicana amastigotes. Mice 
were infected with the GL263 mutant line. Wild- 
type and Acpb controls are shown. Data 
represent mean lesion values of at least 4 mice 
per group with error bars corresponding to 
SEMs. By week 27, mean lesion volume of mice 
infected with the GL263 parasite line was not 
significantly higher than mice infected with the 
Acpb line but at week 21, was significantly 
smaller than wild-type infected mice (p< 0.02).
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Figure 6.3.17 Plasma analysis of antibody 
isotype from BALB/c mice infected 6 mo with L 
mexicana amastigotes. WT, wild-type; N53, 
Acpb null mutant; GL263, Acpb null mutant re­
expressing cpb array as a cosmid vector. 
Values represent mean end-point dilutions +/- 
SEM (n=5).
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6.3.17 IFN-y production from re-stimulated splenocytes from Z. mexicana- 
infected mice
Splenocytes removed from GL263-infected mice and re-stimulated in vitro 
with soluble leishmanial antigen, produced significantly higher levels of IFN-y 
compared with background levels (p< 0.05) (Figure 6.3.18). These levels of IFN- 
y were not significantly different in those splenocytes isolated from Acp6-infected 
(N53) mice but were significantly higher than splenocytes removed from wild- 
type-infected mice (p< 0.01).
IFN-y background levels of splenocytes obtained from mice infected with 
GL263 amastigotes was high and when splenocytes were re-stimulated with 
recombinant CPB2.8ACTE, there was no significant increase over background 
levels (Figure 6.3.19).
Splenocytes from GL263-infected mice polyclonally stimulated with Con 
A produced significantly higher levels of IFN-y compared with background levels 
(p< 0.0001) (Figure 6.3.20). There was no significant difference in IFN-y 
production between splenocytes from GL263, wild-type or Ac/?ô-infected mice.
6.3.18 IL-4 production from stimulated splenocytes from L. mexicana 
GL263- infected mice
Splenocytes removed from GL263-infected mice and re-stimulated in vitro 
with soluble leishmanial antigen, produced significantly higher levels of IL-4 
compared to background levels (p< 0.02) (Figure 6.3.21). These levels of IL-4 
were significantly higher than Acpè-infected mice but also significantly lower than 
wild-type-infected mice (p< 0.05).
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Figure 6.3.18 IFN^ production by cultured 
splenocytes removed from L. mexicana- 
infected BALB/c mice, 7 mo post-infection. 
N53 denotes Acpb null mutant-infected mice. 
Cytokine analysis was performed on SLA- 
stimulated (10 pg/ml) cultures with non- 
stimulated cultures used as controls. Bars 
represent SEMs.
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Figure 6.3.19 IFN-y production by cultured 
splenocytes removed from 1. mexicanaAnfected 
BALB/c mice, 7 mo post-infection. Cytokine 
analysis was performed on CPB2.8ACTE- 
stimulated (5 pg/ml) cultures with non-stimulated 
cultures used as controls. Bars represent SEMs.
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Figure 6.3.20 IFN-y production by cultured 
splenocytes removed from L mexicana- 
infected BALB/c mice, 7 mo post-infection. 
Cytokine analysis was performed on Con A- 
stimulated (5 pg/ml) cultures with non-stimulated 
cultures used as controls. Bars represent 
SEMs.
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Figure 6.3.21 IL-4 production by cultured 
splenocytes removed from L. mexicana infected 
BALB/c mice, 7 mo post-infection. Cytokine 
analysis was performed on SLA-stimulated (10 
pg/ml) cultures with non-stimulated cultures used 
as controls. Bars represent SEMs.
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When splenocytes from GL263-infected mice were re-stimulated with 
recombinant CPB2.8ACTE, they did not produce levels of IL-4 that were 
significantly higher than background levels (Figure 6.3.22).
Splenocytes removed from GL263-infected mice polyclonally stimulated 
with Con A, produced significantly high levels of IL-4 compared to background 
levels (p< 0.0001) but were not significantly different from wild-type or Acpb- 
infected mice (Figure 6.3.23).
6.3.19 Analysis of CP activity from lesions isolated from Z. mexicana- 
infected mice
It was confirmed using gelatin SDS-PAGE analysis that lesions from mice 
infected with the various Z. mexicana single null mutant and re-integrated CPB 
mutants, possessed cysteine proteinase activity (Figure 6.3.24). Lesions for the 
wild-type infected mice were not isolated. Recombinant CPB2.8ACTE was 
loaded as a control for comparison with lesion lysates (lanes 1 and 11, Figure 
6.3.24). All lesion lysates contained proteolytic activity but only lesions from 
mice infected with GL166 L  mexicana parasites (lanes 9 and 10), had any mature 
enzyme activity, which co-migrated with the recombinant CPB2.8ACTE. The 
lowest level of CP activity was observed in the lesions obtained from the Acpb- 
infected mice while lesions from the re-integrated CPB mutant-infected mice 
contained more CP activity than the Acpb null mutant-derived lesions.
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Figure 6.3.22 IL-4 production by cultured 
splenocytes removed from L mexicana 
infected BALB/c mice, 7 mo post-infection. 
Cytokine analysis was performed on 
CPB2.8ACTE-stimulated (5 pg/ml) cultures 
with non-stimulated cultures used as controls. 
Bars represent SEMs.
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Figure 6.3.23 IL-4 production by cultured 
splenocytes removed from L mexicana 
infected BALB/c mice, 7 mo post-infection. 
Cytokine analysis was performed on Con A- 
stimulated (5 pg/mt) cultures with non- 
stimulated cultures as controls. Bars 
represent SEMs.
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Figure 6.3.24 10 % gelatin SDS-PAGE showing CP 
activity derived from lesion material. All lanes were 
loaded with equivalent protein concentrations. Lanes 1 
and 11, recombinant CPB2.8ACTE; lanes 2-5, Acpb 
parasite line; lanes 6-8, GL165 parasite line; lanes 9 and 
10, GL166 parasite line; lanes 12-15, GL167 parasite 
line; lanes 16-18, GL168 parasite line.
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6.3.20 Analysis of CP protein content of lesions isolated from L, mexicana- 
infected mice
In order to analyse leishmanial CPB amounts within lesions from the 
different groups of infected mice, Western blotting was performed using specific 
anti-serum, raised against the pro-mature form of CPB2.8ACTE and the 
appropriate pre-immune anti-serum (Figure 6.3.25).
The specific CPB2.8ACTE anti-serum detected recombinant mature 
enzyme and pro-mature and mature protein in a lysate of wild-type stationary 
phase promastigotes (Figure 6.3.25, gel B). However, the pre-immune anti-senim 
did not detect any leishmanial CPB protein in any of the different groups studied. 
Lanes 3, 4, 5, 6 and 7 represent lesions from one mouse of each group infected 
with the five different mutants of L. mexicana {Acpb, GL 165-168). Other lesion 
lysates were also analysed but results were not different to those observed in 
Figure 6.3.25, gelB.
Detection of a protein (> 40 kDa) by the pre-immune sera (Figure 6.3.25, 
gel A) showed that equivalent protein loadings had been used for the different L. 
mexicana mutants but this protein has also been identified by others using pre- 
immune anti-sera to lesion material from L  mexicana-'mSQcXcd mice (Mottram et 
al, 1996) and is considered to be non-specific.
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F ig u re  6 .3.25 10% SDS-PAGE showing western blot of Acpb and 
re-integrated CPB L  mexicana amastigote lesions.
Lane 1, mature CPB2.8ACTE (frozen/thawed); 
lane 2, wild-type stationary promastigote lysate; 
lane 3, lesion lysate from Ac/?6-infected mouse; 
lane 4, lysate from GL165-infected mouse; 
lane 5, lysate from GL166-infected mouse; 
lane 6, lysate from GL167-infected mouse; 
lane 7, lysate from GL 168-infected mouse.
Lanes were loaded with equivalent protein concentrations of 
lesion preparations. Bands were detected with pre-immune (A) 
or anti-pro CPB2.8ACTE antibody (B) at a 1: 2000 dilution.
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6.4 DISCUSSION
The use of genetic manipulation to study the potential role(s) of the 
leishmanial CPs in the host-parasite interaction has shown that these enzymes are 
virulence factors (Mottram et al, 1996). Furthermore, gene deletion of the cpa 
and cpb genes resulted in an attenuated strain of Z. mexicana that upon infection, 
promoted an IFN-y driven CD4+ Th 1 response and was considered to be a 
potential vaccine candidate (Alexander et al, 1998). Deletion of the cpa and cpb 
genes in Z. mexicana resulted in a no lesion growth phenotype for the mutant 
parasite and increased host IFN-y production but notably it also resulted in a 
decrease in IL-4 production (Alexander fl/., 1998). Susceptibility to Z. 
mexicana infection has previously been shown to correlate with IL-4 production 
(Satoskar et al., 1995). As deletion of cpa and cpb genes resulted in potentiation 
of a Th 1 response, with loss of IL-4 production, it is possible that the leishmanial 
CPs may play some kind of role in IL-4 production, as previously identified for 
other CPs (Finkelman & Urban, 1992). This has been investigated by re­
integrating CPB enzymes into L  mexicana parasites lacking the cpb array and 
also cpa.
Therefore, single {Acpb) and double null {Acpb/cpa) mutants of Z. 
mexicana have been generated using targeted gene deletion and two different cpb 
genes, cpb2 and cpb2.8, have been individually re-integrated into the mutants. In 
the case of the single null mutants, these CP genes were re-integrated using a 
native or chimaeric promoter, in order to analyse whether CP expression could 
alter parasite virulence,the importance of when this expression occurred and the 
subsequent immune response. Conceivably, re-integration of a metacyclic CP, 
CPB2, under control of a native (metacyclic) promoter (GL165) should result in
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less expression in the amastigote form while the reverse may be expected when 
the chimaeric (amastigote-specific) promoter controlled CPB2 expression 
(GL167). For re-integration of CPB2.8, an amastigote CP, into the single null 
mutant under the influence of the native promoter (GL166), one may expect high 
expression levels in the amastigote and the reverse (promastigote expression) for 
a chimaeric promoter (GL168).
Re-expression of CPB2.8 into single null mutants using plasmid vectors 
has been already demonstrated (Mottram et al, 1996) but it was found that the 
loss of antibiotic pressure in vivo resulted in a loss of enzyme activity when 
parasites were recovered from lesions. Re-integration of the gene directly into the 
chromosome removes this problem.
Unfortunately, because of the technical problems associated with re­
integrating all 19 copies of the (haploid) cpb array into the genome of the null 
mutant in order to show complementation of the phenotype in vivo, the 
correlation between phenotype and genotype has never been proven. Thus, re­
expression of the cpb array has been achieved using a cosmid vector and so 
depends on antibiotic selection for increased CP expression (Kelly et al., 1994).
One problem encountered throughout the study was that it was not 
uncommon for several mice to be culled due to parasite-unrelated conditions such 
as bacterial infections of the eye or abnormally large swellings of the abdomen, 
even though inbred mouse strains were used. The BALB/c mouse strain is well 
known for its reduced IL-12 production and this may underlie the IL-4 dominated 
response to infection by Leishmania sp. (Alieva et al, 1998). These mice may 
therefore be prone to opportunistic infections.
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Lesion data were monitored throughout the course of infection and it was 
observed that BALB/c mice inoculated with wild-type L  mexicana amastigotes 
developed rapidly growing, non-healing lesions which far exceeded the lesion 
growth observed with the re-integrated CP mutants, including the GL263 parasite 
line.
L. mexicana wild-type parasites displayed an antibody phenotype 
comparable with that reported by others with high levels of IgGl and very low 
levels of IgG2a, indicative of a Th 2 response and disease exacerbation 
(Alexander et al, 1998). The antibody profile of the hcpb mutant was also in 
agreement with results published by this group with an increase in IgG2a 
production and a subsequent lowering of the IgGl/IgG2a ratio, inferring more of 
a Th 1 response.
CPs have previously been reported to induce IL-4 production (Finkelman 
& Urban, 1992) and at the termination of the experiment, splenocytes fi-om mice 
infected with wild-type parasites were found to produce significantly more IL-4 
following leishmanial antigen stimulation than those infected with the ù^ cpb 
mutant. Furthermore, antigen-induced splenocyte IL-4 production was barely 
detectable in most of the BALB/c mice infected with the â^cpb mutant. These 
results correlated well with Alexander et al (1998) so it was surprising to find 
that most of the CP re-integrated L. mexicana mutants did not produce a 
significant increase in IL-4 compared with the null mutant despite an increase in 
lesion size.
Re-integration of the metacyclic CPB2 (GL165) into the null increased the 
parasite virulence compared with the Acpb null mutant, if one assesses lesion 
volume. However, the humoral and cellular responses suggest a lack of immune
200
Chapter 6
polarisation. Antibody production of the IgG isotypes was similar to Acpb titres 
in terms of IgG2a production but similar in IgGl production to wild-type-infected 
mice, suggesting a mixed Th phenotype. This was further exemplified by the 
production of IFN-y and IL-4 in response to leishmanial antigen-stimulus. IFN-y 
production was comparable with Acp/?-infected mice but IL-4 production was 
also significantly higher than Acpô-infected mice which implies that the re­
integration of this particular CPB was able to promote more of an exacerbative 
response than the Acpb mutant, and the lesion data confirm this. Re-integration 
of this enzyme therefore part restored virulence although the production of IFN-y 
indicates that the Th 2 response was not fully developed as for wild-type-infected 
mice, which produced no IFN-y when stimulated with leishmanial antigen 
stimulus.
Re-integration of CPB2.8 (GL166) did not appear to increase virulence 
when assessing mean lesion volume since it was not significantly different from 
the Acpb null mutant. The antibody titre in these mice was very low with IgGl 
and IgG2a levels considerably lower compared with the other mutants examined, 
less IgG2a being produced than the other CP re-integrated mutants. The low 
antibody titre may also be indicative of a Th 1 response. Analysis of the cytokine 
response to antigen stimulus (leishmanial or polyclonal) provided no further 
understanding of the situation in vivo since there was no detectable production of 
IFN-y or IL-4. Murine cytokine standards developed positively in the assay and 
so there appeared to be no problem with the ELISA system itself, rather the 
problem was attributed to the T cell stimulation assays. The reasons for this are 
unclear since all other L. mexicana infected mice were sacrificed, splenocytes 
recovered and stimulated in exactly the same manner as the GL166 line. The
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number of splenocytes recovered was similar to the number isolated from the 
other L. mexicana lines so a possible explanation is that antigens used for 
stimulation were not at the optimum concentration for cytokine production. 
However, this is unlikely since the same conditions and antigen concentrations 
were used to stimulate all other lines. Trypan blue exclusion indicated that the 
lymphocytes were also viable so this did not appear to be the problem.
The reason for the above discrepancy is not known and one can only 
speculate as to what the problem was. However, this was very disappointing as 
the antibody response was not very indicative of the Th phenotype although low 
antibody titres do suggest a Th 1 response (Alexander et al, 1998). Clearly, the 
experiment needs to be repeated although infection of mice with the GL 166 
mutant L. mexicana will take several months and therefore results could not be 
included in this study.
Parasites re-integrated with the chimaeric form of CPB2 (GL167) 
produced larger lesions than the Acpô-infected mice although the volumes were 
smaller than those observed in wild-type-infected mice. The humoral response 
was suggestive of an intermediate infection, similar to isotype levels seen in 
GL165-infected mice. Splenocyte production of IFN-y from GL167-infected 
mice was significantly higher than that of splenocytes isolated from wild-type 
infected mice but significantly lower than that from GL 165-infected mice. 
Furthermore, splenocytes from GL167 mice produced no IL-4 in response to 
leishmanial antigen whereas GLl 65-infected mice did. With GL167-infected mice 
producing significant levels of IFN-y and no IL-4, one may expect lesion 
formation to be similar to that of the null mutant {Acpb also did not produce IL-4 
but did produce IFN-y), which was not the case and so it is likely that there are
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other fectors involved e.g. other Th 1/2 cytokines such as IL-12 (Weinheber et 
al,. 1998). In retrospect, other Th 1/Th 2 cytokines could have been examined 
such as IL-2, which has been shown to be reduced in wild-type L. mexicana 
infection (Alexander et al, 1998) or IL-12, which is known to be down-regulated 
in macrophages after L. mexicana infection (Weinheber et al, 1998). This may 
have given a clearer understanding of the immune response during infection.
Numerous studies have shown that cytokine interplay during Leishmania 
infection cannot be as simplified as high or low levels of one particular cytokine 
conferring resistance or susceptibility to infection (Scott et al, 1996). For 
example, in vitro experiments may have omitted stimuli that are important in vivo. 
Inhibitors of some IL-4 or IFN-y effects might be present in vivo, so that effects 
of these lymphokines demonstrable in vitro might be blocked e.g. receptor 
expression, in intact animals (Finkelman et al, 1990). Recently, published results 
have shown that there are other mechanisms independent of the IL-4 receptor 
which underlie the default Th 2 development in Leishmania infected BALB/c 
mice (Mohrs et al, 2000). One must be careful in assigning cytokine production 
in vitro to virulence in vivo although the levels of IL-4 and IFN-y are obviously 
important in Leishmania infection as has repeatedly been shown (Heinzel et al, 
1989; Afonso et al, 1994; Alexander et al, 1998).
GL168-infected mice produced a very similar antibody profile to Acpb- 
infected mice with equally high levels of IgG2a and IgGl as the Acpb null mutant, 
although GLl68 mice did have significantly higher mean lesion volumes than the 
Acpb null mutant suggesting an exacerbative role for re-expressed chimaeric 
CPB2.8. However, analysis of the splenocyte response to leishmanial antigen
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stimulus showed significant IFN-y production but no IL-4 production which was 
analogous to the GL167-infected mice.
An obvious disadvantage of the cytokine analysis carried out is that the 
late sample point may miss early events which could alter the phentoype such as 
innate IL-12 production and this should be considered for future experiments. 
However, in conclusion, the data suggest that metacychc CPB2 is more of a 
virulence factor than the other re-expressed CPs since it was the only mutant 
(GLl 65) to produce significant levels of IL-4 although it also produced 
significantly higher levels of IFN-y than its re-integrated chimaeric mutant,
GLl67. The fact that CPB2 was more potent in stimulating IL-4 production than 
the other re-expressed proteinases suggests that CPB2 could play a role in the 
host-macrophage interaction. CPB2 is normally maximally expressed in the 
metacyclic stage of the parasite which is phagocytosed by the macrophage and if 
it does play a role in this interaction, expression of CPB2 in the amastigote using a 
chimaeric promoter may help mediate uptake of the parasite in an as yet, 
undefined mechanism. This hypothetically may help to establish the infection 
more quickly, generating more of a Th 2 response in the early stages. Once the 
parasite was vdthin the parasitophorous vacuole, the enzyme may be redundant in 
its function (during the initial host-parasite interaction) and thus the GLl65 
parasite may behave more like the Acpb parasite. This would explain the higher 
IFN-y level than the chimaeric CPB2 and the plateau effect of the mean lesion 
volume, seen during the latter stages of infection.
In order to analyse the level of CP activity and expression Jfrom the lesions
of the different groups of infected mice, gelatin SDS-PAGE and immuno-blotting
was used. All extracted parasite lesions {Acpb, GLl65-168) displayed proteolytic
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activity on gelatin SDS-PAGE but this did not aid the identification of the 
leishmanial CPB enzymes fi*om the host cathepsins, known to be found in host 
macrophages, and thus likely to be at the site of infection (Maekawa et al., 1998). 
Therefore, immuno-blotting was performed using polyclonal anti-CPB2.8ACTE 
anti-sera to assess the level of CPB expression from lesions prepared from the 
infected mice. However, the results obtained, suggested that there was no 
expression of CPBs in the GLl65-168 mutants analysed {Acpb null would not 
give expression of the cpb enzymes). The antibody recognised the recombinant 
CPB2.8ACTE enzyme and the pro-mature of CPB2.8ACTE from a lysate of wild- 
type promastigotes. Therefore, the antibody was frilly functional. However 
gelatin SDS-PAGE analysis showed that the GLl66 line produced CP activity at 
approximately 23 kDa mobility, similar to that of the recombinant enzyme, 
suggesting there was expression of the CPBs from this particular mutant. The 
question remains un-answered as to the level of CPB expression from the re­
integrated mutants, in vivo. This is an obvious disadvantage when analysing 
expression of CPBs in vivo, since only one time-point was taken for analysis. The 
expression of the CPBs may have been high early in infection and so have a 
significant effect in the host-parasite relationship but by the time of analysis, the 
re-integrated CPBs were possibly expressed at very low levels in that they could 
not be detected by Western blotting.
The re-expression of the cosmid containing the cpb array into the Acpb 
null mutant provided some unexpected results. Mean lesion volumes from the 
infected mice showed that GL263-infected mice had lesions comparable to those 
of the Acpb null mutant. This was further corroborated by the high levels of 
IgG2a isotype (similar to Acph-infected mice) and high IFN-y production in
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response to leishmanial antigen stimulus. However, antigen stimulus also 
promoted a significantly high level of IL-4 fi*om splenocytes which correlated weU 
with the level of IgGl, similar to wild-type titres. Significantly, production of this 
cytokine was not enough to alter lesion development, which was much slower 
than the wild-type infection.
The results obtained for the cosmid re-expressing mutants are surprising 
since one would expect re-expression of the entire cpb array into the Acpb null 
mutant to restore wild-type virulence levels since it has been shown that cosmid 
expression of a CP gene in vitro has been found to be several times higher than 
genomic expression of the gene (Kelly et al., 1994). These authors reported that 
cosmid transfected cells displayed considerable over-expression of the major CP 
fi*om T. cruzi, cruzipain, which correlated with an increase in enzyme activity as 
assessed by gelatin gels. However, these investigators did not infect animals with 
the cosmid-containing parasites, and so the level of activity in vivo was not 
known. It could be that re-expression of the array in the cosmid resulted in re­
arrangement of the array preventing transcription of the CPs which in turn would 
explain the reason for the similarity in lesion progression to the Acpè-infected 
mice since CP expression may be defiinct. Alternatively, the production of IL-4 
could be due to part of the array being expressed sufficiently enough to produce 
some CP activity while the majority or even all of the array was lost. The other 
reason may be due to loss of cosmid expression with loss of antibiotic pressure 
since it has already been established that the absence of neomycin, in vivo, allows 
CPB expression to drop substantially during lesion formation (Mottram et al., 
1996). Recovery of parasites ex vivo would help to identify whether CP activity
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was still present in the cosmid-transfected parasites and should be performed if 
such experiments are to be repeated.
The lesion development of the double null mutants has been reported 
previously, although in that particular study mice were infected with 
promastigotes rather than axenic amastigotes (Alexander e^ur/., 1998). In this 
study, lesions were very small after 8 months (10 mm^) while in the former study, 
there were no lesions after this time-point. However, one would expect challenge 
with amastigotes, rather than promastigotes, to potentiate infection more quickly 
unless they were totally attenuated. Antibody titres of IgGl and IgG2a were veiy 
low (reciprocal end-point dilution of < 1000) indicating that parasite proliferation 
was limited. This is typical of the immunologic status of humans at the resistant 
end of the disease spectrum (Alexander et al, 1998). Interestingly, re-integration 
of CPB2 (GL438) promoted similar development in mean lesion volume to the 
Acpb/cpa mutant while CPB2.8 re-integration (GL439) did not produce any 
development of lesions. Significantly, IgG2a titres were higher in the GL438 and 
GL439 mutant infected mice than the DN8 line which suggests more of a Th 1 
response. Splenocyte responses were not assessed as the experiments were on­
going but it would be of interest to see if production of IgG2a in the re-expressing 
L. mexicana mutants would also result in an increase in IFN-y compared to the 
DN8 mutant (which has already been shown to produce high IFN-y levels in 
response to leishmanial antigen stimulus (Alexander et al, 1998)) since high 
IgG2a is known to correlate with IFN-y production (Finkelman et al, 1990).
It is possible that re-integration of the proteinases, CPB2 and CPB2.8, 
into the double null mutant may not result in fiilly active enzymes since they may 
require other CPs (e.g. the CPA enzyme) to process them. Conceivably, the
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enzymes may not be processed and in order to avoid an accumulation which could 
be toxic, the parasite may have to exocytose these molecules out of the cell into 
the parasitophorous vacuole. From this site, they could be processed and 
presented with host MHC class II molecules and stimulate more of an IFN-y 
driven Th 1 response resulting in a concomitant increase in IgG2a production.
We may expect re-integration of CPB2.8 to produce a more virulent 
infection since this has been shown to be a virulence lactor in vitro. However, the 
Acpb single null mutant re-integrated with CPB2.8 was used to analyse infection 
of explanted PECs which were probably not a true representation of the 
macrophage population seen in vivo (Mottram et al, 1996). Therefore, it could 
be that the Acpb/cpa mutant line re-expressing CPB2.8 (GL439) is unable to 
promote infection as well as the DN8 or GL438 amastigote lines.
The generation of the single and double null mutants is a major aid in 
efforts to elucidate gene function in terms of virulence and has also been shown to 
be a usefiil tool in assessing mutants for potential as attenuated live vaccines 
(Alexander et al, 1998). However, it is clear that further analysis of the re­
integrated CP mutants will need to be carried out in order to elucidate exactly 
what function the metacyclic and amastigote CPs may perform in the host-parasite 
interaction.
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GENERAL DISCUSSION
Cysteine proteinases (CPs) are known to be important in several 
pathological conditions such as cancer, asthma and particularly in infectious 
disease (Mort et al, 1981; Travis et al, 1995; Gough et al, 1999).
CPs have been shown to affect a variety of different mechanisms in the 
mammalian immune system. For example, the house dust mite allergen, Der p  7, 
has been reported to trigger the asthmatic response in several ways by cleaving 
CD23 and CD25 molecules on mammalian cells, which interferes with the IgE 
network and IL-2 receptor, respectively (Hewitt et al, 1995; Schulz et al, 1998). 
Furthermore, Der p  1 can also promote activation of NF-kB, a transcriptional 
factor which regulates GM-CSF, IL-8 and TNF-a (Stacey et al, 1997). This CP 
is just one example of the numerous CPs which are clinically important in 
mammalian disease that have a diverse range of functions attributed to them. In 
parasitic infection, CPs have been implicated as prominent virulence factors in 
diseases such as trichomoniasis, leishmaniasis and Chagas disease(Eakin et al, 
1991; Coombs et al, 1997; Draper et al, 1998) but are also important in a 
number of other infectious diseases.
In order to produce inhibitors to CPs, a common approach is to obtain 
large quantities of the active enzyme by cloning the CP and screening with 
inhibitors to the CP of interest (Selzer et al, 1997). Once lead inhibitors have 
been identified, the compounds can be tested for their effects on mammalian cells. 
If the inhibitors are selectively taken up by parasite cells rather than host cells, 
intensive studies may begin. However, production of large amounts of parasite 
CP also facilitates analysis of the CPs since the enzyme can be tested against a
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number of different biological substrates that it may have proteolytic activity to, in 
vivo. For example, the gingipains of Porphyromonas gingivalis have been found 
to cleave a number of biologically important molecules produced as the site of 
infection with this organism including the inflammatory molecule TNF-a (Calkins 
et al, 1998) and the degradation of this molecule helps to circumvent the host 
immune response.
The generation of parasite mutants lacking the CP gene of interest allows 
for the study of these enzymes, while re-integration or re-expression of CP genes 
back into the mutants can also aid the investigator in elucidating CP function 
(Mottram et al, 1998). Both approaches have been adopted for this study and 
both have their advantages and disadvantages as have been described in previous 
chapters (Barrett et al, 1999).
Successful and heterologous expression and purification of a L  mexicana 
CP, CPB2.8ACTE, yielded a highly active enzyme (Sanderson et al, 2000). The 
developed procedure is now being used for purification of other leishmanial CPB 
isoenzymes over-expressed in E. coli but preliminary experiments with the L. 
infantum CPB containing the C-terminal extension, have shown that the 
methodology may need to be modified as required for each of the enzymes being 
purified.
Over-expression of the pro-region part of the enzyme is also being carried 
out in this laboratory and should aid the identification of highly specific inhibitors 
of the leishmanial CPs since pro-regions have been found to be highly potent 
inhibitors of their respective mature enzymes (Cygler & Mort, 1997). Synthetic 
peptide inhibitors based on the pro-region could be promising chemotherapeutic 
compounds It has already been shown that CP inhibitors administered in vivo can
210
Chapter 7
result in parasite {T. cruzi) killing and subsequently alter the course of infection to 
a healing response (Engel et al, 1998). Recently, it has been reported that 
specific CP inhibitors can kill Leishmania parasites both in vitro and in vivo, at 
concentrations that do not affect mammalian CPs, in terms of cell replication or 
ultra-structural appearance (Selzer et al, 1999). None of the compounds 
produced toxic effects in mice and parasites appeared to accumulate inhibitor 
much more effectively than the host cell organelles (Selzer et al, 1999). Since 
the host also contains cathepsin L-like enzymes, the more specific the inhibitor for 
the parasite CP is, the less risk of side-effects experienced by the host and pro­
regions have been shown to be highly specific inhibitors for their respective 
proteinase (Cygler et al, 1997). In addition to this, exogenously added pro­
region can renature un-folded subtilisin in an intermolecular process (Zhu et al, 
1989). The purified pro-region of CPB2.8ACTE may be able to similarly refold 
pro-mature CPB2.8ACTE in vitro, purified by metal chelate affinity 
chiomatography which proved to be unsuccessful in producing fully active 
enzyme.
Having obtained active recombinant CP, the potential effects on 
macrophage (PECs) cytokine production were analysed since it is this cell which 
is most likely to encounter the active CP during Leishmania infection. PECs are 
composed primarily of inflammatory macrophages but there are other cells present 
such as neutrophils and eosinophils therefore bone marrow derived macrophages 
could be used as they represent a more homogeneous macrophage population.
The enzyme did not affect inflammatory mediators, IL-12 or nitric oxide but did 
inhibit production of IL-10. A recombinant leishmanial protein, LelF, has been 
shown to stimulate IL-12 production fi-om peripheral blood mononuclear cells
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(PBMCs) of leishmaniasis patients so there is precedent for leishmanial molecules 
to induce a Th 1 profile (Skeiky et al, 1995). However, the reduction in IL-10 
from PECs would be more significant if this same effect was demonstrated in 
PBMCs from leishmaniasis patients and this experiment is certainly one worth 
considering. In theory, a number of cytokines could be assessed which are 
considered to be important in leishmanial infection e.g. IL-6, IL-10, IL-12 and 
TGF-p. Alternatively another cell type, the basophil could be analysed in a similar 
fashion since it has been demonstrated that addition of the soluble egg antigen 
from S. mansoni has also been shown to stimulate IL-4 production from human 
basophils (Haisch et al, 2000). Some allergens are also known to stimulate IL-4 
production from basophils {Der /? 7) in atopic individuals (Gough et al, 1999) so 
it is feasible that CPs from lysed Leishmania parasites could trigger an increase in 
IL-4 production in the host by this mechanism. To determine whether 
CPB2.8ACTE can stimulate IL-4 production in vivo, active and inactive enzyme 
could be injected into mice and mRNA from the draining lymph nodes isolated. 
This would mirror work done by Finkelman and Urban (1992) who injected active 
and inactive papain into BALB/c mice and found that active CP promoted high 
IL-4, while inactive CP produced significantly less IL-4, afer 24 hours. In the 
case of leishmanial infection, an early IL-4 burst due to the CPBs could potentiate 
a Th 2 response and allow for establishment of infection.
Vaccination with the active or inactive CPB2.8ACTE and IL-12 was 
found to be partially protective in three different mouse strains against wild-type 
L. mexicana and the results, especially for the susceptible BALB/c mouse strain 
are encouraging in teims of a possible vaccine since this strain is very susceptible 
to infection with L. mexicana (Satoskar et al, 1995). Unfortunately, IL-12 has
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been shown to produce unpleasant side-effects in humans although it is still 
undergoing clinical trials as a potential for cancer therapy (Leonard et al, 1991). 
Since CPB2.8ACTE has been shown to be partially protective as part of a vaccine 
against L. mexicana, other adjuvants should be considered. Effective 
immunisation against cutaneous leishmaniasis with defined membrane antigens 
such as gp63 reconstituted into liposomes has been reported (Russell &
Alexander, 1988). Liposome formulations aie relatively non-toxic and therefore 
CPB2.8ACTE should be incorporated into such a formulation and tested for its 
protective capacity without IL-12. Another potential method of vaccination 
against Leishmania has been through the use of integration of recombinant 
leishmanial proteins into genetically attenuated Salmonella (Soo et al, 1998) and 
infecting with this organism before challenge with Leishmania. This study 
demonstrated protection to L. major infection when the attenuated Salmonella 
strain was integrated vdth gp63 (Soo et al, 1998). Therefore, the possibility also 
exists for the leishmanial CPBs to be incorporated into such a vaccine against 
Leishmania and if successful, would allow efforts to be diverted away fi'om the 
search for a suitable adjuvant.
It has been reported that a DNA vaccine for the gene, LACK {Leishmania 
homologue of receptor of activated C kinase) has resulted in a protective vaccine 
for leishmaniasis which generates short-term immunity in susceptible BALB/c 
mice (Gurunathan et al, 1998). Because DNA vaccines result in expression of 
the antigen in situ, presentation of antigenically relevant epitopes to the immune 
system may be more readily attainable than vaccination with recombinant purified 
proteins (Donnelly et al, 1997). Results suggest that generation of Th l-like T 
ceU help may be a general property of DNA vaccines (Donnelly et al, 1997).
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Therefore, construction of a DNA vaccine incorporating CPB2.8 or even a 
cocktail of CPs including CPA and CPC should be considered since immunisation 
with a DNA vaccine incorporating the gene for a leishmanial metalloproteinase, 
gp63, has afforded significant protection in BALB/c mice against L. major 
infection (Xu & Liew, 1995).
This and other studies have shown that targeted gene deletion of L. 
mexicana is an extremely useful tool for providing evidence that the CPs are 
potential virulence factors (Mottram et al, 1996) while attenuated L. mexicana 
mutants lacking both the cpalcpb genes, are excellent vaccine candidates 
(Alexander et al, 1998). Re-expression into the single null mutant of a CP 
produced a more virulent infection, if one analyses the disparity in the humoral 
response and lesion progression. Analysis of the splenocyte response in mice 
infected with the GL438 {Acpb/cpa re-integrated with CPB2) and GL439 
{Acpb/cpa re-integrated with CPB2.8) parasite lines should give a clearer 
understanding of the infection in vivo, A Acpb/cpa double null mutant re­
expressing an active site mutant of CPB2.8 has been constructed. Infection of 
mice and the resulting humoral and cellular immune responses should be analysed. 
This should provide further insight into the role of CPB activity in leishmanial 
infection. The number of possible CP gene mutations, deletions and re­
integrations which could be performed in this laboratory are limitless but careful 
consideration must be given in order to elucidate the role of each of the CPs.
Since infection with the Acpb/cpa mutant line potentiates a Th 1 response, re­
integration of the active site mutant of CPB2.8 may result in an accumulation of 
CP which may be exocytosed due to non-processing and subsequently presented
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to Th cells. This may promote an even greater Th 1 response and could be a 
more likely vaccine candidate than the double null mutant alone.
This study set out to purify a recombinant leishmanial isoenzyme, 
CPB2.8ACTE, from L  mexicana and identify^  a potential role for this enzyme. It 
has been successful in that purification of active enzyme was achieved and a 
number of roles for the enzyme have been excluded and suggested, while also 
showing that the enzyme was a protective antigen. A method for analysis of 
purified recombinant CPs or genetically mutated parasite lines in L  mexicana 
infection has been generated and shows that leishmanial CPs can potentiate both 
IFN-y and IL-4-type responses in infection. This thesis has also provided the 
theoretical basis for future work and potential elucidation of the leishmanial CPs 
in the host-parasite interaction.
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